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Abstract 
Kinetics and Mechanics of Blood Clot Contraction 
Valerie J. Tutwiler  
Kara L. Spiller, PhD and John W. Weisel, PhD 
 
 
Thrombotic conditions such as heart attacks and strokes are leading causes of 
death and disability worldwide. Clot contraction, which is the volume shrinkage of the 
blood clot, has been implicated to play a role in hemostasis, wound healing, and the 
restoration of blood flow past otherwise obstructive thrombi. Despite these clinical 
implications, clot contraction is the least studied area of the coagulation process, which 
can be largely attributed to a previous lack of methodology. To address this need, we 
developed a novel optical tracking system that allows for the quantitative assessment of 
clot contraction. These studies revealed that clot contraction is a three-phase process that 
can be differently affected by platelets, fibrin, and erythrocytes. Platelet count and 
function have the ability to enhance the extent of clot contraction while increased 
erythrocytes and fibrin dampen the extent of clot contraction.  
We developed a three-element active poroviscoelastic model to improve the 
understanding of how composition of the clot, particularly the presence of erythrocytes, 
affects the process of clot contraction. We determined that erythrocytes influence clot 
contraction through both a tensile and compressive resistance, which resulted in a 
decrease in the extent of contraction coupled with an apparently paradoxical increase in 
generation of contractile force. 
The knowledge that blood composition can influence clot contraction coupled 
with the clinical importance of thrombotic conditions such as stroke and heart attack 
	  	  
xvii	  
revealed a need for studies of clot contraction in patients with (pro)-thrombotic 
conditions. We examined clot contraction in the blood of patients with ischemic stroke, 
sickle cell disease, and deep vein thrombosis.  Interestingly, in all three pathologies we 
have observed a significant reduction in the extent of clot contraction. With respect to 
ischemic stroke and deep vein thrombosis, this reduction in clot contraction correlates 
with a lower platelet count and platelet dysfunction. Whereas, the reduction in 
contraction in sickle cell disease patients can be attributed to their increased erythrocyte 
rigidity.  
Ultimately after a clot is formed it needs to be resolved, which occurs through the 
enzymatic process of fibrinolysis. Here we examined influence of clot contraction on rate 
of physiologic or internal fibrinolysis and clinical thrombolysis or external fibrinolysis. 
Interestingly, clot contraction enhanced the rate of internal fibrinolysis while decreasing 
the rate of external fibrinolysis.  
Collectively, these findings provide new information about basic mechanisms of 
clot contraction and point to its importance with respect to thrombotic conditions, and 
have the potential to lead to the development of diagnostic assays or therapeutic targets. 
 
 
 
 	  	  
	  	  
1	  
	  
Chapter 1 Introduction 	  	  
Cardiovascular diseases such as venous thromboembolism, myocardial 
infarction and ischemic stroke are leading causes of death and disability worldwide. 1,2 
These thrombotic conditions are linked through a disruption of the hemostatic balance. 
The origin of the clot within the vasculature greatly influences its composition; venous 
thrombi tend to be RBC-rich while arterial thrombi tend to be composed largely of 
platelets and fibrin. 3 Blood clot contraction, or the volume shrinkage of the clot, is a 
platelet-driven reduction of the clot volume occurring both in vitro and in vivo, which 
has been implicated to play a critical role in preventing blood loss4 and restoring blood 
flow past otherwise obstructive thrombi. 5 Clot contraction is the least studied aspect of 
blood clotting, at least in part due to a lack of methodology to quantitatively assess the 
mechanism(s) underlying the process. The mechanism of clot contraction is interesting 
in terms of the basic biology of these processes. In addition, gaining a fundamental 
understanding of clot contraction and particularly if it is altered in thrombotic 
conditions has the potential to inform the development of more targeted therapeutics 
and diagnostic assays. 
1.1 Background  
The proper formation and function of the coagulation cascade is critical to the 
stemming of bleeding and the formation of the hemostatic seal. This process can be 
described by several different components: clot initiation, clot formation, clot 
contraction, and clot resolution (Figure 1-1). For hemostasis to occur, coagulation 
	  	  
2	  
needs to be localized with a balance between formation and resolution. When 
coagulation goes on uncontrolled, it can morph into thrombosis.6 	  	  	  
.	  	  	  
1.1.1 Clot	  Initiation	   	  
Platelets naturally circulate through the blood stream in a quiescent state, 
protected from activation through the presence of the endothelial monolayer.  In their 
inactivated state platelets, the smallest of the blood cells, are anucleated discoid cells 
Figure 1-1 Schematic representation of the processes involved in hemostasis.  (A) 
Clot initiation occurs when platelets are exposed to an agonist such as those found in 
the subendothelial layer. (B) Clot formation progress as platelet activation, granule 
release, and cytoskeletal reorganization occur. Concurrently, fibrinogen is cleaved 
into fibrin monomers, which polymerize into a highly elastic fibrin network.  (C) 
Following platelet activation the platelets are able to contract, pulling the clot volume 
toward the vessel wall and effectively reducing the clot volume. (D) Lastly, clot 
resolution must occur through the activation of enzymes such as plasmin, which can 
break down the fibrin network 
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that contain secretory granules. 7 Platelets are ~2 µm in diameter when resting8 and a 
healthy individual contains 150,000-400,000 platelets/µL. 9  
Disruption of the endothelium results in the exposure of coagulation agonists, 
such as tissue factor (TF), 10,11 and subendothelium and endothelial cell released 
components such as collagen and von Willebrand factor (vWF). 12,13 Exposure to said 
agonists results in the tethering, rolling, and adhesion of platelets to the procoagulant 
surface, 14 with activation of platelets and a rise in their free Ca2+ concentration. 15 
Platelets adhere to collagen through α2β1 and GPVI whereas they adhere to vWF 
through αIIbβ3 and GP1b. 16  
Formation of a platelet plug, the initial step in hemostasis, is required to stem 
bleeding.  Initiation of clotting occurs through the activation of the coagulation 
cascade (Figure 1-2). The extrinsic pathway of the coagulation cascade results when 
TF binds to the soluble clotting factor VII. The TF:VIIa complex leads to the 
activation of factors IX and X. 17,18 The activate form of factors IXa, Xa, and XIIa 
have been shown to induce factor VII activation which furthers the activation of the 
coagulation cascade. 19,20 Whereas, the intrinsic or contact pathway results in 
activation of factor XII when coming in contact with a negatively charged surface 
leading to the activation of XIa and ultimately IX. 21 Ultimately, the intrinsic or 
extrinsic pathways are both able to activate factor X, which is able to convert 
prothrombin to thrombin. Thrombin is able to act on a variety of substrates such as 
platelet receptors, fibrinogen, factors V and XI, and proteins S and C that are critical 
propagation and reduction of the coagulation process. 22  
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Figure 1-2 Coagulation and fibrinolytic systems. The coagulation cascade can be 
triggered trauma, inflammation, or damage to the endothelium. The extrinsic pathway 
involves activation of FVII and TF. The intrinsic pathway involves the activation of  
FXII, FXI, FIX, FVIII. The common pathway resuts in the activation of FX and then 
conversion of prothrombin to thrombin. Thrombin can cleave fibrinogen to fibrin, 
which polymerizes and is ultimately crosslinked into fibrin fibers by FXIIIa. 
Degradation of fibrin fibers occurs when plasminogen is activated by tPA into 
plasmin, which acts on fibrin fibers to digest them enzymatically. 
 	  
1.1.2 Clot formation 
Extension of the platelet plug occurs as platelets become fully activated and 
begin to aggregate, due to increased exposure to agonists such as ADP and thrombin. 
As platelets are activated they undergo several fundamental changes that are vital for 
clot formation to occur. First, platelets secrete the components of their three internal 
granules dense granules, alpha granules, and lysosomes. 23 Dense granules release 
small molecules that are important for thrombogensis. 24 Alpha granules release 
growth factors, chemokines, and adhesive molecules such as fibrinogen. 25 Lysosomes 
release molecules ultimately involved in wound healing. 23 In addition, platelet 
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membrane asymmetry is disturbed causing phospholipids to flip to the outside of the 
platelet26 and platelet integrins, such as αIIbβ3, to switch from a low affinity state to a 
high affinity state that is required for platelet-fibrinogen interactions. 27 Fibrinogen is a 
fibrous macromolecule that can bridge platelets through each end binding to αIIbβ3, 
allowing for the platelet aggregates to form. 28,29 Platelets also undergo a cytoskeletal 
rearrangement, resulting in the development of filopods and the localization of the 
actin-myosin cytoskeleton to the periphery of the platelet binding to αIIbβ3.30 
In addition to being able to activate platelets, thrombin is able to cleave the 
monomeric fibrinogen into fibrin (Figure 1-3), via the enzymatic cleavage of 
fibrinopeptides. 31 In a healthy individual fibrinogen circulates at ~2.5 g/L. 32 
Fibrinogen is a homodimeric glycoprotein that is made up of three polymer chains: 
Aα, Bβ, and γ which are held together by 29 disulfide bonds33 with interchain 
disulfide bonds holding the amino termini in the central domain. 32 Due to exposed 
interaction sites binding to always exposed complementary sites; the fibrin monomers 
are able to join in a half staggered pattern, forming a protofibril. 34 The protofibrils are 
capable of aggregating laterally into polymeric fibrin fibers, which branch to make a 
three-dimensional network. 35,36 Factor XIIIa (FXIIa) covalently crosslinks fibrin, 
which stabilizes the clot and makes it resistant to lysis.  37-40 FXIII is a heterotertameric 
zymogen that consists of two catalytic and two noncatalytic subunits. 41,42 When 
catalytically active FXIIIa forms a crosslink between glutamine and lysine residues on 
the γ− and α-chains of fibrin, which can result in the formation of γ-multimers, α-
polymers, or αγ hybrids. 32 The fibrin network provides the structural basis for the 
mechanical stability of the clot, which has major clinical implications. 43 The 
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viscoelastic mechanical properties of the fibrin network are influenced by 
characteristics such as branching, fiber diameter, and FXIIIa crosslinking and are 
responsible for the rigidity of the matrix. 44,45  
RBCs, which make up 35-50% of the circulating blood volume, can be 
incorporated into the forming clots to varying degrees based on the origin of the clot. 
The presence of RBCs can increase the procoagulant nature of the clot through their 
ability to increase thrombin generation. 46-48 They have also been shown to alter fibrin 
structure, 49 clot viscoelastic properties, 49 and increase resistance to fibrinolysis. 50 
Interestingly FXIIIa-crosslinking has been shown to influence RBC retention in a 
model of venous clotting51 mediated though α-polymer crosslinking. 52   
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Figure 1-3. Fibrin Polymerization. Thrombin cleaves fibrinopeptides off fibrinogen 
resulting in fibrin monomer.  Fibrin monomers interact via knob:hole bonds to form 
oligomers, which can aggregate elongate to form protofibrils and aggregate laterally to 
form fibers. FXIIa ligates the γ and α chains to form crosslinked fibers. Plasmin can 
cleave the fibrin network in the middle of the coiled coils. Modified from Weisel, J.W. 
Advances in Protein Chemistry. 2005. 70:247-299. 	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1.1.3 Clot contraction  
Clot formation sets the stage for clot contraction. Clot contraction is the 
reduction of the freshly formed clot volume through the expulsion of serum. 53,54 
Activated platelets can generate contractile forces4,55 due to the cytoskeleton 
reorganization that results in actin and non-muscle myosin IIa interaction4,56 following 
platelet activation. 57,58 During platelet activation polymerized actin is able to interact 
with αIIbβ3 integrin through focal adhesion proteins such as vinculin, and talin, where 
vinculin serves as a connection between actin bundles and is needed for the 
transmission of force. 59 It has been shown that myosin force generation is critical for 
clot contraction to occur. 60 These contractile forces are propagated cooperatively 
through the interconnecting platelet-fibrin meshwork61,62 due to the strong platelet-
fibrin interactions through the exposed and activated αIIbβ3 integrin. 63-65 The efficacy 
of clot contraction has been shown to be dependent on the covalent crosslinking by 
FXIIIa. 66  
As the platelet-fibrin network is formed and clot contraction progresses, the 
platelets and fibrin move to the outside of the clot and RBCs become packed in the 
core. 67 When the RBCs are compacted into the core of the clot they form a tessellated 
array and deform from their resting biconcave shape into a polyhedra, resulting in the 
terminology polyhedrocyte. 67  
1.1.4 Clot resolution 
The coagulation cascade consists of several inhibitory mechanisms that are 
meant to limit the action of both the coagulation and fibrinolytic systems. C1 
inhibitors largely limit the intrinsic pathway through its action on factor XIIa. 68 
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Antithrombin (ATIII) inhibits thrombin activity, as thrombin is able to form a complex 
with ATIII rendering thrombin inactive. Tissue factor pathway inhibitor inhibits the 
TF:VIIa activity. α2−Antiplasmin inhibits plasmin and limits the fibrinolytic process 
where it is not needed. 69  
Fibrinolysis, which limits the coagulation process, is set into motion following 
thrombus formation and is needed to avoid problematic thrombus growth. During 
coagulation plasminogen, that is present in the plasma and released from platelets, is 
localized to the clot via specific binding to fibrin and converted into plasmin by 
plasminogen activators (tPa or uPA). 70 Plasmin degrades the fibrin meshwork by 
cleaving fibrin in the αC region of fibrin, in the middle of the coiled-coil and 
elsewhere, 71,72 which exposes additional plasmin binding sites, allowing plasmin to 
break fibrin down into smaller fragments. 71 The efficacy of plasminogen activators is 
influenced by the permeability of the thrombi. 73 FXIIIa crosslinking has the ability to 
mitigate fibrinolytic potential through the influence on clot permeability and the 
crosslinking of α2−Antiplasmin  to the fibrin fibers. 74,75 As plasmin cleaves fibrin 
there are fibrin degradation products released into circulation. 76 While the process 
described above occurs endogenously when a thrombus obstructs blood flow and has 
the potential to lead to life threatening complications tPA can be administered 
exogenously to promote fibrinolysis.  
1.1.5 Hemostasis versus thrombosis  
When the regulation of the clotting process is in balance hemostasis occurs, 
however, if the coagulation cascade is dysfunctional thrombosis can occur. Excess 
platelet activation, thrombin generation, and clot growth can result in the development 
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of a thrombus that has the potential to block blood flow through the vessel. Occlusive 
thrombosis can result in life threatening conditions such as ischemic stroke and 
myocardial infarction.  Thrombosis can develop both in the artery (arterial thrombosis) 
or the vein (venous thrombosis). Typically, arterial thrombosis results due to amplified 
coagulation response to an injury of the blood vessel that occurs over the course of 
many hours to days. 77 For example, in atherosclerosis plaque accumulation in the 
vessel wall leads to a lesion that can rupture, which leads to the activation of the 
coagulation cascade and the potential occlusion of the blood vessel. This can cause 
heart attacks or ischemic stroke depending on the origin of the plaque. Deep vein 
thrombosis, a common type of venous thrombosis, can result in edema, sores and pain 
although the most pressing potential complication is pulmonary embolism. 
Thromboembolism is a major complication that can arise in both arterial and venous 
thrombosis. This occurs when a piece of the thrombus breaks off and eventually 
becomes stuck in a downstream blood vessel. In the case of a patient with a 
cardioembolic stroke an embolism could travel to the brain and cause the stroke. An 
embolus in a patient with deep vein thrombosis could become lodged in the lungs. 
Understanding the mechanisms of process involved in hemostasis and thrombosis has 
the potential to lead to better diagnostic assays or therapeutics resulting in improved 
patient outcomes.  
1.2 Significance  
1.2.1 Importance of clot contraction 
Clot contraction plays an important role in preventing blood loss, 4 reducing the 
volume of the clot, 53,54 and restoring blood flow past otherwise obstructive thrombi. 5 
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The ability of platelets to generate considerable contractile forces has been confirmed 
in vitro for platelet-rich plasma clots. 54 Individual platelets begin to contract 
immediately following contact with fibrinogen and generate forces as large as 29nN. 4   
The importance and complexity of clot contraction can be exemplified through 
diseases and disorders disrupting the generation and propagation of contractile force.  
Mutation of non-muscle myosin IIa results in macropthrombocytopenia where platelet 
activation occurs without the development of stress fibers around the periphery of the 
platelet, which are needed for the generation of contractile force. 78,79 Patients who 
have this non-muscle myosin IIa mutation have an increased tendency to bleed, 
decreased thrombus stability, and decreased clot contraction; as normal platelet 
aggregation occurs it is believed that this results from impaired generation of 
contractile force. 79,80 A predisposition to bleeding and an absence of clot contraction is 
also present in murine MYH9 mutations. 80,81 Furthermore, inhibition or deletion of 
non-muscle myosin IIa lends additional support to the theory that platelet contraction 
is vital for a stable hemostatic plug to form in vivo independent of platelet aggregation 
and/or fibrin formation. 60  
 While the platelet's ability to generate contractile force is paramount to clot 
contraction, contraction cannot occur without platelet-fibrin(ogen) interaction and 
propagation of contractile force. Platelets undergo activation through outside-in 
signaling by exposure to agonists, such as thrombin, ADP etc. This signaling process 
results in the activation of αIIbβ3, 82 inside-out signaling and platelet aggregation via 
binding of fibrinogen. Clinically, a disruption in this signaling or binding results in 
diseases such as Glanzman’s thrombocytopenia, which is typically associated with a 
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reduction in platelet aggregation and a tendency to bleed. 83 Development of diYF 
mice, which allows for the selective impairment of outside-in signaling, has revealed 
that tyrosine phosphylation of β3 within the ICY motif is particularly important for clot 
contraction. 64,84 Importantly these diYF mice do not have a defect in platelet 
aggregation or clotting but do have a bleeding tendency, which is likely due to the lack 
of clot contraction. 64,84 Platelet integrin αIIbβ3 is necessary for platelet-fibrinogen and 
platelet-platelet interactions, but is also involved in metabolic processes, alpha-granule 
secretion, dense-granule secretion, and platelet cytoskeleton reorganization, among 
others. 64 Particularly, outside-in signaling is involved in the translation of Bcl-3, 85 
that has been shown to regulate clot contraction where overexpression results in 
enhanced clot retraction, and deletion of Bcl-3 results in impaired clot contraction. 86 
Collectively, these results point to the importance of clot contraction in addition to 
platelet-fibrin interactions and the subsequent physiological processes of thrombus 
stabilization.  
 The density and structure of the fibrin fibers is modulated by the 
microenvironment, 45 which can in turn affect the propagation of contractile force 
throughout the clot volume61,62 and the mechanical properties of the clot. 87 Both 
FXIIIa crosslinking and fibrin structure can affect clot contraction. 66 
Dysfibrinogenemias, which are specific mutations of fibrinogen that can lead to 
disruptions in functionality, have been shown in some cases to result in abnormal 
bleeding and/or thrombosis in patients. 88  
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1.2.2 Clot composition in thrombosis  
The location of the blood clot within the vasculature greatly influences the clot 
composition; venous thrombi tend to be RBC-rich while arterial thrombi tend to be 
composed largely of platelets and fibrin. 3 Increased RBC inclusion in the thrombus 
volume increases the incidence of morbidity and mortality in patients with thrombi. 89 
While it was previously believed that RBCs play a relatively passive role in clot 
contraction, recent results suggest that they may be important for hemostasis and 
thrombosis. Deformable biconcave RBCs can become tightly packed, which results in 
the RBCs taking on a polyhedral shape, called polyhedrocytes. 67 The compaction of 
RBCs within the core of contracted clots generated in vitro suggests a critical role for 
RBCs in thrombosis and hemostasis. 67 Importantly, polyhedrocytes were also found in 
vivo in thrombi from patients with ST-elevation myocardial infarction. 67,90 In addition, 
diseases with altered RBC content, such as polycythemia vera, and altered RBC 
rigidity, such as sickle cell disease, have been shown to have an increased tendency to 
develop venous thromboembolism. 91 These compacted RBCs may be important for 
creating an impermeable seal that is necessary for hemostasis; however, it could also 
lessen the ability of plasminogen activators to travel through the clot volume and 
consequently result in increased resistance to fibrinolysis.  
Genetics92,93, diseased states94-99, and medications100-102 have an effect on fibrin 
structure.  Importantly, individuals with diseases linked with altered fiber density and 
stiffness are predisposed for either bleeding or thrombosis and wound healing 
complications98. It is known that thin compact fibers form a dense network that is 
associated with an increased risk of thrombosis103,104 while a looser network made up 
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of thicker fibers is associated with an increased risk of bleeding105,106. Increased fibrin 
stiffness has the ability to alter the stability of the blood clot but also has the potential 
to influence the process of clot contraction.  
1.2.3 Clot contraction and fibrinolysis  
Thrombolytic drugs are frequently used as treatment for thrombosis, ischemic 
stroke, or myocardial infarction. Such drugs work by converting plasminogen that is 
bound to fibrin into the active protease plasmin. 107 Plasmin is able to cleave fibrin and 
break down the clot structure. 108 The rate of lysis is directly related to the fibrin 
structure109-113 and it is known that the incorporation of cells into the clot volume can 
result in changes in fibrin network structure. 49 Collectively, these findings suggest that 
pathological changes in cell/fibrin stiffness or concentration could affect the extent of 
clot contraction and the efficacy of treatment by fibrinolytic drugs. 
1.2.4 Current gaps in knowledge  
While much is known about clot formation and the processes that constrain 
propagation and promote dissolution, very little is known about the mechanism(s) 
involved in the process and regulation of clot contraction. Despite the fact that there 
have been some studies looking at the effects of various agonists on platelet 
contractility and/or platelet and fibrin behavior on the end point of clot contraction, 
there is a distinct lack of any quantitative systematic studies of the kinetics of clot 
contraction. In addition, the vast majority of clot contraction studies have involved 
platelet-rich plasma, without the presence of RBCs. Despite recent clinical 
implications that RBCs play a critical role in the mechanisms and function of clot 
contraction, 67 the interactions of RBCs with the platelet-fibrin network in clot 
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contraction have not been well investigated. The study of clot contraction in patients 
with pathological conditions is even more limited.  
1.2.5 Contribution of research  
Thrombotic vascular occlusion is a leading cause of death and disability. 1 Despite 
the fact that clot contraction has been implicated to play a role in hemostasis, 67 there 
has been little research examining the mechanism(s) through which clot contraction 
occurs and the potential role it plays in the regulation of hemostasis and thrombosis. 
Here, I have systematically assessed the time-dependent process of clot contraction 
and the interaction of extent of clot contraction and rate of fibrinolysis. A better 
understanding of clot contraction could assist in the development of more effective 
and timely treatments to promote hemostasis and limit thrombosis and bleeding.  
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Chapter 2 Research Goals 
 A thorough characterization of the mechanism(s) involved in clot contraction 
would present the potential to develop targeted treatments that modulate bleeding and 
thrombosis. While much is known about the processes that regulate clot formation, 
propagation, and resolution, there is a gap in knowledge relating to the process and 
regulation of clot contraction. In this work I systematically characterized the time-
dependent process of clot contraction by investigating the effects of 1) the cellular 
and molecular composition of the blood and 2) certain pathological alterations in the 
blood composition and to evaluate the effect of extent of clot contraction on 
sensitivity to fibrinolysis. This project proposes to use a novel continuous tracking 
approach that will allow for clot contraction and fibrinolysis to be quantitatively 
tracked over time. To thoroughly characterize the mechanism(s) of clot contraction 
first samples from healthy individuals were examined while probing the role of the 
blood composition. Secondly, clot contraction was studied in blood of patients with 
thrombotic conditions to further characterize the mechanism of contraction and how it 
is altered in a pathological setting. The overall hypothesis of this work is that clot 
composition affects the extent of clot contraction, which in turn influences the 
rate and efficacy of fibrinolysis.  
The project has been divided into the following aims: 
1. To assess the effect of the cellular and molecular blood composition on 
the mechanism(s) of clot contraction.  The hypothesis of Aim 1 is that platelets, 
RBCs, fibrin, and the molecular components of the clot that affect them have the 
ability to enhance or limit the process of clot contraction. It is believed that increased 
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platelets will enhance clot contraction while increased RBCs and fibrin will limit 
extent of contraction. To assess this hypothesis I utilized both experimental and 
theoretical approached. Chapter 3 focuses on the use of a novel methodology to 
quantitatively track changes in clot volume over time in combination with high 
precision rheometry to study the generation of contractile forces. This allowed for the 
time-dependent interplay of the contracting blood clot to be determined. Chapter 4 
supplements the experimental analysis of contracting blood clots through the use of 
scanning electron and confocal microscopy to assess the structure of the blood clot and 
in particular the compaction and deformation of RBCs. The combination of results 
obtained in Chapters 3 and 4 were used to inform the development of a three-element 
active viscoelastic model of contracting blood clots, which is detailed in Chapter 5 and 
provides a theoretical understanding of the mechanical interplay of the clot 
composition in the process of clot contraction. In all, these chapters provide the 
foundation needed to understand the mechanism of clot contraction with respect to the 
varying composition of the blood along with providing a baseline of contraction in 
healthy individuals.  
2. To assess the role of clot contraction in certain thrombotic diseases. To 
further explore the mechanisms of blood clot contraction I examined differences in 
contraction between the healthy individuals examined in Specific Aim 1 and patients 
with certain (pro)-thrombotic diseases. The diseases examined where were chosen so 
that a pro-thrombotic disease, arterial thrombosis and venous thrombosis were all 
assessed. By studying each of these conditions it is possible to explore the mechanistic 
nature of clot contraction in a pathological setting.  The hypothesis of this aim is that 
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the extent of clot contraction is modified in patients with thrombotic conditions. 
Chapter 6 details the examination of clot contraction in blood from patients with 
Sickle Cell Disease, which is a pro-thrombotic condition, meaning that these patients 
are more likely to develop thrombotic conditions. The examination of a pro-
thrombotic condition is needed to fully understand the mechanisms of blood clot 
contraction as these individuals are predisposed to thrombotic events but do not 
currently have thrombosis. In particular, in Chapter 6 I explore the influence of RBC 
rigidity on the process of clot contraction as patients with many pro-thrombotic 
conditions have been shown to have increased RBC rigidity. As the nature of arterial 
and venous thrombosis differs it is imperative to study both conditions to fully detail 
the mechanism of clot contraction. Arterial thrombosis, specifically ischemic stroke, is 
detailed in Chapter 7, and examines differences between these patients and healthy 
individuals while looking at correlations between clot contraction and clinical 
parameters of ischemic stroke. In Chapter 8 I examine the role of increased TF on clot 
contraction, increased TF is associated with increased brain damage and/or 
inflammation. Lastly, Chapter 9 details differences in clot contraction between healthy 
individuals and those with venous thromboembolism and explores differences in 
patients with deep vein thrombosis and pulmonary embolism. Importantly, these 
results are not only the first studies of clot contraction in thrombotic conditions but 
they also provide thorough picture of how the mechanisms of clot contraction is 
altered in thrombotic conditions compared to healthy individuals.  
3. To assess the effect of clot contraction on sensitivity to fibrinolysis. 
Ultimately, after a clot has served its hemostatic role it is important that the clot is 
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resolved through a process called fibrinolysis.  The hypothesis of this aim is that the 
extent of clot contraction will decrease the rate and extent of fibrinolysis. Optical 
tracking of clot intensity and release of fibrin degradation products were used to assess 
sensitivity to fibrinolysis. Extent of clot contraction was modulated through the 
addition of various inhibitors to mimic the reduction in clot contraction that was 
observed in the thrombotic conditions examined in Specific Aim 2 compared to the 
healthy individuals examined in Specific Aim 1. The influence of the extent of clot 
contraction on the efficacy of both internal and external fibrinolysis is detailed in 
Chapter 10.  
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Chapter 3 Kinetics and mechanics of clot contraction are governed by the 
molecular and cellular composition of the blood 	  	  
The goal of Specific Aim 1 was to examine the role of clot composition on the process 
of clot contraction. This chapter specifically explores how the cellular and molecular 
composition of the blood influences the time-dependent kinetics and mechanics of 
blood clot contraction through the systematic examination of the volume shrinkage of 
the clots. This quantitative examination was possible due to the development of a novel 
methodology described in this chapter. 
 
This research was originally published in Blood. V. Tutwiler, R.I. Litvinov, A.P 
Lozhkin, A.D. Peshkova, T. Lebedeva, F.I. Ataullakhanov, K.L. Spiller, D.B. Cines, 
J.W. Weisel. Kinetics and mechanics of clot contraction are governed by the molecular 
and cellular composition of the blood. Blood. 2016;127(1):149-159.  
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3.1 Introduction  
Bleeding and thrombotic vascular occlusion are predominant causes of death 
and disability. 1,2 Much is understood about the initial steps of blood clot formation 
and the processes that limit its propagation and promote dissolution. In contrast, little 
is known about the processes that regulate clot contraction (retraction). Clot 
contraction is the active squeezing of a clot that reduces its volume53,54 preventing 
blood loss4 and restoring blood flow past otherwise obstructive thrombi. 5 The 
importance of clot contraction is most evident in disorders that affect the platelet’s 
ability to generate non-muscle myosin-driven contractile forces, such as MYH9 
defects, which result in increased bleeding and decreased thrombus stability associated 
with a reduced extent of clot contraction notwithstanding normal platelet aggregation 
and secretion in response to agonists. 80 The multiplicity of factors that can affect clot 
contraction is exemplified by their impact on alterations in fibrin structure. For 
example, factor XIII (FXIII) deficiency, where fibrin crosslinking is defective, can 
impair wound healing and lead to premature clot lysis and bleeding. 114 Some forms of 
dysfibrinogenemias also lead to bleeding, while others predispose to thrombosis as a 
result of abnormal polymerization that may affect contraction. 88 However, the role of 
clot contraction in the development of thrombotic vascular occlusion and resistance to 
endogenous and exogenous thrombolysis has only recently been explored.115 
 Clot contraction is driven by platelet-generated contractile forces4 that are 
propagated through the platelet-fibrin meshwork61 and result in the expulsion of 
serum. 54 Platelets contract due to the interaction of actin4 and non-muscle myosin IIa, 
which is initiated when platelets are activated by various stimuli, including thrombin. 
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57,58 Thrombin converts fibrinogen to fibrin, which assembles into a highly elastic 
polymeric network, 43,116,117 to which platelets attach through the integrin αIIbβ3. 29,64 
The mechanical properties of fibrin depend on crosslinking by FXIIIa. 66 In addition, 
FXIIIa is required for clot contraction to occur, 118 in part by mediating translocation 
of fibrin to sphingomyelin-rich rafts where it is able to co-localize with myosin and 
αIIbβ3.66 
Red blood cells (RBCs) comprise a substantial portion of thrombus mass, 
especially those formed in veins. 3 However, evidence on the role of RBCs in clot 
contraction is only beginning to emerge. The contractile forces generated by the 
platelet-fibrin meshwork tightly pack and compress RBCs, resulting in a shape change 
from biconcave to polyhedral (called polyhedrocytes). 67 This deformation of RBCs 
was observed in vitro as well as in thrombi from patients with ST-elevation 
myocardial infarction. 67,90 Compaction of RBCs may help seal the clot but may also 
impair permeability to plasminogen activators, contributing to fibrinolysis resistance. 
The converse process, i.e. the effect of RBCs on clot contraction, has received little or 
no investigation. 
Notwithstanding the implied medical and biological importance of clot 
contraction, gaps in our understanding can be attributed, at least in part, to a lack of 
methodology to quantify the dynamics of the process. In this work, we continuously 
tracked clot shrinkage in vitro, which, in combination with rheometry, provided 
detailed quantitative information on the dynamics of clot contraction. The kinetics of 
clot contraction was found to be tri-phasic and by varying the cellular composition, 
coagulation factors, and fibrin structure, the effect of blood composition on each of the 
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phases of clot contraction could be followed. Detailed kinetic and mechanical 
characterization of the process of clot contraction presents the opportunity to better 
identify its role in thrombotic vascular occlusion and to develop novel and targeted 
approaches to promote hemostasis and prevent thrombosis. 
3.2 Materials and Methods  
3.2.1 Reagents  
Purified human fibrinogen, human α-thrombin, prostaglandin E1 (PGE1), 2-
methylthio-AMP triethylammonium (MeSAMP), blebbistatin, iodoacetamide, and 
cystamine were from Sigma-Aldrich (St. Louis, MO). RGDS peptide was from 
Bachem Americas (Torrance, CA). All other reagents were analytical grade.	  
3.2.2 Human blood samples  
Blood samples were collected from healthy donors and sickle cell disease 
patients after informed consent under approval by the University of Pennsylvania’s 
IRB and the Ethical Committee of the Interregional Clinical Diagnostics Center 
(Kazan, Russia). Blood was collected into 3.2% sodium citrate (9:1,v/v). Only blood 
samples with a normal hematocrit, fibrinogen level, activated partial thromboplastin 
time, prothrombin time, and platelet count were used in clot contraction experiments. 
Blood was stored at room temperature and used in experiments within 4 hours.	  
3.2.3 Reconstituted samples  
To assess the roles of individual blood components, we mixed various amounts of 
isolated RBCs, platelet-rich plasma (PRP), platelet-free plasma (PFP), and purified 
fibrinogen. RBCs were isolated from blood through centrifugation at 200g for 10 
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minutes at room temperature and washed three times in phosphate buffered saline 
(PBS). PRP was obtained by centrifuging whole blood at 170g for 15 minutes at room 
temperature; PFP was obtained by centrifuging PRP at >13,000g for 10 minutes. 
Isolated platelets were collected by centrifuging PRP at 640g for 10 minutes in the 
presence of PGE1 (1 µg/ml final concentration), washed, and re-suspended in modified 
Tyrode’s buffer.	  
3.2.4 Continuous optical tracking of contracting clots  
 Clot size dynamics were tracked by measuring light scattering over time 
followed by computational processing of the serial images using a Thrombodynamics 
Analyser System (HemaCore, Moscow, Russia) (Fig. 3-1). 12×7×1 mm plastic 
cuvettes were pre-lubricated with a residual layer of 4% (v/v) Triton X-100 in PBS to 
prevent fibrin sticking to the chamber. Samples were incubated with CaCl2 (2 mM 
final concentration) at 37°C for 3 minutes followed by addition of 1 U/ml thrombin to 
initiate clotting. Samples (80 µl) were quickly transferred to the cuvette, which was 
placed into the thermostatic chamber (37°C) between a red LED and a CCD camera 
(Fig. 1A). Clot size was tracked from digitized images every 15 seconds for 20 
minutes (Fig. 1B). Subsequently, images were analyzed computationally to measure 
lag time (time to 95% of relative clot size, Fig. 1C.a), area under-the-curve (Fig. 1C.b), 
relative clot size at end-point (Fig. 1C.c) and average velocity (average of first 
derivative at each time point).  
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3.2.5 Rheometry of contracting clots  
 Reconstituted samples activated with thrombin and CaCl2 were placed in a 
rheometer (ARG2, TA Instruments, New Castle, DE) and the mechanical properties of 
the blood clot were tracked from the onset of coagulation through clot contraction. 
Low oscillatory strain (3%, 5 rad/sec) was applied using a 20-mm parallel plate to 
measure the storage (G′) and loss (G′′) moduli, which correspond to the elastic and 
viscous properties of the clot, respectively (Fig.S1.A-C). As the clot polymerized in a 
400 µm gap between the top and bottom plates, the contractile force generated by the 
platelet-fibrin meshwork was measured as the negative normal (perpendicular) force 
on the plates. (Fig.S1.D-F) 
3.2.6 Phase kinetic analysis of clot contraction  
Transitions between different phases of contraction were determined by finding 
local maxima and minima points within the instantaneous first derivative of kinetic 
and normal force curves (Fig.1C). Curves were fit using GraphPad Prism 5.0 using a 
piecewise function, and the rate parameters and extent of contraction in each phase 
were determined. 
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Figure	   3-­‐1	   Schematic of the Optical Analyzer System. (A) Blood samples were 
added to the cuvette and allowed to clot. The cuvette was placed in the thermostat and 
exposed to light every 15 seconds, and images were recorded using a CCD camera. 
(B) Images of blood clots during the process of contraction. (C) Data on clot size was 
compiled into a time course (kinetic) curve (solid line) with the following parameters 
extracted: lag time – time to 95% relative clot size (a), area under the curve (b), and 
final degree of contraction (c). The original curve of kinetics is segregated to the three 
parts: phase 1, phase 2 and phase 3; determined by assessing the local maximum and 
minimum of the instantaneous first derivative (dashed). Phase 1 shows the initial 
exponential phase of contraction; k1 is the rate constant associated with this phase of 
contraction. Phase 2 shows the middle linear region of contraction; k2 corresponds to 
the slope or rate of contraction in this region. Phase 3 shows the final phase of 
contraction, an exponential phase, and k3 corresponds to rate constant at which this 
decay occurs. Scanning electron microscopy was used to visually compare the 
ultrastructures of contracted blood clots in PRP (D) and whole blood (E). Note that in 
PRP (D) fibrin fibers radiate from platelet aggregates and form bundles that likely 
propagate tension produced by the contracting platelets. In whole blood (E) the regular 
platelet-fibrin meshwork is partially impaired by RBCs that change the ability of fibrin 
to propagate the contractile force generated by platelets.  
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3.2.7 Non-linear regression analysis  
The kinetic and normal force curves were fit by a piecewise function using 
GraphPad Prism 5.0. 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝐶𝑙𝑜𝑡  𝑆𝑖𝑧𝑒 = 𝑡! < 𝑡 < 𝑡!                𝑦! − (𝑦! − 𝑦!)(1− 𝑒!!! ! )𝑡! < 𝑡 < 𝑡!                                                                𝑦! − 𝑘!𝑡𝑡! < 𝑡 < 𝑡!"#                 𝑦! − (𝑦! − 𝑦!)(1− 𝑒!!! ! ) 
 
where t1 and t2 are the times at which the first derivative of the curve is a local 
maximum or minimum, and y1 and y2 are the corresponding degrees of contraction at 
these points. Smoothing of the first derivative curves with the 4 closest neighbors was 
completed to obtain a clear maximum and minimum point. y0 and y3 correspond to the 
initial and end point size of the clot, respectively. k1, k2 and k3 are determined through 
the curve fitting and correspond to the rate or rate constant for the portion of the 
piecewise function (Supplemental Fig. 2). Decay rates at individual time points (50 
and 750 seconds) were calculated by taking the derivative of the relative clot size 
equation at that particular time point. The rates at these time points are negative as the 
clot size is decreasing over time.  
 
3.2.8 Scanning electron microscopy of contracted clots  
Thrombin-induced clots from citrated PRP (Fig. 1.D) and whole blood 
(Fig.1.E) containing 2 mM CaCl2 were allowed to contract at 37ºC for 30 minutes, 
washed in PBS (3 times for 15 min each), then fixed in 2% glutaraldehyde, 
dehydrated, dried with hexamethyldisilazane, and sputter-coated with gold-palladium. 
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The samples were examined in an FEI Quanta250 scanning electron microscope (FEI, 
Hillsboro, OR). 	  
3.2.9 Statistical analysis  
Data are represented as mean±SEM. Data were assessed for statistical significance 
using GraphPad Prism 5.0. All sample parameters were assessed by repeated measures 
ANOVA followed by Tukey’s test or a two-tailed paired t-test, as specified in the text. 
Significance was assessed at 95% confidence interval.	  
3.3 Results  
3.3.1 Optimization of in vitro clot contraction using thrombin and calcium 
chloride  
As both thrombin and CaCl2 have been shown to impact platelet contraction, 
57,119 we varied the concentration of each to determine optimal conditions for 
subsequent experiments (Fig.2A). The final CaCl2 concentration was varied from 0 to 
10 mM in citrated whole blood samples and clotting was initiated by addition of 1 
U/ml thrombin. Exogenous Ca2+ was not required for clot formation and contraction to 
occur. However, when clots were formed in the absence of CaCl2, a portion of the 
incorporated RBCs were seen to fall out of clots in one-third of the samples (8 of 25) 
as contraction progressed and changes in clot size were tracked (Fig.S2). Addition of 2 
mM and 5 mM CaCl2 did not significantly impact the ability of the clot to contract but 
did stabilize clot structure and eliminate RBC fallout (Fig.2A;Table 1; Fig.S2). No 
escape of RBCs from the clot was visualized in the presence of CaCl2 at all thrombin 
concentrations. Addition of 0.5 U/ml of thrombin resulted in a significant decrease in 
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the average velocity, AUC and final extent of contraction compared to 1 U/ml 
thrombin (Fig.2B; Table 1). Thrombin concentrations at and below 0.5 U/ml resulted 
in RBC settling, which introduced delay and non-uniform spatial contraction. Based 
on these results, clot contraction was initiated with 2 mM CaCl2 and 1 U/ml thrombin 
in all subsequent experiments, unless otherwise noted. These conditions allowed for 
fast, uniform, and stable clot formation and contraction.  
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Figure 3-2 Kinetics of clot contraction in whole blood. Curves tracking changes in 
the size of contracting clots formed in citrated whole blood. (A) Samples were clotted 
with 1 U/ml thrombin in the presence of 0, 2, 5, and 10 mM CaCl2. (B) Samples were 
clotted with 0.5 or 1 U/ml of thrombin and 2 mM CaCl2. (C-F) Samples were clotted 
with 1 U/ml and 2 mM CaCl2. (C) Myosin IIA was inhibited through the addition of 
blebbistatin at 25, 50, 100, and 200 mM final concentrations. (D) Fibrin-platelet 
interactions were impaired by adding RGDS at 0.5, 1, and 2 mM final concentrations. 
(E, F) Crosslinking of fibrin was suppressed with (E) 1 mM iodoacetamide and (F) 
0.1, 0.5, 1.0, and 2.0 mM cystamine. 
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3.3.2 The role of platelet contractile proteins in clot contraction  
 Contraction has been shown to depend on the development of actin-myosin 
interactions. 5,66,120,121 To assess the contribution of nonmuscle myosin IIA in volume 
shrinkage within our system, we performed experiments in the presence of 
blebbistatin, a selective inhibitor of myosin II. 122 Addition of 25-200 mM blebbistatin 
resulted in a dose-dependent decrease in the extent and average velocity of contraction 
(Fig2.C; Table 1), which confirms that clot contraction is driven by platelet contractile 
proteins.  
 
 
Table 3-1 Overall quantitative characterization of blood clot contraction in 
different experimental conditions 
Compound added to 
whole blood 
Degree of 
contraction, % 
Lag time, 
sec. AUC, a.u. 
Average 
velocity, 
%/sec. (×10-3) 
Calcium chloride 
(n=25)     
   0 (control) 54±1 78±11 762±15 43±1 
   2 mM 53±1 76±9 772±9 42±1 
   5 mM 52±1 67±8 79±14 41±1 
   10 mM 49±2 * 65±9 797±15 39±1 * 
     
Thrombin (n=11)     
   0.5 U/ml 32±3 89±16 948±21 25±2 
   1 U/ml 50±2 *** 79±16 832±23 *** 40±1 *** 
     
Blebbistatin  (n=3)     
   0 (control) 40±2  155±28  890±25 33±2  
   25 µM 28±3 ** 165±22 994±21 * 23±2 ** 
   50 µM 25±2 *** 169±24 1054±41 *** 20±1 *** 
   100 µM 18±2 **** 185±50 1056±17 *** 15±2 **** 
   200 µM 15±1 **** 218±45 1088±9 **** 12±1 **** 
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RGDS peptide (n=8)     
   0 (control) 43±1 111±7 913±18 36±2 
   0.5 mM 24±2 *** 251±45 
1020 ±23 
*** 23±3 ** 
   1 mM 24±1 *** 332±55 * 1061±13 *** 21±3 *** 
   2 mM 22±1 *** 273±59 1067±12 *** 17±1 *** 
     
Iodoacetamide (n=5)     
   0 (control) 49±3 75±22 820±30 38±2 
   1 mM 33±1 ** 78±27 950±20 * 26±1 *** 
     
Cystamine (n=4)     
   0 (control) 53±3 71±22 793±66 43±3 
   0.1 mM 48±3 101±17 836±44 40±2 
   0.5 mM 43±3 139±28 909±29 35±2 
   1 mM 38±5 161±65 931±27 31±4 
   2 mM 36±5 * 124±62 960±20 28±4 * 
Mean ± SEM  
* P<0.05 when compared to control  
** P<0.01 when compared to control  
***P<0.001 when compared to control or 0.5 U/ml for thrombin 
****P<0.0001 
 
3.3.3 The role of platelet-fibrin interactions in clot contraction 
Platelet integrin αIIbβ3 has been shown to be important in development of clot 
tension in the presence of washed platelets and in PRP via its interaction with fibrin in 
vitro66,123-125 as well as in in vivo mice studies. 53 To test if the αIIbβ3-fibrin(ogen) or 
other integrin-mediated interactions affect the rate and extent of clot contraction, 
experiments were performed with increasing concentrations of RGDS peptide, 
inhibiting fibrin(ogen) binding. Addition of 0.5 mM RGDS peptide decreased the 
average velocity, AUC, and extent of clot contraction, likely by competitively 
blocking platelet-fibrin interactions mediated by αIIbβ3. Further increases in RGDS to 2 
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mM did not show a greater effect (Fig.2D; Table 1), suggesting that additional 
platelet-fibrin binding sites are also involved in clot contraction.  
3.3.4 	   The role of fibrin cross-linking in clot contraction  
To assess the role of fibrin cross-linking in clot contraction, iodoacetamide, an 
inhibitor of FXIIIa, was added to blood prior to CaCl2 and thrombin, which caused a 
significant decrease in the average velocity, AUC, and extent of clot contraction 
(Fig.2E; Table 1). To confirm the specific role of FXIIIa crosslinking, cystamine, 
another transglutaminase inhibitor that blocks FXIIIa activity as a competitive 
substrate, unlike iodoacetamide, which blocks FXIIIa activity by alkylation, was also 
used. Cystamine, like iodoacetamide, caused a dose-dependent decrease in the average 
velocity and extent of clot contraction (Fig.2F; Table 1). In addition to slowing the 
overall kinetics of contraction, both inhibitors of FXIIIa also affected the individual 
phases of the process as described (Table 2).  
 
Table 3-2 Characteristics of the three phases of clot contraction under different 
experimental conditions 
 Phase 1 Phase 2 Phase 3 
Compound or 
cells added  
% 
Contraction 
Decay Rate 
at t=50 sec 
%/s (x10-2) 
tt, 
sec. 
% 
Contraction 
k2, 
%/s (x10-
2) 
t2, 
sec. 
% 
Contraction 
Decay Rate 
at t=750 
sec 
%/s (×10-2) 
Effect of 
thrombin 
(n = 5) 
        
1 U/ml 6±0.7 4.2±0.7 98 10±1.0 6.7±0.5 278 35±2.8 1.4±0.1 
0.5 U/ml 6±1.0 3.2±0.7 103 2±0.3*** 5.2±0.6 144 25±1.0*** 1.2±0.3 
         
Blebbistatin  
(n=3)         
   0 (control) 4±0.8 2.2±0.8 90 10±1.7 5.9±1.0 270 28±0.7 1.0±0.08 
   25 µM 5±0.6 2.9±0.4 150 5±1.0** 3.3±0.7* 300 18±2.8** 0.8±0.1 
   50 µM 4±0.6 2.5±0.4 97 6±0.8* 2.9±0.4** 315 15±1.4*** 0.7±0.07* 
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   100 µM 5±1 3.1±0.6 120 2±0.2**** 1.7±0.2*** 225 12±1.6**** 0.5±0.06*** 
         
Effect of 
crosslinking         
Control (n = 5) 5±1.1 2.6±0.3 101 7±0.7 5.3±0.6 259 35±0.7 0.7±0.09 
Iodoacetamide 
(1 mM) (n = 5) 10±1.5
* 4.6±1.1 225 6±0.3 2.8±0.1** 458 18±1.6*** 0.7±0.1 
Cystamine (0.5 
mM) (n=4) 4±0.6
 2.3±0.6 105 14±3.0 4.0±0.8 450 19±5.0* 0.8±0.2 
Cystamine (2 
mM) 
(n = 4) 
10±2.8 5.3±1.2 307 15±3.0* 1.6±0.3** NA NA NA 
         
Platelets (n=4)         
<150 k/µl 2±0.5 1.2±0.4 NA NA NA NA NA NA 
250-300 k/µl 9±2.0
*** 
 5.7±1.8
** 357 NA NA NA 7±1.2 0.2±0.03 
>500 k/µl 17±1.8***,+ 10.5±1.4*** 357 NA NA NA 14±1.8+ 0.5±0.06++ 
         
Red Blood 
Cells 
(n >4) 
        
<10% NA NA NA 15±1.5 7.5±0.8 240 52±1.8 1.9±0.07 
15-20% NA NA NA 14±2.6 5.2±1.4 255 41±3.8** 1.4±0.07** 
30-40% NA NA NA 12±1.0 4.1±0.9* 232 43±0.5** 1.2±0.09** 
>40% NA NA NA 12±2.5 3.4±0.9* 285 34±1.0***,xxx 1.1±0.1** 
         
Mean ± SEM 
* or + P<0.05 when compared to control  
** or ++ P<0.01 when compared to control  
*** or +++ or xxx P<0.001 when compared to control, 250, 000-300,000/ul platelets or 
30-40% hematocrit, respectively  
**** or ++ P<0.0001 when compared to control  
NOTE: RGDS and 200 mM blebbistatin abrogated the presence of different phases  
 
 
3.3.5 Platelet count and fibrinogen levels have opposing effects on the extent of 
clot contraction  
Since platelets and fibrin interact during the process of clot contraction 
(Fig.1D), 126 we investigated the independent contribution of each. Isolated platelets 
were re-suspended in varying amounts of PFP, to maintain constant fibrinogen level. 
	  	  
35	  
At platelet counts below 150,000/µl, contraction was barely detectable (Fig.3A). When 
the platelet count was increased to 250,000-300,000/µl, total contraction increased 12-
fold relative to identical experiments performed at platelet counts <75,000/µl 
(Fig.3A,B). At platelet counts >500,000/µl, there was a 23-fold increase in the extent 
of contraction. To assess the role of fibrin(ogen) concentration, isolated platelets were 
re-suspended in buffer containing purified fibrinogen at concentrations varying from 
0.5 to 5 mg/ml, with the platelet-count kept constant (~400,000/µl). There was a 40% 
and 60% decrease in the extent of contraction at fibrinogen concentrations of 
2.5mg/ml and 5mg/ml, respectively, compared to concentrations below 1mg/ml 
(Fig.4A,B). Because crosslinking is needed to optimize clot contraction 
(Fig.2E,F;Table 1), it is important to note that fibrin in the reconstituted samples was 
cross-linked as shown by SDS-PAGE (Fig.S3). Collectively, this suggests that the 
ratio of platelets to fibrinogen plays a critical role in determining the extent of 
contraction.  
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Figure 3-3 Effects of platelet count on clot contraction and dynamic viscoelastic 
properties. Platelet-rich plasma (PRP) was diluted with autologous platelet-free 
plasma (PFP) to final platelet concentrations of <75,000/µl, 125,000-150,000/µl, 
250,000-300,000/µl, and >500,000/µl. Samples were incubated with 2 mM CaCl2 and 
1 U/ml thrombin. The plots show the effect of platelet count on: (A) the kinetics of 
clot contraction, (B) the final extent of contraction, and (C) the ratio of viscous to 
elastic components of the blood clot (tan δ = G΄΄/G΄)). * corresponds to P <0 .05, ** 
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corresponds to P <0.01, and *** corresponds to P <0.001. (C) Significance 
comparison for <75,000/µl and >500,000/µl. 	  	  	  
	  
Figure 3-4 Effect of fibrin(ogen) concentration on clot contraction. (A) The 
kinetics of clot contraction in washed platelets (~400,000/µl) re-suspended buffer 
containing purified fibrinogen at a final concentration of 0.5, 1.0, 2.5 and 5.0 mg/ml 
and clotted with 1 U/ml thrombin and 2 mM CaCl2. (B) The final extent of clot 
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contraction observed under conditions described in A at 1 hour. * corresponds to P <0 
.05, ** corresponds to P <0.01, and *** corresponds to P <0.001 
	  	  	  
3.3.6 Effect of RBCs on extent of clot contraction  
Since RBCs are embedded within the platelet-fibrin network (Fig.1E), we 
studied the effect of the volume fraction of RBCs (hematocrit) on contraction. RBCs 
were isolated and re-suspended in mixtures of PRP and PFP, thereby independently 
varying hematocrit while maintaining platelets and fibrinogen. Notable optical 
differences were observed upon addition of RBCs (Fig.5A). Freshly formed clots 
containing RBCs were more opaque than those without RBCs. The extent of clot 
contraction was inversely related to the fractional volume of RBCs, whereby 
hematocrits between 30-40% decreased the extent of contraction by about one-third 
compared to clots prepared in the presence of less than 10% hematocrit. Small 
perturbations in hematocrit (comparing 15-20%, 30-40%, and >40%) also resulted in 
significant differences in the extent of contraction (Fig.5B), indicating that RBCs 
comprise an important component of the contracting blood clot. ADP released from 
RBCs can potentially enhance platelet activation. Therefore, we assessed the possible 
effect of RBC-produced ADP on the contraction process. We found that inhibition of 
platelet ADP receptors did not affect any measured parameters of thrombin-induced 
contraction (Fig.S4) suggesting that the influence of RBCs on contraction is not 
biochemical.  
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Figure 3-5 Effects of RBCs on clot contraction and dynamic viscoelastic 
properties. RBCs were re-suspended in mixtures of PRP and autologous PFP to vary 
the volume fraction of RBCs from <10% to >40% while keeping a platelet count and 
fibrinogen concentration constant. (A) Images of the clots before (upper row) and after 
(bottom row) 30-minute contraction induced by thrombin and CaCl2. The plots show 
the effects of RBCs on: (B) the final extent of contraction at 30 minutes; (C) the 
kinetics of clot contraction; (D) the elastic properties of the contracting clot (storage 
modulus, G΄) and (E) the ratio of viscous to elastic properties (tan δ = G΄΄/G΄). * 
corresponds to P <0 .05, ** corresponds to P <0.01, and *** corresponds to P <0.001. 
(D) Storage modulus over time. 0% hematocrit is significantly different from <10%, 
15-20%, >40% hematocrit (P<0.001).  
 	  	  	  
3.3.7 Effects of platelets and RBCs on the mechanics of clot contraction 
 In vivo, clots and thrombi are exposed to shear forces generated by blood flow 
in the circulation. Through rheological studies performed in parallel we examined the 
viscous and elastic properties of clots. Elasticity is the ability of a clot return to its 
original shape following deformation while viscosity refers to irreversible deformation 
following application of force. Studies conducted on reconstituted samples prepared 
by varying platelets (at a constant fibrinogen level) and by varying RBCs (at constant 
platelet counts) revealed that addition of either platelets or RBCs induced a shift 
toward viscous properties of the clot (increase of tan δ) (Fig.3C;Fig.5E). While the 
shift toward viscous behavior with RBCs did not reach statistical significance, the 
presence of RBCs consistently decreased clot stiffness or elasticity (storage modulus 
(G′)) throughout the contraction process compared to samples lacking RBCs (Fig.5D).  
 To complement the optical tracking experiments, which measured the change 
in clot size, the rheometer measured the contractile force generated by the clot, with 
clot volume constrained. Addition of 200 µM blebbistatin resulted in an 8-fold 
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reduction of the contractile force, indicating that it was due almost exclusively to 
myosin-driven contraction (Fig.6A). The presence of RBCs caused a 60% increase in 
the contractile force compared to samples with the same concentration of platelets in 
the absence of RBCs (Fig.6B). To confirm these results, we compared clots formed in 
whole blood (~35-40% RBCs) and PRP (no RBCs) normalized based on the platelet 
count of each individual donor (n=10). The contractile force per platelet was over 2-
fold higher when RBCs were present compared to clots formed with platelets alone 
(Fig.6C).  
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Figure	  3-­‐6 Effect of RBCs on the generation of contractile force. (A) Whole blood 
samples were in incubated with 200 µM blebbistatin or vehicle control and the 
contractile stress generated by the platelet-fibrin meshwork was measured as normal 
(perpendicular) stress between the rheometer plates. (B) Samples were reconstituted to 
the same platelet concentration (~200,000/µl) in the absence or following the addition 
of RBCs to attain volume fraction of 40%. (C) The dynamics of contractile stresses 
generated by the clots formed in whole blood and PRP. Because the samples in B 
differ in platelet concentrations, the contractile stress generated in the whole blood and 
PRP clots was normalized to the platelet count obtained by a complete blood count, 
i.e. presented as normal stress per platelet. 
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3.3.8 The complex kinetics of clot contraction  
Three phases: Analysis of the instantaneous derivative of the curves describing 
clot contraction of whole blood over time (n=42) revealed that contraction involved 
three phases (Fig.1C). Analysis of how the different phases of clot contraction respond 
to specific perturbations in cellular and plasma components provides insight into their 
mechanistic origin. Under the conditions applied in this study, the time at which the 
first exponential phase transitioned to the linear phase (t1) occurred at 83±6 seconds 
and the time at which the linear phase transitioned to the second exponential phase (t2) 
occurred at 270±12 seconds. Similarly, changes in the first derivative of the curves 
describing the normal force (n=10) studied by rheometry also showed three distinct 
phases of contraction with insignificantly different critical points of change at 102±10 
seconds and at 226±14 seconds. 
Phase effects of thrombin and FXIIIa: Lowering exogenous thrombin from 1 
U/ml to 0.5 U/ml did not affect the initial rate or duration of the exponential decay 
phase of contraction; however, it did shorten the duration and slightly decrease the 
extent of contraction in phases 2 and 3 (Table 2; Fig.S5A). Blocking crosslinking with 
1 mM iodoacetamide decreased the rate of phase 2 and increased the overall time spent 
in the first two phases of contraction (Table 2). Similar effects were seen in the 
presence of 0.5 mM, where there was an increase in the duration of the first two 
phases and a slight, albeit not statistically significant, decrease in the rate of phase 2 
(Table 2). It is important to note that in the presence of 2 mM cystamine, the 
elongation of time spent in the first two phases of contraction was so pronounced that 
it extended beyond the measured 20 minutes. Similar to the effect of iodoacetamide, 
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the rate of phase 2 was decreased (Table 2). Collectively these results suggest that 
covalent crosslinking of fibrin is critical for the last stage of clot contraction to occur 
(Table 2; Fig.S5B).  
Blocking of myosin-driven contraction by blebbistatin resulted in a dose-
dependent decrease in the rate and extent of contraction in phases 2 and 3 (Table 2; 
Fig.S5C). In the presence of 200 mM blebbistatin, the rates were so slow that it was 
impossible to distinguish beyond a single exponential phase of contraction. This result 
affirms that the generation of myosin-driven contraction within phase 1 is critical for 
the progression of clot contraction into phases 2 and 3 (Table 2).  
Phase effects of platelets and RBCs: Without RBCs present, a linear region 
(phase 2) in the contraction curve was not observed, even at higher platelet counts. It is 
of interest that at platelet counts <150,000/µl, the behavior of the curve was best 
described by a single exponential decay, while at platelet counts above 250,000/µl, the 
curve was better described with two exponential decay curves, where the faster phase 
of contraction occurs in the first ~360 seconds after platelet activation followed by a 
slower phase. Increasing platelet concentration increased the rate and extent of 
contraction in samples with 250,000-300,000/µl and >500,000/µl platelets (Table 2). 
 In the reconstituted samples with increasing concentrations of RBCs, the 
instantaneous derivative revealed a transition point within the first 30 seconds of 
contraction. However, due to its short duration, it was not possible to determine 
conclusively if this period followed a linear or exponential decay. At hematocrits 
>40%, the linear phase of contraction was not only slightly lengthened, but the rate 
was decreased by more than half when compared to hematocrit <10% (Table 2). The 
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rate and extent of contraction in phase 3 was also decreased with increasing hematocrit 
(Table 2; Fig.S5E). This further points to the major contributions of RBCs to the 
multiphasic clot contraction process.  
	  	  
Figure	   3-­‐7	  Schematic of the phase dynamics of blood clot contraction. (A) The 
process of clot contraction results in the shrinkage of clot volume over time. This 
process can be roughly separated into three phases: Initiation of Contraction, Linear 
Contraction, and Mechanical Stabilization. (B) Various processes involving platelets, 
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fibrin, and/or RBCs impact the procession of clot contraction through the three phases. 
(C) Clot contraction is driven by a dynamic equilibrium between effects of the major 
blood components that can increase or decrease the extent of contraction.  
 
 
3.4 Discussion 
  
Clot contraction has been implicated as playing an essential role in hemostasis 
and the restoration of blood flow past otherwise obstructive thrombi. 54 Although many 
thrombotic and bleeding disorders, e.g. clotting factor and platelet function defects, 
can be diagnosed through end-point assays such as clot times88 and light transmission 
aggregometry127 respectively, it is quite likely that others are overlooked128 because 
they are best characterized by alterations in rate constants or because the defect 
involves platelet-fibrin interactions (e.g. platelet nonmuscle myosin IIa disorders) 
rather than impaired platelet secretion or platelet-platelet interactions. 129 There are 
also substantial differences between the avidity of activated platelets for fibrin vs. 
fibrinogen, and it is fibrin, but not fibrinogen, that promotes fibronectin assembly and 
expression of phosphatidylserine on the platelet surface, 130-132 which amplifies 
platelet-dependent generation of thrombin and fosters recruitment of additional 
platelets to sites of fibrin formation, among other differences. 133 Lastly, the 
contribution of RBCs and other components of whole blood to contraction cannot be 
assessed using bulk endpoint assays of plasma. 
The results of our study show that clot contraction is a dynamic process that is 
best described as following three kinetically discernable phases (Fig.7A): an initiation 
period (Phase 1), followed by “linear contraction” (Phase 2) and then clot stabilization 
(Phase 3). These phases also involve differences in requirements and contribution of 
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fibrinogen and cellular elements for optimization. Specifically, Phase 1 requires 
platelets and fibrinogen, Phase 2 requires the additional presence of RBCs, and Phase 
3 requires cross-linking of fibrin by factor XIIIa.  
It is clear from many studies that platelet contractile proteins and platelet-
fibrin(ogen) interactions are required for the overall process of contraction to occur. 
60,66,80 Here we see that these interactions are required for Phase 1 of clot contraction. 
Platelet counts >75,000/ul; platelet contractile proteins, as studied through inhibition 
of myosin IIa; and platelet-fibrin(ogen) interaction, as studied through addition of 
RGDS, are requisite to initiate clot contraction and for clot contraction to progress 
beyond Phase 1. Increasing the platelet count from <150,000/µl to >250,000/µl 
increased the rate of contraction 4.75-fold, while raising the platelet count to 
>500,000/µl increased the rate 8.75-fold (Table 2).  
What was not anticipated was the complex interaction between fibrinogen 
concentration, platelet count and hematocrit. Raising the fibrinogen concentration 
above 1 mg/mL impaired contraction of cross-linked clots, suggesting that the ratio of 
platelets/fibrin plays an important role, likely by providing sufficient local tension to 
reassemble fibrin-fibrin networks.  
Additional evidence for this interpretation comes from the finding that the 
extent of clot contraction is inversely related to the hematocrit, as is seen in Phase 2 
and, therefore, the probability of inclusion of RBCs in the fibrin network. RBCs are 
known to be prothrombotic134,135 and thromboembolism is a leading cause of death in 
some patients with elevated hematocrit, e.g. polycythemia vera. 91 The presence of 
RBCs is associated with larger thrombus volumes and increased fatality rates. 89 
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However, the mechanism by which RBCs are incorporated into a clot, their role in clot 
contraction, and lytic resistance are only beginning to be appreciated.67 
Our results reveal that RBCs primarily modulate Phase 2 of clot contraction 
(Table 2). Incorporation of RBCs into the clot appears to interfere with the biphasic 
contraction evident in PRP, which previously had been attributed to the two phases of 
non-muscle myosin IIa light chain phosphorylation seen in platelets. 136 Our analysis 
of Phase 2 suggests that RBCs within the clot confer resistance to contraction, which is 
more pronounced with increasing hematocrit and which leads to temporary reduction 
in platelet-driven contractile forces.  
It appears that progression into Phase 3 of contraction occurs when the 
contractile forces generated by platelets exceed the resistance of the RBCs, as shown 
by the exponential contraction. Linear contraction occurs independently of the driving 
force, whereas exponential contraction is proportional to the concentration of what 
drives contraction, in this case platelet-generated forces. Increasing the platelet count 
from 250,000-300,000/µl to >500,000/µl leads to a 2.5-fold increase in the rate and a 
2-fold increase in the extent of Phase 3 contraction, respectively (Table 2). The forces 
generated at higher platelet counts are thus able to overcome the resistance by RBCs, 
demonstrated by the reduction in extent and rate of Phase 3 of contraction at higher 
hematocrit (Table 2).  
One remarkable feature of Phase 3 is that clot stabilization is most reliant on 
fibrin crosslinking by FXIIIa (Table 2), in addition to the presence of platelet 
contractile proteins and platelet-fibrin interactions that are required for the earlier 
phases. FXIIIa translocates fibrin to sphingomyelin-rich rafts, a process required for 
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clot contraction to occur, 66 and increases the stiffness of the clot. 137 When FXIIIa 
crosslinking is blocked, the overall extent of contraction is reduced (Fig.2; Table 1) 
and the duration of times spent in Phases 1 and 2 is lengthened (Table 2), showing that 
FXIIIa, and clot stability is required for the progression into Phase 3 and maintenance 
of Phase 3 clot structure (Fig. 2; Table I), where the extent of contraction is greatest.  
Clot stabilization can be disrupted by the volume of RBCs, by competition 
with platelets for binding to fibrin, 138 or possibly by limiting the propagation of the 
contractile force through the fibrin network. In part, this can account for the reduced 
rate and extent of contraction in Phase 3 with increasing hematocrit.  
However, the reduction in Phase 3 contraction observed at higher hematocrits 
was counterbalanced by an increase in the generation of contractile force when platelet 
counts were kept constant or normalized (Fig.6B,C). It is unlikely that this can be 
attributed to ADP released from RBCs139, as inhibition of P2Y12 receptors did not 
affect the contraction process (Fig.S4).  Rather, it is known that single platelets 
mechanically sense the stiffness of the surrounding clot4,140 and generate differing 
contractile forces based on this property. 61 RBCs decrease the elastic component of 
the clot (Fig.5D) on a time scale similar to the onset of Phase 3 and might transiently 
increase the contractile force generated by platelets. Collectively, these results show 
that RBCs greatly impact the behavior of contracting clots mainly due to mechanical 
rather than biochemical influence. 
Both the addition of platelets and RBCs increase the viscous properties of the 
clot relative to their elastic behavior (Fig.3C, Fig.5E). Notwithstanding similar effects 
on the mechanical properties of the clot, additions of RBCs and platelets have 
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contradictory effects on the kinetics of the contraction process. This is probably 
because platelets, in addition to their viscoelastic properties, have active contractile 
machinery, while RBCs provide a passive viscoelastic filling of the fibrin meshwork 
while resisting contraction. 
In sum, our studies reveal that clot contraction is a dynamic multistep and 
multifactorial process. By tracking the kinetics of clot contraction, we are able to gain 
detailed information about how individual components of the blood affect each step in 
the process (Fig.7.b). We found that thrombin, high platelet counts, platelet-fibrin 
interactions, FXIIIa crosslinking and activation of platelet myosin enhance clot 
contraction, while high fibrinogen and hematocrit limit the extent of clot contraction. 
The balance of these forces determines the overall extent of contraction (Fig.7.c).  
Endogenous or acquired factors that impair the velocity, extent and stability of 
contraction might increase the propensity to hemorrhage, whereas rapid, but less 
extensive and more durable contraction might impair endogenous or therapeutic 
fibrinolysis. It is possible that RBC disorders associated with thrombosis (e.g. sickle 
cell disease and other hereditary hemolytic anemias accompanied by alterations in 
RBC mechanical properties) might enhance clot formation while reducing clot 
contraction. Studies can be performed to see if platelets from patients with essential 
thrombocytosis and thrombosis show enhanced propensity to cause clot contraction 
with impairment of fibrinolysis when compared to platelets from patients with reactive 
thrombocytosis, and whether patients with essential thrombocytosis who present with 
a bleeding phenotype show impaired clot contraction and rapid clot dissolution. A 
major limitation of coagulation tests based on clotting times is that more than 95% of 
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all thrombin generation occurs after the gel point. 141 Therefore, some of the major 
sequelae of thrombin generation, including the late phases of platelet activation and 
fibrin formation, and the process of clot contraction, are missing. Additional studies 
are needed to determine if quantification of clot contraction will provide a novel and 
clinically important assay that permits study of hemostatic and thrombotic disorders 
not revealed by contemporary approaches that are predicated on end-point clotting 
assays.  
3.5 Supplement  
	  
Figure 3-8 Schematic of rheometry and representative results. (A) Contracting 
blood clots are exposed to low oscillatory shear which results in the measurement of 
mechanical properties based on (B) the deformation of the sample. (C) This allows for 
the dynamic measurement of storage and loss moduli to characterize the time-
dependent changes of elastic and viscous properties of the clot, respectively. (D) The 
upper plate of the rheometer is equipped with a normal (perpendicular) force sensor. 
As the gap of the plates is constant it is possible to measure (E) the overall negative 
pulling of the contracting clot on the upper plate. (F) This results in output of a 
negative contractile force curve. 
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Figure 3-9 RBC fallout in the absence of calcium.  The top line shows 
representative images of the extent of contraction in a whole blood sample in the 
presence of 2 mM calcium ions after the addition of 1 U/ml thrombin for 0, 5, 10, 15, 
and 20 minutes. The bottom row shows the extent of clot contraction in the same 
whole blood sample in the absence of calcium ions after the addition of 1 U/ml 
thrombin. RBC fallout can be observed after 10 minutes of contraction only in the 
samples without addition of calcium ions. 
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Chapter 4 Characterization of mechanically deformed erythrocytes 
into polyhedrocytes 	  	  
This chapter complements the kinetics and mechanics of contracting blood clots 
described in the previous chapter through an examination of the structure of 
contracted blood clots, and particularly through the examination of deformed 
erythrocytes.  The compaction and deformation of erythrocytes occurs during the 
process of clot contraction. 	  	  
In collaboration with A. Mukitov, C. Nagaswami, R.I. Litvinov, J.W. Weisel 
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4.1 Introduction 	  Erythrocytes were commonly believed to be a passive bystanders in the 
processes involved in coagulation, but recent studies revealed that they actually play a 
more influential role. Erythrocytes have the ability to influence fibrin structure49,142 
and the viscoelastic properties of the clot. 49,143,144 In particular, the incorporation of 
erythrocytes into the clot volume has been shown to result in a reduced extent of clot 
contraction. 143 Clot contraction, or the volume shrinkage of the clot, results when 
activated platelets pull on the fibrin network. 54 This results in the compaction of 
erythrocytes to the core of the clots and platelets and fibrin toward the outside of the 
clot.  67 The erythrocytes in the core of the clot undergo a shape deformation from their 
native biconcave shape to that of a polyhedron, resulting in the terminology 
polyhedrocytes. 67 This shape is able to minimize the space between cells, due to more 
efficient packing, which helps to create an impermeable seal. 67  
 Erythrocytes are able to undergo dramatic changes in shape due to their highly 
deformable nature. 145 This combination of the viscosity of their cytoplasm, unique 
cytoskeleton and plasma membrane determines their viscoelastic properties. 146  
Erythocytes must change from their native biconcave shape to a bullet-like shape 
every time they squeeze through the microcirculation. This unique biconcave shape 
affords additional surface area that allows for easier shape changes without the need 
for an increase in surface area. 147 The spectrin cytoskeleton of the erythrocytes 
provide the mechanical properties need for the erythrocytes to deform under the 
application of force. 148 While the core of a contracted clot is filled largely with 
polyhedrocyte, deformed erythrocytes called intermediate forms and biconcave 
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erythrocytes can still be observed toward the edges of the clot. It has been suggested 
that the polyhedrocyte is an additional physical form of erythrocytes such as 
echinocytes, spheroechinocytes, ovalocytes, elliptocytes, and stomatocytes. 67  
 Polyhedra have been observed in nature149 and in non-biological materials150,151 
and it has been shown that some polyhedral shapes allow for the minimization of 
interface area between cells, 152 the minimization of potential energy in the system, 149 
and the stabilization of the membrane skeleton. 153 Importantly, polyhedrocytes have 
been observed in clots and thrombi obtained from human and murine samples. It is 
known that composition of the clot influences the extent of clot contraction, here; we 
examine the influence of clot composition on polyhedrocyte deformation. In addition, 
we use confocal microscopy to more thoroughly examine differences between 
biconcave erythrocytes and polyhedrocytes.  
4.2 Materials and Methods  
4.2.1 Sample preparation  Whole	   blood	   was	   collected	   in	   3.2%	   sodium	   citrate	   (9:1	   vol:vol)	   following	  informed	  consent	  in	  accordance	  with	  the	  guidelines	  set	  forth	  by	  the	  Institutional	  Review	  Board	  at	  the	  University	  of	  Pennsylvania.	  Whole	  blood	  was	  centrifuged	  at	  175	   g	   to	   obtain	   platelet	   rich	   plasma	   (PRP).	   PRP	  was	   centrifuged	   at	   >3000	   g	   to	  obtain	   platelet	   poor	   plasma	   (PPP).	   Whole	   blood	   was	   centrifuged	   at	   200	   g	   to	  obtain	   erythrocytes,	   which	   were	   washed	   in	   phosphate	   buffered	   saline	   three	  times.	  Whole	  blood	  or	  reconstituted	  samples	  were	  activated	  with	  2mM	  CaCl2	  and	  1U/ml	  thrombin	  unless	  otherwise	  noted.	  Samples	  were	  allowed	  to	  contract	  for	  30	  minutes	  prior	  to	  preparation	  for	  imaging.	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For confocal microscopy isolated erythrocytes were labeled with DiD according 
to the manufacture’s directions (Thermo Fischer, Waltham, Massachusettes) and 10 ul 
of labeled erythrocytes were mixed with 90 ul of unlabeled erythrocytes and 100 ul of 
platelet rich plasma. Clots were activated with 2mM CaCl2 and 1U/ml thrombin and 
transferred to an 8-well u-Slide (Ibidi, Martinsreid, Germany). Clots were allowed to 
contract for 30 minutes at 37C and then fixed with 2.5% glutaraldehyde. 
4.2.2 Transmission electron microscopy  
Contracted clots were fixed in 2% glutaraldehyde and then added to a 2% aqueous 
OsO4 solution with a 1:1 dilution. Samples were then dehydrated serially in 35, 50, 
70, 96, 96, 96% ethanol for 15 minutes and then added to propylene oxide two times. 
Samples were stores in a 1:1 PO/Epon resin overnight. Samples were sectioned using a 
ultramicrotom LKB-III and stained in uranyl acetate for 2 hours at room temperature, 
and then exposed to lead citrate for 10 minutes. Sections were imaged using a Jem-
1200 EX (Jeol, Japan). 
4.2.3 Scanning electron microscopy  
Reconstituted or whole blood contracted clots were fixed in 2.5% glutaraldehyde 
(final concentration) and then rinsed three times. Samples were dehydrated serially in 
30, 50, 70, 50, 90, 95% and three times in 100% ethanol. Then they were dried 
overnight in hexamethyldisilazane. Samples were sputter-coated with a thin layer of 
gold-palladium. Micrographs were obtained using an FEI Quanta250FEG scanning 
electron microscope (FEI, Hillsdale, Oregon) 
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4.2.4 Confocal Microscopy  Images	  of	  contracted	  clots	  were	  collected	  using	  a	  Zeiss	  LSM	  710	  or	  Leica	  SP8	  confocal	  microscope	  through	  excitation	  at	  633	  nm	  (LSM	  710)	  or	  638	  nm	  (SP8).	  	  Plan=Apochromat	  63x/1.4	  Oil	  DIC	  objective	  was	  used	  with	  a	  6-­‐10	  µs	  pixel	  dwell	  time	  and	  a	  voxel	  size	  of	  70x70x170	  nm.	  	  
4.2.5 Image analysis 
3-dimension reconstruction of confocal microscopy stacks of images was 
performed using Volocity (PerkinElmer, Waltham, Massachusettes) and Imaris 
(Bitplan, Zurich, Switzerland). All image analysis was conducted using Imaris 
software. Erythrocytes were reconstructed using the contour surface generation based 
on the fluorescence intensity of the cells. Erythrocytes were detected using the local 
contrast mode which applies a Gaussian filter to determine the intensity of each 
voxel. This allowed for information about cell size, volume, and shape to be obtained.  
4.2.6 Statistical Analysis 
All analysis was completed using Prism 6.0 (GraphPad). A one-way ANOVA with 
an alpha value of 0.05 was used to compare differences between biconcave, 
intermediate, and polyhedral erythrocytes. 	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4.3 Results  
	  
Figure 4-1 Influence of platelet count on polyhedrocyte formation. Reconstituted 
blood samples with platelet counts from 0 to 900,000 k/ul were activated with CaCla 
and thrombin allowed to contract and then imaged using scanning electron 
microscopy. Increased platelet count results in increased polyhedrocytes visible.  	  
4.3.1 Effect of clot composition on polyhedrocyte formation  
Clot contraction is differentially influenced by the cellular and molecular 
composition of the blood. As polyhedrocyte formation has been shown to result from 
contractile forces generated by platelets we hypothesized that clot composition could 
influence polyhedrocyte formation.  In was observed by scanning electron microscopy 
that polyhedrocytes become more pronounced with increasing platelet concentration 
(Figure 1) which corresponds to the increased extent of clot contraction that occurs 
with increased platelet counts. 143 In the absence of platelets and at low platelet counts, 
only biconcave erythrocytes were evident. At platelet counts of ~100,000 platelets/µl 
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intermediate forms became visible. Whereas, when platelet counts reached ~300,000 
platelets/ul and above polyhedrocytes were largely observed in the core of the clot. 
Thrombin concentration influenced the erythrocyte deformation where more 
intermediate forms were observed at lower thrombin concentrations while more 
polyhedrocytes were observed at higher thrombin concentrations (Figure 2). This 
corresponds to the increase in extent of clot contraction observed with higher thrombin 
concentrations. 143 In contrast increased volume fraction of erythrocytes, or hematocrit, 
results in a decreased extent of clot contraction. 143 Here, we see that while there is 
erythrocyte deformation and intermediate forms observed at all hematocrits there is 
more pronounced polyhedrocyte formation at lower hematocrit levels (Figure 3). This 
supports the idea that the extent of polyhedrocyte formation corresponds to the extent 
of clot contraction and provides the needs for a more thorough examination of the 
process of erythrocyte deformation.  	  
 
	  
Figure 4-2 Influence of thrombin concentration on polyhedrocyte formation. 
Higher thrombin levels (1U/ml) results in more pronounced deformation than lower 
thrombin levels (0.5U/ml). 	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Figure 4-3 Effect of hematocrit (volume fraction of erythrocytes) on the 
formation of polyhedrocytes. Reconstituted blood samples with varying volume 
fractions of erythrocytes revealed that lower hematocrit resulted in more pronounced 
polyhedrocyte formation whereas more intermediate forms were present in contracted 
clots with higher hematocrit.  
 
 
4.3.2 Analysis of polyhedrocytes  
Importantly, deformed erythrocytes including both intermediate forms and 
polyhedrocytes can be observed using transmission electron microscopy, scanning 
electron microscopy, and confocal microscopy (Figure 4). Transmission electron 
microscopy images give a cross-sectional view of the deformed erythrocytes compared 
to the biconcave cells (Figure 4) but the structural information is difficult to interpret 
in terms of three0dimensions. Similarly, while scanning electron microscopy images 
illustrate the deformation of the erythrocytes they can only provide information about 
several faces of each polyhedrocyte. In mathematics polyhedra are made up of several 
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polygonal faces. Since scanning electron microscopy images allow visualization of the 
faces of the polyhedrocytes we were able to assess the distribution of polygonal faces 
and determined the types and frequency. All of the polygons were triangle, 
quadrilateral, pentagon, or hexagon with the over 50% of the polygons being 
quadrilaterals (Figure 5). Confocal microscopy was used to visualize the 3-
dimensional structure of the polyhedrocytes and likewise the polygons that make up 
the polyhedrocytes were quantified. The distribution of polygons corresponded to what 
was observed with scanning electron microscopy (Figure 5), confirming that confocal 
microscopy could be used to visualize the deformation of erythrocytes. Importantly, 
where scanning electron microscopy is limited to 2-dimensional views of these cells, 
confocal microscopy allows for an examination of the whole structure of the 
polyhedrocytes. Through the use of 3-dimensional reconstruction we found that the 
polyhedrocytes were normally distributed and made up of 10-16 sides with a median 
of 13 sides (Figure 6, Table 1). The number of sides on a polyhedrocytes are normally 
distributed around the median as determined by a D’Agostino & Pearson normality 
test. Interestingly, there was no correlation between the total number of sides that 
made up the polyhedrocyte and the distribution of faces but there is a correlation 
between the relative percentages of the polygon faces (Table 1, Supplemental Table 
1). 
Through the detailed analysis of a single polyhedrocyte, which was made up of 14 
sides, we were able to calculate the edge length and angles for each polygonal face 
(Figure 7). Each polygonal face was a triangle, quadrilateral or pentagon. The spread 
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distribution of lengths and angles revealed that the polygons making up this 
polyhedrocyte were not congruent, equiangular, or equilateral.  
  
	  
Figure 4-4 Visualization of biconcave erythrocytes and polyhedrocytes. 
Transmission electron microscopy, scanning electron microscopy, and confocal were 
used to image biconcave erythrocytes and polyhedrocytes.  	  	  	  
	  	  
63	  
	  
Figure 4-5 Quantification of the polygon sides on polyhedrocytes. The polygon 
shapes were quantified for scanning electron micrscopy and confocal images of 
contracted blood clots. N>140 polygons for each imaging modality.   	  	  	  
Table 4-1  Polygonal faces vs total number of sides on polyhedrocytes 
Total 
Sides 
Polygonal Faces 
 Triangle  Quadrilateral  Pentagon Hexagon  
10 4 5 1 0 
10 3 6 1 0 
11 0 7 4 0 
12 2 9 1 0 
12 5 7 0 0 
12 3 6 3 0 
12 4 7 1 0 
13 2 8 3 0 
13 1 8 4 0 
13 1 9 3 0 
13 3 9 1 0 
13 2 8 3 0 
14 6 4 4 0 
14 10 4 0 0 
14 4 8 2 0 
15 7 7 1 0 
15 2 10 1 2 
16 5 10 1 0 
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4.3.3 Analysis of deformed erythrocytes  
While it is critical to assess the structure of the polyhedrocyte to better 
understand how the erythrocytes deform and pack into a tessellated network the 
application of mechanical deformation to the erythrocytes can result not only in the 
formation of polyhedrocytes but also the presence of intermediate and bioconcave 
forms based on their location within the contracted clot. To understand how the 
erythrocytes deform into polyhedrocyte we compared the volumetric changes in the 
cells, which was completed using 3-dimensional reconstructions of cells from 
contracted clots imaged with confocal microscopy. Erythrocytes were imaged from the 
edge of the clot into the core of the clot (~50µm in depth), which allowed for not only 
polyhedrocytes but also intermediate and biconcave erythrocytes to be assessed. Cells 
were separated into three categories: biconcave, intermediate, and polyhedrocytes. 
Biconcave cells were defined as being an oblate spheroid with two concave dimples. 
Polyhedrocytes were defined as cells where all faces of the cell were polygons. 
Intermediate forms were defined as having deviated from the biconcave shape but all 
faces could not be characterized by polygons, some faces were not flat and some edges 
were not straight. ~70% of the erythrocytes analyzed were intermediate forms. 
Interestingly, the surface area to volume ratio did not differ between cell categories 
(Figure 7A). The sphericity of the cells did not differ between cell categories (Figure 
7B). Intermediate and polyhedrocytes are both less oblate (Figure 7C) than biconcave 
erythrocytes and polyhedrocyes are more prolate than biconcave erythrocytes (Figure7 
D).   
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Figure 4-6 Distribution of polyhedrocytes by total number of sides. The total 
number of sides on individual polyhedrocytes were counted for confocal images on 
cells in contracted blood clots.  	  	  	  	  	  
	  
Figure 4-7	  Quantification of polygonal face length and angle. The edge length and 
angles were quantified for the 14 faces of a single poyhedrocyte using the Imaris 
measurement software.	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Figure 4-8 Analysis of volumetric properties of erythrocytes. 3-dimensional 
reconstructions of biconcave (n=12), intermediate (n=86) and polyhedral (n=22) 
erythrocytes from contracted whole blood clots were assessed for the surface area to 
volume ration, sphericity, and ellipticity. N>120. One way ANOVA with an alpha of 
0.05 was used to assess statistical significance,  ** corresponds to P <0.01. 	  	  	  
4.4 Discussion  
Following clot contraction the erythrocytes are compacted into the core of the 
clots67 and undergo a shape deformation from biconcave to intermediate and finally to 
polyhedral. The erythrocyte cytoskeleton allows the cell to undergo large deformations 
over a wide range forces. 154 We have found that the shape changes correspond the to 
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the extent of clot contraction that has previously been described with respect to 
varying the clot composition. Increased platelet count and high levels of thrombin 
result in an enhanced presence of polyhedrocytes while an increased hematocrit results 
in the presence of more intermediate forms.  
While these deformed erythrocytes can be observed through imaging in many 
different modalities such as transmission electron microscopy, scanning electron 
micrscopy and confocal microscopy the level of the detail that can be obtained from 
each varies. Polyhedrocytes can be defined as having polygons make up all of their 
faces. Importantly, using both scanning electron microscopy and confocal microscopy 
we were able to determine that the polygon distribution ranges from 3-6 sides with the 
majority of the faces being quadrilaterals. The total number of sides on the 
polyhedrocytes ranged from 10-16 with a median of 13 sides.  
The shape of the erythrocyte is highly important for the cell to be able to 
deform and fit through capillaries; if it were shaped as a sphere this would not be 
possible. 155,156 It is not surprising that the sphericity of the biconcave cells was much 
below 1; however, it is striking that the polyhedrocytes had a sphericity not different 
from the biconcave cells. While a sphere would have a sphericity of 1, uniform 
polyhedra have a sphericity of ~0.8. The oblate and prolate profile of the 
polyhedrocytes reveals that it takes on an ellipsoidal form. Importantly, it has been 
shown that red cells in other species with an ellipsoidal form are still able to bend and 
have a higher surface area than expected while still being able to maintain a low 
volume. 157-159 The presence of different polygonal faces reveals that the 
polyhedrocytes are non-uniform. The presence of a range of angles and lengths show 
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that the polyhedrocytes are also irregular, as they are not made up of congruent 
polygonal faces (Figure 7).  
The sphericity not changing between a biconcave erythrocyte and a 
polyhedrocyte is intriguing as it has been shown that erythrocytes before more 
spherical in shape and transitively less deformable in shape in diseased states. 160 It is 
also important that the surface area to volume ratio does not change between 
biconcave erythrocytes and polyhedrocytes as a decrease in surface area to volume 
ratio would imply that a decrease in the deformability of the erythrocytes160 occurred 
during the formation of the polyhedrocytes.  
 
4.5 Supplement  
Table 4-2 Correlation between total sides on polyhedron and polygon faces  
 Total Sides  Triangle  Quadrilateral Pentagon Hexagon  
Total Sides   0.246 -0.208 -0.137 0.036 
Triangle  0.247  -0.775** -0.642** -0.173 
Quadrilateral -0.208 -0.775**  0.0125 0.362 
Pentagon -0.137 -0.642** 0.012  -0.166 
Hexagon 0.036 -0.173 0.362 -0.166  **	  P<0.01	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Chapter 5 Interplay of Platelet Contractility and Elasticity of 
Fibrin/Erythrocytes in Blood Clot Retraction 	  	  
The combination of the experimental results obtained in Chapters 3 and 4 were used 
to study the effect of clot composition on clot contraction through a theoretical 
approach. Here we developed the active poro-viscoelastic mathematical model of 
contracting blood clots described in this chapter. The development of this model 
allowed for a more thorough examination of the role of cellular composition on the 
process of clot contraction and particularly on the influence of erythrocytes. 	  	  
This research was originally published in the Biophysical Journal. V. Tutwiler, H. 
Wang, R.I. Litvinov, J.W. Weisel, V.B. Shenoy. Interplay of platelet contractility and 
elasticity of fibrin/erythrocytes in blood clot retraction. Biophys J. 2017;112(4):714-
723.  
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5.1 Introduction 
The development of contractile forces by cells such as platelets, fibroblasts, 
endothelial cells, and smooth muscle cells is known to play important physiological 
roles in processes ranging from blood clot formation to wound healing to metastasis. 
The functionality and response of these contractile cells is often linked to their 
interaction with the surrounding matrix. 4,140 To quantitatively assess the interplay of a 
viscoelastic matrix with active contractile cells we have coupled analytical and 
numerical methods with in vitro experiments on whole blood clots (Fig. 1). 
Constrained and unconstrained contraction is followed through the use of optical 
tracking and rheometery for samples with and without red blood cells (RBCs), which 
allowed for the viscoelastic component of the clot to be varied while the active 
contractile cells were kept constant. These experimental samples informed the 
development of the model by separating the relative contribution of the viscoelastic 
matrix. The model predicts the extent of contraction, which can be tested 
experimentally through unconstrained clot contraction studies.   
 Whole blood clots are composed largely of platelets, fibrin, and RBCs.  
Platelets are contractile cells4 that are activated by various chemical stimuli, such as 
thrombin, 57,58 which results in the reorganization of the platelet cytoskeleton. 161 This 
reorganization is driven by the energy-dependent interaction of non-muscle myosin IIa 
with actin and is followed by the relocation of actin filaments to the filopodia on the 
periphery of the platelet. 161 In addition to activating platelets, thrombin converts 
fibrinogen to fibrin32,43,116,117 and activates factor XIII (FXIII → FXIIIa) that catalyzes 
crosslinking of fibrin. 32 Crosslinking results in the stabilization of the viscoelastic 
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fibrin network which has many fibers originating from platelet aggregates. 32,43,116,117 
The activated platelets are able to generate contractile forces that are propagated 
through the crosslinked fibrin fibers61,62 effectively resulting in the reduction of the 
clot volume. 53,54 The volume reduction of the clot, or clot contraction, has been 
implicated to play a critical role in hemostasis, 67 wound healing, and the restoration of 
blood flow past otherwise obstructive blood clots.5 
While much is known about the mechanical properties of the constitutive 
components of the clot, there is little known about the dynamics of their interactions. 
Single contractile cells such as platelets display a force-velocity relationship that is 
well characterized by the Hill equation due to the conservation of the kinetics of clot 
contraction across different cell types. 162-164 Fibrin is a non-linear viscoelastic material 
that can be modeling using a Kelvin-Voigt model. 165 It is possible to theoretically 
understand the origin of the macroscopic viscoelastic properties of the blood clot by 
modeling the biopolymer as a semiflexible polymer network. 44,166,167 The 
incorporation of RBCs in the blood clot volume disrupts the uniformity of the fibrin 
network, 49 affects the mechanical properties of the clot, 143 and influences the process 
of clot contraction. 143 RBCs are easily deformed153 and when subjected to 
compressive forces such as those generated by contracting platelets the RBCs become 
packed in the core of the blood clot and take on a polyhedral shape.67 
 Mathematical models have been used to assess the feedback effect that matrix 
stiffness has on the mechanics of active contractile cells168 and to describe 
morphological changes and mechanical responses in an active elastic material169,170. 
Due to the structural similarities between the previously described contracting micro-
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tissue and contracting blood clots, we chose to couple the basis of these 
aforementioned mathematical models with what is known about the individual 
components of clots to, for the first time, couple active contractile mechanics with a 
viscoelastic matrix (Fig. 1). The model developed is informed by experimental 
examination of contracting blood clots to elucidate additional information about the 
process of clot contraction. Extent of unconstrained clot contraction for clots with 
varying volume fractions of RBCs was used to independently validate the predictions 
of the model developed here.  
5.2 Materials and Methods 
 The objective of this study was to develop a mathematical model that can be 
used to elucidate information about the process of blood clot contraction. To obtain 
this object the experimental results on constrained and unconstrained clot contraction 
were used to inform the development of a model of active contractile cells interacting 
with a viscoelastic material (Fig. 1). Independently collected experimental results were 
used to validate the model.  
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Figure 5-1 Model development and comparison with experiments. (a) 
Experimental results and (b) a three-element mathematical model were combined to 
describe the process of clot contraction. (c) Independent experimental results were 
used to validate the predictive value of this model. 𝝈𝒔𝒕𝒂𝒍𝒍, 𝜼𝒂 denote the stall stress and 
the active viscosity of the platelets (active element).𝑲𝒇𝒑, 𝑲𝒓𝒑 denote the bulk modulus 
of compressed fibrin and RBCs (parallel element). 𝑲𝒇𝒔, 𝑲𝒓𝒔 denote the bulk modulus 
of compressed fibrin and RBCs (parallel element). All the material properties in the 3-
element model are fitted using the experimental data, where m represents the matured 
blood clot. 𝒕𝟎 corresponds to time of clot development. 	  	  	  	  
5.2.1 Human blood samples  
 Blood samples were obtained from healthy donors following informed consent 
in accordance with the University of Pennsylvania’s Institutional Review Board. All 
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procedures were carried out in accordance with the approved guidelines. Platelet rich 
plasma (PRP) and RBCs were obtained through centrifugation of whole citrated blood 
at 200g for 15 mins at room temperature. Then PRP was centrifuged at 3,000g for 10 
minutes at room temperature to obtain platelet free plasma (PFP).  RBCs were re-
suspended and washed three times in phosphate buffer saline (PBS), pH 7.4. To 
generate samples with and without RBCs the PRP, PFP, and RBCs were mixed to 
obtain constant platelet counts between parallel, donor-paired samples. Likewise, 
samples with varying volume fraction of RBCs were mixed to keep platelet counts 
constant. Reconstituted blood samples were clotted with 1U/ml thrombin after addition 
of 2 mM CaCl2 (final concentrations). 
5.2.2 Measuring kinetics of unconstrained clot contraction  
  Following initiation of clot formation, samples were added to a 12 x 7 x 1 mm 
plastic cuvette that was pre-lubricated with a thin coating of 4% Triton X-100 in PBS 
to prevent sticking to the cuvette and allowing clot contraction to be unconstrained. 
Sample clot size was then tracked using a Thrombodynamics Analyser System 
(HemaCore, Moscow, Russia) by accumulating digitized images based on the light 
scattering properties of the clot every 15 seconds for 20 minutes. 143  
5.2.3 Measuring contractile stress in constrained clot contraction   
  Clotting blood and reconstituted plasma samples were added to a rheometer 
with a 20-mm parallel plate (ARG2, TA Instruments) As the samples were allowed to 
polymerize across a constant 400-µm gap between the plates, it was possible to 
measure continuously the negative normal stress of the system. This negative normal 
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stress corresponded to the contractile force with which the constrained sample was 
pulling on the rheometer plate, trying to bring the two plates together. 
5.2.4 Statistical Analysis  
  Experimental samples were compared using a paired two-tailed student t-test 
with an alpha value of 0.05 on data collected after 20 minutes of contraction. All 
statistical analysis was completed using Prism GraphPad 6.0.  
 
5.3 Results  
5.3.1 Experimental Effects of RBCs on Clot Contraction 
 We studied the time course of clot contraction through two separate 
methodologies (Fig 2). By optically tracking the light scattering properties of the clot, 
the changes in clot size were followed during unconstrained (free to change volume) 
clot contraction. This experiment revealed that the addition of RBCs lessened the 
degree of clot contraction (Fig. 2c). Complementary studies were conducted using a 
rheometer, which allowed for the clot size to be constrained (constant volume) and the 
generation of contractile stress to be tracked over time. In this instance it was seen that 
the presence of the RBCs increased the contractile stress generated within the clot 
(Fig. 2f).  
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Figure 5-2 Unconstrained and constrained clot contraction. (a) Unconstrained clot 
contraction was tracked optically to measure (b) the change in clot size over time for 
(c) paired reconstituted plasma samples without RBCs (blue) and with RBCs (red). (d) 
Constrained clot contraction was assessed using a rheometer (e) and following the 
generation of the negative normal stress for (f) paired reconstituted plasma samples 
without RBCs (blue) and with RBCs (red). Data are shown as mean ± SEM at 20 
minutes post activation. Statistical significance was determined using paired Student’s 
t-tests with an alpha value of 0.05. 	  	  
5.3.2 Model Development  
	   Relation of model to contracting clots - Structurally, blood clots are a 
collection of platelets, fibrin, and RBCs (Fig. 3a) with distinct areas showing fibrin 
and RBCs in association with platelets and areas where they are spatially separated 
from platelets (Fig. 3a) To better understand how the structure and distribution of 
components of the clot, particularly the incorporation of RBCs, affect the process of 
clot contraction and the increase of contractile force, we developed a three-element 
model consisting of two passive viscoelastic elements and an active contractile 
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element (Fig. 3), based on the known components of blood clots and our experimental 
observations (Fig. 2). The stiffness of the blood clot, which is influenced by both fibrin 
and RBCs, is expected to have passive components that act in parallel (Fig. 3c) and in 
series (Fig. 3c) to the active contractile element (representing the contractility of 
platelets). In the full model, an additional series element, accounting for platelet 
stiffness, platelet-platelet contact stiffness and aligned fibrin network between 
platelets, is in series with the active contractile element (Supplemental Fig. 7). 
However, the presence of this additional element does not influence the process of clot 
contraction due to the fact that platelets have a much high elastic modulus than fibrin.  
4,117,165 As such, the model can be simplified by removing this element (details in 
Supplemental methods G).  
The initial position and the position following initiation of contraction or 
deformation (at time t) are given by 𝑿  and 𝒙   = 𝒙(𝑿, 𝑡) , respectively. The total 
deformation gradient is expressed as	  𝑭 = 𝜕𝒙/𝜕𝑿.	   The deformation gradient of the 
blood clot or the total strain (𝑭) is multiplicatively decomposed into the stress of the 
platelet-RBC-fibrin element and RBC-fibrin element that is in series169,170	  𝑭 = 𝑭𝒔𝑭𝒂,𝑭𝒑 = 𝑭𝒂,                                                                                                                                                                                                                  (1)	  
where the subscripts a, p, and s are used to denote the contributions from platelet 
activity, parallel passive elasticity, and series passive elasticity. Note that the parallel 
RBC-fibrin element deforms in parallel with the active platelet element (Fig. 3), so 
their deformation gradients are the same. 
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Figure 5-3 An active viscoelastic three-element model for clot contraction. The 
model was developed from (a) scanning electron microscopy images of whole blood 
clots and (b) each component of the clot was incorporated into the model. In (a) and 
(b), platelets are gray (i), fibrin is brown (ii), and RBCs are red (iii). The 3-D model 
developed consists of three elements and is represented here in 1-D (c.i): an active 
contractile element made of platelets, passive (c.ii) parallel and (c.iii) series elements 
made up of fibrin and RBCs. σa is the stress of the active elements,  ηa is the 
viscoelastic coefficient,  t0 is the fibrin network formation time,   Kfp,rp,fs,rs  is the bulk 
modulus where p represents the parallel element and s represents the series element, r 
corresponds to RBCs and f corresponds to fibrin. 	  	  	  
Properties of constitutive components - The total stress is the sum of the stress 
from the parallel RBC-fibrin and contractile platelet components, 169,170  
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𝝈 = 𝝈𝒂(𝑭𝒂)+ 𝝈𝒑(𝑭𝒑) = 𝝈𝒔(𝑭𝒔)                                                                                                                                                               2  
Note that the stress in the series RBC-fibrin element is same as the total stress (Fig. 3). 
The constitutive laws for each mechanical component are considered to relate the 
stress at any material point to deformation.  
We use the neo-Hookean hyperelastic stress-strain relations to model the 
passive strain-hardening response of the series and parallel elements. 
𝝈𝒑 = 𝐾! ln   𝐽!𝐽! 𝑰+ 𝐺!  dev   𝑩𝒑𝐽!!/! ,                                                                                                                                                (3) 
𝝈𝒔 = 𝐾! ln   𝐽!𝐽! 𝑰+ 𝐺!  dev   𝑩𝒔𝐽!!/! ,                                             
where 𝐽 = det 𝑭 , 𝑩 = 𝑭𝑭𝑻 are the Jacobian representing the relative volume change 
and the left Cauchy Green deformation tensor, respectively, and K and G are the initial 
bulk and shear moduli, respectively.  
 Recent experiments show that contractile cells, such as fibroblasts, subjected 
to uniaxial loading have an active stress vs. strain-rate response that obeys the classic 
Hill relation. 164,171 Contraction in platelets also involves myosin-actin interactions like 
other contractile cells.  172 According to the Hill relation, the rate of contraction is 
largest in the absence of any applied stress, monotonically decreases with increasing 
applied stress, and eventually vanishes when the applied stress reaches the stall stress. 
171 Therefore, in our 3D large-deformation analysis, we assume that the rate of active 
deformation, 𝑫𝒂 depends on the active stress, 𝝈𝒂 (18), 𝑫𝒂 = !! 𝑭𝒂𝑭𝒂!𝟏 + (𝑭𝒂𝑭𝒂!𝟏)! = !!! 𝝈𝒂 − !!"#$$!!!/! 𝑰 ,                                                                          (4)  
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Where 𝐽 = det 𝑭  is  the Jacobian that represents the relative volume change, 𝜂! is the 
active viscosity, and 𝜎!"#$$ is the stall stress, which we assume to be isotropic. The 
active viscosity of the blood clot has the same mathematical form as that of a 
viscoelastic material, but arises from the Hill relation (which postulates that 
contraction rate linearly decreases with stress) of platelet contraction not the 
viscoelasticity of fibrin networks. 
 While fibrin and RBCs are viscoelastic in nature they are modeled as elastic 
materials due to the elastic nature of their mechanical response at low levels of strain 
rate (Supplemental methods H).  As fibrin is shown to behave as a semi-flexible 
polymer166,167 it is possible to determine the theoretical bulk and shear moduli for 
fibrin alone (Supplemental methods B), which are in agreement with reported 
experimental mechanical properties of fibrin 62,173. This can transitively be used to 
determine the development of the fibrin network. 165 As the propagation of the platelet-
generated contractile force through the volume of the clot is highly dependent on the 
presence of fibrin, it is reasonable to assume that the time scale onset is similar for 
both fibrin network formation and clot contraction (Supplemental methods B).  
 Active and poroelastic limits - As clot contraction results in the expulsion of 
serum from the volume of the blood clot, it was critical to determine whether the 
dynamics of clot contraction are due to the activation limit associated with active 
contraction of a viscoelastic material or the diffusion limit associated with a 
poroelastic material. Therefore, we developed the active-poroelastic model to consider 
the expulsion of serum from the blood clot (Supplement Methods A; Supplemental 
Fig. 1). The extent of unconstrained contraction was found to be independent of size as 
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not significant differences occurred over a range of volumes (Fig. 4), which showed 
that the clot for the current characteristic size was active viscoelastic rather than 
poroelastic. This can be captured with the three-element model we use here 
(Supplemental Methods D; Fig. 4).  As the sample size is comparable to the intrinsic 
material length scale, (𝑘𝜂!/𝜂!"#)!/!, then viscoelasticity and poroelasticity must be 
considered simultaneously. The clot contraction dynamics is governed by the 
viscoelasticity of the clot for smaller volumes, whereas larger clot volumes are better 
described by the poroelastic limit. The visco-poroelastic model can also describe the 
polymeric gels by accounting for both solvent migration and viscoelastic 
deformation174.  Macroscopic biological 175 and semi-interpenetrating network gels 176 
have a relatively long viscoelastic relaxation time compared to that needed for solvent 
migration through a relatively long distance, which can be predicted by a poroelastic 
model. 
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Figure 5-4 Clots undergoing unconstrained contraction behave as an active 
viscoelastic material, not a poroelastic material. (a) Unconstrained clot contraction 
for volumes ranging from 10 to 100ml revealed no difference in relative clot size at the 
measured time points. The statistical significance was assessed using a repeated 
measure ANOVA. Computational comparison of the (b) activation time and (c) 
poroelastic diffusion time revealed that clot contraction is not a result of poroelastic 
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diffusion due to the length scale of the diffusion. The relative volume ratio of blood 
clot, 𝐽, is a function of the scaled radius, 𝑎/𝑅, and scaled time, 𝑡/𝑡! , using the 
spherically symmetric model for the activation limit (b) and the poroelastic limit (c). 
Here 𝑅 and 𝑎 denote the radial distance from the center and the initial radius of the 
clot, respectively. 
	  	  	  	  
Contraction dynamics - The constitutive equations (equations 1-4), the 
equilibrium condition (𝝏𝝈𝒊𝒋/𝝏𝒙𝒋 = 𝟎) , the initial stress-free condition, and the 
unconstrained or constrained boundary conditions constitute a well-posed initial value 
problem (Supplement methods A). The boundary conditions used here allow the shear 
modulus to be removed from equation 3, as shear deformation does not play a role in 
blood clots that are not under fluid flow.  Since the time progression of the stress and 
deformation gradients is homogeneous and isotropic, the constitutive equations can be 
simplified as (Supplemental methods E) 𝜎 = 𝜎! + 𝜎! = 𝜎!,𝐽 = 𝐽!𝐽! ,                                                                                                                                                                                                  (5) 
𝜎! = 𝜎!"#$$𝐽!!/! + 𝜂!3𝐽! 𝑑𝐽!𝑑𝑡 , 𝜎! = 𝐾! ln 𝐽!𝐽! , 𝜎! = 𝐾! ln  (𝐽!)𝐽! ,                                           
The active contractile stress (𝜎!) generated by the platelets is balanced with the 
tension of the series element (𝜎!) and the compression of the parallel element (𝜎!). 
The total stress (𝜎) is the same as the tension of the series element (𝜎!) (Fig. 3). Note 
that the mechanical properties of contracting blood clots are dependent on time 
(Supplemental methods E),  
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𝐾!𝐾!! = 𝐾!𝐾!! = 𝜂!𝜂!! = 𝜎!"#$$𝑆!! 1− 𝑒! !!! ! = 1− 𝑒!
!!! ! ,                                                                                    (6) 
where 𝐾!!  and 𝐾!!   are the bulk moduli of the parallel and series elements, 
respectively; 𝑆!!  and 𝜂!!  are the stall stress and viscosity of platelets for clot, 
respectively; 𝑡! corresponds to time of clot development.  The stiffness of the fibrin 
network is time-dependent during network formation or maturation. The superscript 
‘m’ denotes the variables for the matured fibrin network. 
 
Unconstrained clot contraction - In unconstrained blood clot contraction, as 
studied through optical tracking, the net applied stress at all times points is equal to 0 
and does not depend on the series element (Eq. 2). As such the boundary conditions 
for this homogenous and isotropic deformation is σ t = 0. This allows for elucidation 
of the parameters affecting the parallel element.  
𝐽!/! 1− 𝑒! !!! ! + 13 𝜂!!𝑆!! 𝑑𝐽!𝑑𝑡 + 𝐾!!𝑆!! ln 𝐽 = 0                                                                                                        (7) 
where 𝐾!!/𝑆!!, 𝜂!!/𝑆!!, and 𝑡! can be determined by fitting the computed degree of 
contraction (𝐽!/!) over time to the experimental results (Supplement methods E). For 𝑡 ≫ 𝑡!, the scaled equilibrium Jacobian can be derived from Supplemental equation 25  𝐾!!𝑆!! ln 𝐽 + 𝐽!/! = 0.                                                                                                                                                                              (8) 
We find that the relative clot size , 𝐽!/!, increases with increasing scaled parallel 
stiffness,   𝐾!!/𝑆!!. 
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 Constrained clot contraction - To assess constrained contraction, as studied 
with a rheometer, the clot volume is constant while the contractile stress changes over 
time. Since the parameters describing the parallel element were determined through 
the fitting of unconstrained clot contraction, constrained contraction can be used to 
determine the parameters affecting the series element.  𝜎𝑆!! 11− 𝑒! !!! !   = 1𝐽!!/! 1− 𝑒! !!!
! + 13𝐽! 𝜂!!𝑆!! 𝑑𝐽!𝑑𝑡 + 𝐾!!𝑆!! ln  (𝐽!)𝐽!
= −𝐾!!𝑆!! ln 𝐽! 𝐽!      (9) 
where 𝑆!! and 𝐾!!/𝑆!! can be determined by fitting computed total stress (𝜎) vs time (𝑡) curves to actual experimental results (Supplement methods E). 
For 𝑡 ≫ 𝑡!, the scaled equilibrium stress can be derived from Eq 9, 𝜎𝑆!! = 1𝐽!!/! + 𝐾!!𝑆!! ln  (𝐽!)𝐽! = −𝐾!!𝑆!! ln 𝐽! 𝐽!                                                                                            (10) 
We find that the scaled equilibrium stress, 𝜎/𝑆!!, decreases with increasing scaled 
parallel stiffness,     𝐾!!/𝑆!! , and increases with increasing scaled series stiffness, 𝐾!!/𝑆!!. 
 
  Linear analysis - The key features of the unconstrained and constrained clot 
contraction observed in our experiments can be understood quantitatively through the 
use of linear analysis on equilibrium clots (𝑡 ≫ 𝑡!).  The volumetric strain  𝜀! = 𝐽 −1 ≪ 1 for small deformation, the equilibrium volumetric strain, 𝜀!, for unconstrained 
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contraction and equilibrium total stress, 𝜎 , for constrained contraction can be 
simplified from equations 6 and 7, respectively.   
𝜀! = − 𝑆!!𝐾!! , 𝜎𝑆!! = 11+ 𝐾!!𝐾!! ,                                                                                                                      (11) 
The equilibrium volumetric strain,  𝜀!, increases with parallel stiffness,  𝐾!!, which is 
consistent with the experimental result that the addition of RBCs lessened the degree 
of clot contraction (Fig. 2 & 5). The equilibrium total stress, 𝜎 , increases with 
decreasing parallel stiffness,  𝐾!!, or increasing series stiffness, 𝐾!!. As the increase of 
series stiffness is more significant than that of parallel stiffness, the presence of RBCs 
increased the generation of contractile stress within the clot. The equilibrium degree of 
contraction and total stress for finite deformation can be numerically solved from 
equations 7 and 9 as 𝑡 ≫ 𝑡!, which show the same trend as linear analysis.	  	  
5.3.3 Comparison with Time Course Experimental Data  
 To assess the validity of the model developed we compared the experimental 
curves with curves obtained through the linear analysis (Supplemental Methods F). 
Similar concentrations and mechanical properties of the components of the clot were 
used in the experiments and the model (Supplemental Table 1). By tracking the change 
in clot size over time, we were able to quantify the dynamics of unconstrained clot 
contraction and found that the presence of RBCs results in a reduced extent of clot 
contraction. Comparison between the experimental data and the data generated by our 
three-element model reveals that they are in close agreement (Fig. 5).  
The contractile stress generated by the platelets is measured using a precise 
rheometer. When the clot polymerizes, it is adherent to the upper and lower plates of 
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the rheometer, thus allowing measurement of the negative normal stress during 
constrained contraction. As the clot volume is constant, it is possible to track the force 
with which the platelets are contracting. In the presence of RBCs, the platelet-fibrin 
meshwork generates larger contractile forces when compared to platelets and fibrin 
alone. Comparison of the experimental data and that obtained through our model 
reveals contraction following similar trends (Fig. 5). Extension of the duration of 
constrained contraction revealed that while samples in the absence of RBCs reached a 
stall stress at ~25 minutes while the presence of RBCs lengthened this time to stall 
stress to ~40 minutes (Supplemental Fig. 5). 
 
	  
Figure 5-5 Comparison of experimental and modeled clot contraction. (a) 
Unconstrained clot contraction was tracked for 20 minutes by recording the change in 
clot size. Contraction was followed for reconstituted samples with platelets and fibrin 
alone (blue) and with the addition of RBCs (red).  Likewise, unconstrained contraction 
was calculated using the three-element model taking into account the presence (gray) 
and absence (black) of RBCs. (b) Constrained clot contraction was tracked for 20 
minutes by recording the generation of contractile force (negative) using a high 
precision rheometer. Contraction was followed for reconstituted samples with platelets 
and fibrin alone (blue) and with the addition of RBCs (red).  Constrained contraction 
was calculated using the three-element model taking into account the presence (gray) 
and absence (black) of RBCs.  
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5.3.4 Model Verification  	   To	   verify	   the	   model	   developed,	   we	   collected	   independent	   experimental	  data	  with	  a	  range	  of	  volume	  fractions	  of	  RBCs	  (<10%,	  15-­‐20%,	  30-­‐40%,	  >40%).	  Experimental	  results	  showed	  that	  extent	  of	  clot	  contraction	  varied	  inversely	  with	  volume	   fraction	   of	   RBCs	   (Fig.	   6).	  We	   compared	   the	   experimental	   extent	   of	   clot	  contraction	  with	   the	  extent	  of	   clot	   contraction	   that	  was	  predicted	  by	   the	  model	  with	  200,000/µl	  platelets,	  2.5mg/ml	   fibrinogen	  and	  varying	  volume	  fractions	  of	  RBCs	   (Fig.	   6).	   The	   predicted	   values	   are	   within	   the	   standard	   deviation	   of	   the	  experimental	  data	  for	  the	  tested	  ranges	  of	  volume	  fraction	  of	  RBCs,	  showing	  that	  the	  model	   is	   in	   close	   agreement	  with	   experimental	   results	   and	   can	   be	   used	   to	  predict	  how	  changes	  in	  clot	  composition	  affect	  clot	  contraction.	  	  	  
	  
Figure 5-6 Validation of clot contraction model. Unconstrained clot contraction was 
tracked optically for 20 minutes at varying volume fractions of RBCs: <10%, 15-20%, 
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30-40%, and >40% (represented as bars). Data are shown as a mean±SD. The model 
developed was used to predict the extent of clot contraction at 20 minutes for 
200,000/ml platelets, 2.5mg/ml fibrinogen, and varying volume fractions of RBCs. 
The predicted extent of clot contraction for volume fractions ranging from 0% RBCs 
to 60% RBCs is represented at the solid red line.   	  	  	  
5.4 Discussion  
Our study of clot contraction has revealed that the presence of RBCs in the clot 
volume results in an increase in the magnitude of contractile force generated by the 
platelet-fibrin meshwork while reducing the overall extent of contraction. Clot 
contraction has been shown to be important for the restoration of blood flow past 
otherwise obstructive thrombi. 5 It is known that mortality after a thrombotic event can 
be correlated with the composition of the thrombus and the presence of RBCs in the 
clot volume. 89 The examination of how the presence of RBCs affects the compaction 
of a thrombus, and consequently the blood flow past the thrombus, has the potential to 
guide future therapeutic applications and clinical implications in patients with 
pathological conditions associated with increased (polycythemia) or reduced (anemia, 
hemodilution) RBC count in the blood.  
 By studying the combination of unconstrained and constrained clot 
contraction, we have developed a macroscopic three-element model that couples active 
contractile cells with a passive viscoelastic matrix. Due to the conservation of 
contractile machinery between varying cell types, this novel model has implications 
far beyond blood clot contraction and can inform a variety of fields where active 
contractile cells are resisted by and interacting with a viscoelastic matrix. For example 
during wound healing, contractile myofibroblasts interact with a fibrous extracellular 
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matrix, but it is known that there are endothelial, epithelial, and inflammatory cells 
present in the wound bed. 177,178 As our model revealed that the presence of cells in the 
viscoelastic matrix influences the active contraction of cells, it would suggest that 
proportion and type of cells that are present in the wound bed could affect the 
contraction of myofibroblasts.  
Contractile cells such as fibroblasts, myoblasts and platelets have been shown 
to individually generate contractile forces ranging from 0.1-300nN/cell. 4,164,179,180 The 
accumulation of force generated by these individual active contractile cells results in 
the macroscopic contraction of the matrix. While it is known that cells can sense and 
respond differently based on the stiffness of the surrounding matrix, 4,181 our results 
reveal that the composition and distribution of the matrix can influence the force and 
extent of macroscopic contraction.  
  Lam et al.  4 previously showed in single cell studies that platelets are able to 
generate forces from 1.5 to 79 nN per cell, with the average cell generating forces of 
20 nN. In data generated by our experiments and the three-element model, we found 
that platelets are able to generate contractile stresses of 175 and 300Pa in the absence 
and presence of RBCs, respectively. Based on an average platelet count of 200,000/µl, 
it was found that individual cells were generating forces of ~51nN/platelet in the 
absence of RBCs and ~88nN/platelet in the presence of RBCs. Likewise, Lam et al. 
saw that platelets generate greater contractile force varies with increased substrate 
stiffness4. Since RBCs are known to alter fibrin structure and hence matrix stiffness 49, 
it is not surprising that the addition of RBCs has the potential to influence the extent 
and force of clot contraction.  
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  Our combination of an active contractile component with a passive viscoelastic 
material reveals that the active component is not only affected by the stiffness of the 
viscoelastic matrix as modulated through the addition of RBCs but also by the 
distribution of the RBCs within the passive elements (equation 4). The RBC influence 
on the parallel stiffness results in a compressive resistance and transitively a reduced 
degree of contraction (Fig. 7d) while the influence on the series stiffness results in 
tensile resistance to contraction, which influences the stall stress and results in an 
increased contractile force generated by the platelet-fibrin network (Fig. 7e).  
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Figure 5-7 Effect of RBCs on clot contraction. (a) As time progresses, platelet 
activation and the development of the fibrin network occur simultaneously. (b) The 
contractile force generated and propagated through the platelet-fibrin meshwork is 
affected by the presence of RBCs (c), which will ultimately become compacted due to 
the contractile force, resulting in the volumetric shrinkage of the clot. Linear static 
analysis reveals that (d) the larger the parallel stiffness, which is due to more blood 
cells, results in compressive resistance and a reduced degree of clot contraction. (e) A 
larger series stiffness, induced by the presence of more cells, results in a tensile 
resistance, disruption of the stall stress, and consequently a larger normal force.  
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The validation of the three-element model developed with varying volume 
fractions of RBCs (Fig. 6) shows that our model can be used to predict how changes in 
the composition and spatial non-uniformity of a blood clot influences the process of 
clot contraction. Through the combination of experimental results and the model 
developed, we are able to distinguish between and develop equations for both 
constrained and unstrained clot contraction.  
This validated model lays the groundwork needed for an examination of in vivo 
blood clot contraction where portions of the clot are constrained through attachment to 
the vessel wall and other portions are unconstrained; this model provides vital 
information about differences in clot contraction based on the structure of in vivo 
blood clots. While others have modeled fluid flow over of blood clots, 182 they have 
not accounted for active contraction of the blood clots. By modifying the boundary 
conditions of our model we will be able to expand to examine contracting blood clots 
under shear forces such as those that would occur in vivo.  
   Collectively, our results reveal that clot contraction dynamics are dominated by 
the active contraction of platelets interacting with a viscoelastic material and not by 
the poroelastic nature of fibrin. The addition of RBCs to the matrix results in an 
increase in the series and parallel stiffness and changes in the tensile and compressive 
resistance and the applied contractile force, showing that the presence of RBCs can 
influence the process of clot contraction. By analyzing the time evolution of 
volumetric contraction and contractile stress of the unconstrained and constrained 
clots, we have developed a validated model of active contractile cells interacting with 
a passive viscoelastic material. In the future, we hope to integrate this model with 
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methods to calculate fluid shear stresses acting on the surface of the clot to analyze 
the stability of blood clots in the presence of flow.  
 
5.5 Supplement  
5.5.1 3D active-poroelastic Model 
To quantitatively analyze the dynamics of contracting blood clots, we designed an 
active-poroelastic model that consists of two passive elastic elements to represent the 
elasticity of the fibrin network and the RBCs, an active contractile element, and a 
porous element, as shown in Supplemental Fig. 1. The stiffness of the blood clot, 
including the fibrin network and erythrocytes, is expected to have components that act 
in series and in parallel to the active contractile element (representing the contractility 
of platelets). The porous element, which accounts for the contribution due to expulsion 
of the plasma, is added in parallel with the other elements. With position vectors to a 
material point in the reference and current configurations (at time t) given by 𝑿 and 𝒙   = 𝒙(𝑿, 𝑡) , respectively, the total deformation gradient tensor is expressed as 𝑭 = 𝜕𝒙/𝜕𝑿. A reference state is assigned when the clot is stress-free and the solvent 
(plasma) in the clot is in equilibrium with the pure liquid solvent. In the reference 
state, the clot is undeformed (𝑭 = 1), the chemical potential of plasma in the gel is set 
to be zero (𝜇 = 0), and the concentration of plasma is denoted by 𝐶!. The deformation 
gradient of the blood clot (𝑭) is multiplicatively decomposed into active contractile 
(𝑭𝒂) and series passive components (𝑭𝒔),169 𝑭 = 𝑭𝒔𝑭𝒂, 𝑭𝒑 = 𝑭𝒂, 𝑭𝒔𝒐𝒍 = 𝑭,                                                                                                                                                                                  (1)  
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where the subscripts a, p, s, and sol are used to denote the contributions from platelet 
activity, parallel passive elasticity, series passive elasticity, and the contribution from 
plasma, respectively. Note that the parallel element deforms in parallel with the active 
element, and the porous element deforms in parallel with the other elements, so their 
deformation gradients are the same. 
The total stress at a material point is the sum of the stress from the parallel 
passive, contractile, and porous components,  𝝈 = 𝝈𝒂 + 𝝈𝒑 + 𝝈𝒔𝒐𝒍,     𝝈𝒔 = 𝝈𝒂 + 𝝈𝒑.                                                                                                                                                                                                                                 2  
Note that the stress in the series passive element is the sum of the contractile stress and 
the parallel passive element. The constitutive laws for each mechanical component are 
considered to relate the stress at any material point to deformation.  
We use the neo-Hookean hyperelastic stress-strain relations to describe the 
passive strain-hardening response of the parallel and series elements, 
𝝈𝒑 = 𝐾! ln   𝐽!𝐽! 𝑰+ 𝐺!  dev   𝑩𝒑𝐽!!/! ,                                                                                                                                                          (3) 
𝝈𝒔 = 𝐾! ln   𝐽!𝐽! 𝑰+ 𝐺!  dev   𝑩𝒔𝐽!!/! ,                                                                                                                                                         
where 𝐽 = det 𝑭 , 𝑩 = 𝑭𝑭𝑻 are the Jacobian representing the relative volume change 
and the left Cauchy Green deformation tensor, respectively, and K and G are the initial 
bulk and shear moduli, respectively.  
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Recent experiments on fibroblasts164 subject to uniaxial loading have shown 
that their active stress vs. strain-rate response obeys the classic Hill relation171. 
Therefore, in our 3D large-deformation analysis, we assume that the rate of active 
deformation, 𝑫𝒂 depends on the active stress, 𝝈𝒂, 
𝑫𝒂 = 12 𝑭𝒂𝑭𝒂!𝟏 + (𝑭𝒂𝑭𝒂!𝟏)! = 1𝜂! 𝝈𝒂 − 𝜎!𝐽!!/! 𝑰 ,                                                              (4) 
where 𝜂! is the active viscosity, and 𝜎! is the stall stress, which we assume to be 
isotropic. 
Since biological materials satisfy the criterion of molecular incompressibility 
183 (i.e. any change in the volume of the clot is due to the flow of plasma), the stress 
and relative change in plasma volume can be expressed as 
𝝈𝒔𝒐𝒍 = − 𝜇Ω 𝑰,                                                                                                                                                                                                              (5) 𝐽!"# = 1+ 𝐶 − 𝐶! Ω, 
where 𝜇 is chemical potential of the plasma, and 𝛺 is its molar volume.  𝑰 is identify 
tensor and 𝐶 and 𝐶! are the current and reference plasma concentrations, respectively. 
Since the clot is always in a state of mechanical equilibrium, we have 𝜕𝝈𝒊𝒋𝜕𝒙𝒋 = 0  .                                                                                                                                                                                                                            (6) 
As the platelets contract, the clot moves to a different state of mechanical 
equilibrium, in which the gel deforms and the plasma in the clot will no longer be in 
chemical equilibrium with the surroundings. Therefore, the gradient of the chemical 
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potential of plasma, drives flow in the clots: 𝑱 = −𝑘∇𝜇/𝜂!"#Ω!. The conservation of 
mass dictates 𝜕𝐶𝜕𝑡 = −∇ ∙ 𝑱 = 𝑘𝜂!"#Ω! ∇!𝜇,                                                                                                                                                                (7) 
where k is the permeability of the clot, 𝜂!"# is the viscosity of the solvent (plasma), 
respectively. 
Initial conditions 
The initial clot is in the reference state, 𝝈 𝑿, 0 = 0,              𝜇 𝑿, 0 = 0.                                                                                                                                                                          (8) 
Boundary condition for unconstrained contraction 
The clot surface is always traction-free and in equilibrium with the surrounding fluid,   𝝈 𝑿, 𝑡 = 0, 𝜇 𝑿, 𝑡 = 0.                                                                                                                                                                      (9) 
Boundary condition for constrained contraction 
Since the lateral size (20mm) of the blood clot is much larger than the thickness 
(400µμm) and the volume is kept unchanged, we assume that all the surfaces are fixed 
in the constrained contractions by ignoring the boundary effects. Therefore, the clot 
surface is fixed and in equilibrium with the surrounding fluid, 
𝒙 𝑿, 𝑡 = 𝑿, 𝐽 = − 𝑘𝜂!"#Ω! ∇𝜇 𝑿, 𝑡 = 0                                                                                                        (10) 	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5.5.2 Mechanical properties of forming blood clots  
Recent experimental and computational study shows that the mechanical rigidity 
increases as fibrin network forms or matures, and the time-dependent stiffness can be 
described by this relation 165,  
𝐾!𝐾!! = 𝐺!𝐺!! = 𝐾!𝐾!! = 𝐺!𝐺!! = 𝜒 𝑡 = 1− 𝑒! !!! ! ,                                                                                (11) 
where 𝐾!!  and 𝐺!!  is the bulk and shear modulus of the clotted parallel element, 
respectively, and  𝐾!! and 𝐺!! is the bulk and shear modulus of the clotted series 
element, respectively.   𝜒 𝑡  is the time-dependent relative concentration of fibrin 
network. 𝑡! is the characteristic time for the formation of fibrin network, which can be 
estimated as 500 sec for 3 mg/ml fibrinogen 165. Similar to the stiffness of the fibrin 
network in Supplemental equation 11, the stall stress and viscosity of platelets are 
proportional to the concentration of fibrin network, 𝜎!"#$$𝜎!! = 𝜂!𝜂!! = 𝜒 𝑡 ,                                                                                                                                                                                                                          (12) 
where 𝜎!! and 𝜂!! are the stall stress and viscosity of platelets for matured platelets, 
respectively. 
The recent experiments show the attachment and spreading of adherent cells on 
microplates take 100-200 sec 4,164. We further consider the time-dependent formation 
of stall stress in platelets, which follows the formation of the fibrin network. For 
simplicity, we assume that the ratio of the current and maximum levels of stall stress 
has the same function with that of fibrin network formation, 
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𝜎!! = 𝑆!!    1− 𝑒! !!! ! ,                                                                                                                                                                                                            (13) 
where 𝑆!! is the maximum stall stress of activated platelets. Note that we assume that 𝑡! = 𝑡! since the attachment and spreading time of adherent cells (100-200 sec) has 
the same order as the formation time of fibrin network (about 500 sec). 
5.5.3 Spherically symmetrical active-poroelastic model  
For simplicity, we assume the clot is spherical in shape and that the distribution of 
fibrin network, the platelets and erythrocytes are spherically symmetric. The 
mechanical and chemical states of the clot are characterized by the radial and hoop 
stresses, (𝜎!,  𝜎!), the concentration,  𝐶, and the chemical potential,  𝜇. The deformation 
of the clot is then described by the radial displacement field, 𝑢(𝑅, 𝑡), which depends 
on the radial distance from the center of the clot in the initial configuration, 𝑅  and 
time, 𝑡.  The spherically symmetrical deformation gradients can be expressed as  
𝑭 = 𝑭𝒘 = 𝜆! 0 00 𝜆! 00 0 𝜆!
= 1+ 𝜕𝑢/𝜕𝑅 0 00 1+ 𝑢/𝑅 00 0 1+ 𝑢/𝑅 ,                                                      (14) 
𝑭𝒂 = 𝑭𝒑 = 𝜆!! 0 00 𝜆!! 00 0 𝜆!! , 𝑭𝒔 =
𝜆!! 0 00 𝜆!! 00 0 𝜆!! ,  
where 𝜆! 𝑅, 𝑡 , 𝜆! 𝑅, 𝑡  are the radial and hoop stretches, respectively. 
Substituting Supplemental equation 14 into Supplemental equation 1, the geometrical 
relations can be rewritten as 
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𝜆! = 1+ 𝜕𝑢𝜕𝑅 = 𝜆!!𝜆!! ,𝜆! = 1+ 𝑢𝑅 = 𝜆!!𝜆!! .                                                                                                                                (15) 
Substituting Supplemental equation 14 into Supplemental equations 2-5, we get the 
radial and hoop stress,    
𝜎! = 𝐾! ln   𝐽!𝐽! + 2𝐺!3𝐽!!/! (𝜆!!)! − (𝜆!! )!− 𝜇Ω   ,                                                                                                                                        (16) 
𝜎! = 𝐾! ln   𝐽!𝐽! +  !3𝐽!!/! (𝜆!! )! − (𝜆!!)! − 𝜇Ω, 
𝐾! ln   𝐽!𝐽! + 2𝐺!3𝐽!!/! 𝜆!! ! − 𝜆!! !
= 𝜎!𝐽!!/! + 𝜂! 1𝜆!! 𝜕𝜆!!𝜕𝑡 + 𝐾! ln   𝐽!𝐽! + 2𝐺!3𝐽!!/! 𝜆!! ! − 𝜆!! ! , 
𝐾! ln   𝐽!𝐽! + 𝐺3𝐽!!/! (𝜆!! )! − (𝜆!!)!
= 𝜎!𝐽!!/! + 𝜂! 1𝜆!! 𝜕𝜆!!𝜕𝑡 + 𝐾! ln   𝐽!𝐽! + 𝐺!3𝐽!!/! 𝜆!! ! − 𝜆!! ! , 
where 𝐽! = 𝜆!!(𝜆!!)! , 𝐽! = 𝜆!!(𝜆!! )! , and 𝐽 = 1+ 𝜕𝑢/𝜕𝑅 1+ 𝑢/𝑅 !  are the 
Jacobians representing the relative volume change. 
Combining equations. 6, 7, and 14, we can get further the spherically symmetric force 
balance and plasma diffusion, 𝜕𝜎!𝜕𝑟 + 2𝑟 𝜎! − 𝜎! = 0,                                                                                                                                                                                                                (17) 
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𝜕𝜕𝑡 𝐽 = 𝑘𝜂!"# 1𝑟! 𝜕𝜕𝑟 𝑟! 𝜕𝜕𝑟 𝜇Ω   ,     
where  𝑟(𝑅, 𝑡) = 𝑅 + 𝑢(𝑅, 𝑡) is the radial distance from the center of the clot in the 
current configuration. 
Initial conditions 
The initial clot is in the reference state, 𝜎! 𝑅, 𝑡 = 0, 𝜎! 𝑅, 𝑡 = 0, 𝜇 𝑅, 0 = 0.                                                                                                                    (18) 
Boundary conditions for unconstrained contraction 
If the initial radius of the clot is denoted by 𝑎, the clot surface is always traction-free 
and in equilibrium with the surrounding fluid, 
𝑢 0, 𝑡 = 0, 𝐽 0, 𝑡 = − 𝑘𝜂!"#Ω! 𝜕𝜕𝑟 𝜇 0, 𝑡 = 0,                                                                                                      (19) 𝜎! 𝑎, 𝑡 = 0, 𝜇 𝑎, 𝑡 = 0. 
Boundary conditions for constrained contraction 
The clot surface is fixed and in equilibrium with the surrounding fluid, 
𝑢 0, 𝑡 = 0, 𝐽 0, 𝑡 = − 𝑘𝜂!"#Ω! 𝜕𝜕𝑟 𝜇 0, 𝑡 = 0                                                                                                      (20) 𝑢 𝑎, 𝑡 = 0, 𝜇 𝑎, 𝑡 = 0 𝜎! 𝑟, 𝑡 ,𝜎! 𝑟, 𝑡 ,𝑢 𝑟, 𝑡 , 𝜇 𝑟, 𝑡  can be solved numerically from these partial 
differential Supplemental equations (Supplemental equations 15-17) with initial 
condition (Supplemental equation 18) and boundary condition (Supplemental equation 
19 or 20) using Mathematica software. 
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5.5.4 Poroelastic and active limits 
Now we consider two limits for the spherically symmetrical active-poroelastic 
model: poroelastic limit (𝜂!"#𝑎!/𝜂!𝑘 ≫ 1) and active limit (𝜂!"#𝑎!/𝜂!𝑘 ≪ 1), shown 
in Supplemental Fig. 2.  
By fitting the computed degree of contraction vs time curves (Fig. 3 in main text) 
to actual experimental results, we are able to quantify all of the parameters in our 
constitutive model under these two limits. The details of the fitting method can be 
found in section E.  
We estimated these parameters: the minimum dimension sample size 𝑎 = 1𝑚𝑚, 
the viscosity of plasma (mostly water up to 95% by volume) at room temperature 𝜂!"# = 1.002  𝑚𝑃𝑎. 𝑠 , the permeability 𝑘 = 120×10!𝜇𝑚!   for fibrinogen with a 
concentration of 3mg/ml (1), the active viscosity of these samples 𝜂! = 22.5𝑘𝑃𝑎. 𝑠 
(the estimation details are in section E). The scaled characteristic size can be estimated 
as 𝜂!"#𝑎!/𝑘𝜂! = 4×10!!, which indicates the activation limit is dominant in the 
dynamics of contraction for the current sample size. Both the poroelastic and active 
viscoelastic models fit the unconstrained experimental data well (Supplemental Fig. 
3). However, the experiments show that there is no size effect on the unconstrained 
contraction of a blood clot (Fig. 2 in main text), which is consistent with the activation 
limit. The permeability of fibrin is dependent on fibrinogen concentration (or 
deformation), which may result in a transition to the poroelastic limit. Now we 
estimate the effective fibrinogen concentration of the contracted clot based on the 
initial fibrinogen concentration and maximum volumetric change. The permeability of 
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fibrin is 𝑘 = 7×10!𝜇𝑚!  (1). The scaled characteristic size can be estimated as 7×10!!, which indicates the dynamics of contraction for the current sample size is in 
the activation limit. 
5.5.5 Contraction dynamics of maturing blood clot for activation limit 
For the activation limit ( 𝜂!"#𝑎!/𝑘𝜂! ≪ 1 ), the active-poroelastic model 
(Supplemental Fig. 1) is the same as the three-element model in the main text (Fig. 3c 
in the main text), and the stress and deformation relations in these elements, 
Supplemental equations 1-2, are rewritten 
as𝑭 = 𝑭𝒔𝑭𝒂 = 𝑭𝒔𝑭𝒑,                                                                                                                                                                                                                   21  𝝈 = 𝝈𝒂 𝑭𝒂 + 𝝈𝒑 𝑭𝒑 = 𝝈𝒔 𝑭𝒔 . 
The constitutive equations (Supplemental equations 3, 4, 21), the equilibrium 
condition (Supplemental equation 6), the initial conditions (Supplemental equation 8) 
and the boundary conditions (Supplemental equations 9 or 10) constitute a well-posed 
initial value problem. Since the solution is homogeneous and isotropic, the stresses 
and deformation gradients can be expressed as 𝜎 𝑡 𝑰, 𝜎!(𝑡)𝑰, 𝜎!(𝑡)𝑰, 𝜎!(𝑡)𝑰, 𝜆 𝑡 𝑰, 𝜆!(𝑡)𝑰, 𝜆!(𝑡)𝑰, and 𝜆!(𝑡)𝑰.  
Therefore, the governing equations (Supplemental equations 3, 4, 6, 21) can be 
rewritten by using the time-dependent mechanical properties (Supplemental equations 
11-13),  𝜎 = 𝜎! + 𝜎! = 𝜎!, 𝐽 = 𝐽!𝐽! ,                                                                                                                                                                  (22) 
𝜎! = 𝑆!!𝐽!!/! 1− 𝑒! !!! ! + 𝜂!!3𝐽! 𝑑𝐽!𝑑𝑡 1− 𝑒! !!! !, 
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𝜎! = 𝐾!! 1− 𝑒! !!! ! ln 𝐽!𝐽! , 𝜎! = 𝐾!! 1− 𝑒! !!! ! ln  (𝐽!)𝐽! , 
where 𝐽 = 𝜆!, 𝐽! = 𝜆!! ,  𝐽! = 𝜆!! are the Jacobians representing the relative volume 
change. 
The initial condition (Supplemental equation 8) for homogenous and isotropic 
deformation can rewritten as 𝐽 0 = 1.                                                                                                                                                                                                                                      (23) 
Unconstrained contraction 
The boundary condition (Supplemental equations 9) for homogenous and 
isotropic deformation can be rewritten as 𝜎 𝑡 = 0.                                                                                                                                                                                                                                          (24) 
Therefore, the governing equations (Supplemental equation 22) can be 
expressed as 
𝐽!/! 1− 𝑒! !!! ! + 13 𝜂!!𝑆!! 𝑑𝐽!𝑑𝑡 + 𝐾!!𝑆!! ln 𝐽 = 0,                                                                                                      (25) 
 
where 𝐾!!/𝑆!!, 𝜂!!/𝑆!!, and 𝑡! can be determined by fitting the computed clot size , 𝐽!/! vs time (𝑡) curves to actual experimental results, shown in Fig. 5a in the main 
text. 
For 𝑡 ≫ 𝑡! , the scaled equilibrium Jacobian can be derived from Supplemental 
equation 25  𝐾!!𝑆!! ln 𝐽 + 𝐽!/! = 0.                                                                                                                                                                                                      (26) 
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We find that the relative clot size , 𝐽!/!, increases with increasing scaled parallel 
stiffness,   𝐾!!/𝑆!!, shown in Fig 5a.  
For small deformation, the volumetric strain  𝜀! = 𝐽 − 1 ≪ 1 can be simplified 
using Supplemental equation 26, 
𝜀! = − 𝑆!!𝐾!!                                                                                                                                                                                                                                             (27) 
Constrained contraction 
The boundary condition (Supplemental equation 9) for homogenous and 
isotropic deformation can be rewritten as 𝐽 𝑡 = 1                                                                                                                                                                                                                                                          (28) 
Therefore, the governing equations (Supplemental equation 22) can be 
expressed as 
!!!! !!!!! !!! !   = !!!!/! 1− 𝑒! !!! ! + !!!! !!!!!! !!!!" + !!!!!! !"  (!!)!! = − !!!!!! ln 𝐽! 𝐽!          (29)                                      
 
where 𝑆!! and 𝐾!!/𝑆!! can be determined by fitting the computed total stress (𝜎), vs 
time (𝑡) curves to actual experimental results, shown in Fig. 5b in the main text. 
For 𝑡 ≫ 𝑡!, the scaled equilibrium stress can be derived from Supplemental 
equation 29, 𝜎𝑆!! = 1𝐽!!/! + 𝐾!!𝑆!! ln  (𝐽!)𝐽! = −𝐾!!𝑆!! ln 𝐽! 𝐽!                                                                                                    (30) 
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We find that the scaled equilibrium stress, 𝜎/𝑆!!, decreases with increasing 
scaled parallel stiffness,   𝐾!!/𝑆!!, and increases with increasing scaled series stiffness, 𝐾!!/𝑆!!, shown in Fig 5b. 
For small deformation 𝜀! = 𝐽 − 1 ≪ 1, the total stress  𝜎 can simplified using 
Supplemental equation 30.  
𝜎 = 𝑆!!1+ 𝐾!!𝐾!!                                                                                                                                                                                                         (31)   
5.5.6  Fitting curves using a random search algorithm 
We assume that  𝑆!!, 𝜂!!, 𝑡!,𝐾!!(0),  𝐾!!(40%),𝐾!!(0), 𝐾!! 40%  are the same 
for different samples under constrained and unconstrained contraction, where 0 and 40% are the concentrations of red blood cells. By fitting the computed degree of 
contraction and contractile stress vs time curves (Fig. 3 main text) to actual 
experimental results using a random search algorithm184, we are able to quantify all of 
the parameters in our constitutive model in Supplemental Table 1. For each group of 
parameters, the simulation curves were generated and compared with the experimental 
data. The optimized parameters were obtained by minimizing the sum of squared 
residuals (defined as the difference between the experimental and simulation data).   
5.5.7 The active viscoelastic model with active-series element 
The model was simplified to focus on the underlying physics; however, the full 
model can be found below.   The fibrin network is either under tension due to the 
contraction of platelets (iii or iv), or compression to balance the contractile force 
generated by the platelets (ii). The stretched fibrin (i and iii) is either directly 
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connected to platelets (iv), or located between the small bundles (which consist of 
platelets and compressed fibrin) (iii), which can be modeled by an active-series 
element and series element, respectively. Note that the mechanical response of the 
active element (i) is the same as that of a dashpot, as it arises from the Hill relation for 
the platelet. All the passive elements (ii, iii, iv) are generally viscoelastic and solvent 
migration (v) is also considered in the full model.  
The governing equations for this full model (Supplemental equation 22) can be 
written as, 
 𝜎 = 𝜎! + 𝜎! = 𝜎!" + 𝜎! = 𝜎!, 𝐽 = 𝐽!𝐽! = 𝐽!𝐽!"𝐽! ,                                                                                        (32) 𝜎! = 𝑆!!𝐽!!/! 1− 𝑒! !!! ! + 𝜂!!3𝐽! 𝑑𝐽!𝑑𝑡 1− 𝑒! !!! !, 𝜎!" = 𝐾!"! 1− 𝑒! !!! ! ln 𝐽!"𝐽!"  𝜎! = 𝐾!! 1− 𝑒! !!! ! ln 𝐽!𝐽! , 𝜎! = 𝐾!! 1− 𝑒! !!! ! ln  (𝐽!)𝐽! , 
Here the subscript 𝑠𝑎 denotes the active-series element. 𝐾!"!,  𝐽!", and 𝜎!" represent the 
bulk modulus, stress, and Jacobian of the active-series element. 
For unconstrained contraction: 𝐽!!! 1− 𝑒! !!! ! + 13 𝜂!!𝑆!! 𝑑𝐽!𝑑𝑡 + 𝐾!!𝑆!! 𝐽!𝐽 ln 𝐽 = 0                                                                                                          (33) ln 𝐽 = 𝐾!"!𝐾!! + 𝐾!"!𝐽! ln(𝐽!) 𝐽! 
 
For constrained contraction: 𝜎𝑆!! 11− 𝑒! !!! !   = 1𝐽!!/! 1− 𝑒! !!!
! + 13𝐽! 𝜂!!𝑆!! 𝑑𝐽!𝑑𝑡 + 𝐾!!𝑆!! ln 𝐽!𝐽!
= −𝐾!!𝑆!! ln 𝐽! 𝐽!                                                                                                        (34) 
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𝐾!! ln 𝐽! + 𝐾!"! ln 𝐽!/𝐽! 𝐽! = −𝐾!!ln  (𝐽!)(𝐽!)! 
 
There is no significant difference between for the simulation results using the 
full model and the simplified model for both unconstrained and constrained 
contraction. Here the fitted bulk modulus of active series element  is  𝐾!"! = 16𝑆!! =7.2𝑘𝑃𝑎. This conclusion is consistent with the fact that the elastic modulus of platelets 
is ~10kPa (2), which is much higher than that of the fibrin network, which has an 
elastic modulus below 1kPa (3, 4). Therefore, we can further simplify the full model to 
the 3-element model by assuming that the active-series stiffness is infinite. 
Furthermore, if there is no series element (iii) in our model, the normal stress will be 
same for the constrained clot with or without the RBCs (Supplemental Fig. 6). From 
both the electron microscopy image (Supplemental Fig. 7a) and experimental 
measurement (Supplemental Fig. 8), we can conclude that the active-series element is 
not necessary while the fibrin-RBC series element should be included.  
5.5.8  Viscoelasticity of fibrin and RBCs 
Fibrin only behaves in a viscoelastic manner at high strain rates but remains 
elastic at low strain rates due to the fact that the loss modulus of fibrin, 𝐺!!, is 
dependent on the strain rate while the storage modulus,  𝐺!, is not. For the oscillation 
tests completed by Kim et al117, the frequency used is 𝑓 = 0.5− 10𝐻𝑧 and strain 
amplitude is 𝜀 = 0.005− 0.03, so the strain rate is estimated as 𝜀 = 4𝜀𝑓 = 0.01−0.12𝑠!!. The strain rate for free contraction in our manuscript can be estimated as 𝜀 = 0.8/3/1000 = 0.0004𝑠!! based on an area change of 0.8 and time scale of 
1000s. The strain rate for our experiments is much smaller than that of the oscillation 
tests completed by Kim et al117, as such it is reasonable to treat fibrin as an elastic 
	  	  
109	  
material. In the oscillation tests by van Kempen et al165, the loss modulus is at least 2 
orders smaller than 𝐺! for the frequency of 1-3Hz and the amplitude 0.01 (strain rate 
0.04 to 0.12𝑠!!).  This is again consistent with the conclusion that 𝐺!! is negligible 
compared to 𝐺! for the low strain rate used in our manuscript, confirming that fibrin 
will behave as an elastic material rather than a viscoelastic one.  
The viscosity of blood, 𝜇! ,  at room temperature can be estimated at 10 times 
that of water, around 10.02  𝑚𝑃𝑎. This allows for the viscous stress on RBCS to be 
calculated as 𝜎! = 𝜇!𝜀 = 1.002×10!!  𝑃𝑎 based on the strain rate in our experiments 𝜀 = 0.0004𝑠!!. The elastic stress contribution of fibrin network is 𝜎! = 𝐾𝜀 = 0.4−40𝑃𝑎, where 𝐾 = 1− 100𝑃𝑎 is the stiffness range of fibrin network and 𝜀 = 0.4 is 
the strain amplitude in our experiment. The RBCs and fibrin networks are in parallel in 
our model, thus we can directly compare the viscous stress on RBCs (𝜎!) and elastic 
stress on fibrin network (𝜎!), and conclude that the viscous contribution of RBCs is 
negligible and can be treated as an elastic material. 
The full active viscoelastic poroelastic model including an active, active-series, 
parallel, and series element is shown in Supplemental Fig. 9. 1) The poroelastic 
element, 2) the active-series element, and 3) the viscoelasticity of parallel and series 
element can be ignored to obtain the current 3-element model for the following 
reasons:   
a) The poroelastic element: As the sample size, 𝑎, is comparable to the intrinsic 
length of a material, (𝑘𝜂!/𝜂!"#)!/!, the viscoelasticity and poroelasticity must 
be considered simultaneously, where 𝜂! is the active coefficient, 𝜂!"# is the 
viscosity of the solvent, 𝑘 is the permeability of the clot. For small clots 
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𝑎 ≪ (𝑘𝜂!/𝜂!"#)!/!, the contraction dynamics of clot is controlled by active 
viscoelasticity. (Details in Supplemental methods D) 
 
b) The active-series element: The elastic modulus of platelet is around 10kPa, 4  
which is much stiffer than that of the fibrin network which has an elastic 
modulus below 1kPa. 117,165  Furthermore, there is almost no difference 
between the full model and the simplified models. (Details in Supplemental 
methods G) 
 
c) The viscoelasticity of the series and parallel elements: Fibrin only behaves in a 
viscoelastic manner at high strain rates but remains elastic at low strain rates, 
because the loss modulus of fibrin, 𝐺!!, is dependent on the strain rate and the 
storage modulus,  𝐺! remains unchanged. In the oscillation tests in van Kempen 
et al , the loss modulus is at least 2 orders of magnitude smaller than 𝐺! in the 
frequency range of 1-3Hz and strain amplitude of 0.01 (strain rate 0.04 to 
0.12𝑠!!). We can conclude that 𝐺!! is negligible compared to 𝐺! for the low 
strain rate case considered in our manuscript (0.0002𝑠!!); so fibrin will 
behave as an elastic material rather than viscoelastic. (Details given in 
Supplemental methods H) 
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5.5.9 Supplemental Figures 
	  
Figure 5-8 An active – poroelastic model for blood clots (a) The whole blood clot is 
made up of a branched network of fibrin network (tan), platelet aggregates (gray), and 
RBCs (red). (b) The active-poroelastic model consists of two passive elastic elements 
to represent the elasticity of the series (ii) and parallel (iii) elements, an active 
contractile element (i), and a porous element (iiii). 	  	  	  	  	  
	  
Figure 5-9. Poroelastic and active limit of contraction. (a) poroelastic limit as 𝜂!"#𝑎!/𝑘𝜂! ≫ 1. (b) active limit for 𝜂!"#𝑎!/𝑘𝜂! ≪ 1. 
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Figure 5-10 Supplemental Figure 3. Poroelastic and active viscoelastic model. The 
unconstrained contraction for (a) the poroelastic limit: 𝜂!"#𝑎!/𝑘𝜂! ≫ 1, and for (b) 
the active limit: 𝜂!"#𝑎!/𝑘𝜂! ≫ 1 . For simplicity, we assume that 𝐾! ≫ 𝐾! and 𝐺!/𝐾! = 3(1− 2𝜈!)/2(1+ 𝜈!),  where the initial Poisson's ratio   𝜈! = 0.3  for the 
poroelastic limit. 
 
 
 
	  
Figure 5-11 Supplemental Figure 4.  The influence of scaled parallel and series 
stiffnesses (𝑲𝒑𝒎/𝑺𝒔𝒎  and 𝑲𝒔𝒎/𝑺𝒔𝒎 , respectively) on degree of unconstrained 
contraction (𝑱𝟐/𝟑) and stress of constrained contraction (𝝈/𝑺𝒔𝒎) for 𝒕 ≫ 𝒕𝟎. (a) 
Equilibrium 𝐽!/! versus 𝐾!!/𝑆!!. (b) Contour plots of equilibrium 𝜎/𝑆!! as a function 
of 𝐾!!/𝑆!! and 𝐾!!/𝑆!!. Colors (blue to red) represent 𝜎/𝑆!! (0.1–0.95). 
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Figure 5-12 Simulation of stall stress. Contractile stress was modeled to extend until 
stall stress was reached for samples with RBCs (green) and samples without RBCs 
(red).  
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Figure 5-13 Contractile stress in the absence of a series element. Contractile stress 
was simulated for samples without and with RBCs (black and red lines, respectively) 
without series element (𝑲𝒔𝒎 𝟎% → ∞,𝑲𝒔𝒎 𝟒𝟎% → ∞). 	  	  
 
 
	  
Figure 5-14 The full active viscoelastic model with active, active-series, parallel, 
and series element. 	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Figure 5-15 Comparison of unconstrained (a) and constrained (b) clot contraction  
using the full model with the active–series element (solid lines) and the simplified 3-
element model (dashed lines). The fitted active-series stiffness the provides the best fit 
is 𝐾!"! = 16𝑆!! = 7.2𝑘𝑃𝑎.   
 
 
 
 
 
 
	  
Figure 5-16 The full active visco-poro-elastic poroelastic with active, active-series, 
parallel, serial, and serum element. The active-series element, the serum element, 
the viscoelasticity of parallel element, the viscoelasticity of parallel element can be 
ignored to obtain the current 3-element model. The full active visco-poro-elastic 
poroelastic with active, active-series, parallel, serial, and serum element. The active-
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series element, the serum element, the viscoelasticity of parallel element, the 
viscoelasticity of parallel element can be ignored to obtain the current 3-element 
model. 	  	  	  	  	  
Table 5-1 Comparison of fitting parameters to known literature values 
 	   Stall	  stress	  𝑆!!(𝑃𝑎)	  
Active	  viscosity	  𝜂!!/𝑆!!(𝑠)	  
Time	  delay	  𝑡!(𝑠)	  
Parallel	  stiffness	  𝐾!!(0%)	   Parallel	  stiffness	  𝐾!!(40%)	   Series	  stiffness	  𝐾!!(0%)	   Series	  stiffness	  𝐾!!(40%)	  
Fitting	   450	   50	   500	   90	   392	   360	   1948	  Experimental	  estimation	   270	  (2)	   250	  (2)	   500	  (3)	   1− 100	  (4)	   	   500	  (3)	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Chapter 6 Blood clot contraction is reduced in sickle cell disease due to 
increased rigidity of erythrocytes 	  
In Specific Aim 2 the goal was to supplement the examination of contracting blood 
clots with an assessment of blood clot contraction in blood from patients with 
thrombotic conditions. To obtain a thorough understanding of the mechanisms of clot 
contraction it was critical to study clot contraction under both physiological and 
pathological conditions. To thoroughly examine if clot contraction was altered in 
thrombotic conditions it is imperative to investigate blood from patients with 
pathological conditions of various origins. In this chapter clot contraction in blood 
from patients with sickle cell disease, which is a pro-thrombotic condition is analyzed. 
In addition, the role of erythrocyte rigidity in the process of clot contraction is 
explored as the origin of the reduced extent of clot contraction described here. This 
provides an examination of blood from patients with a (pro)-thrombotic condition. 	  
 
In collaboration with R.I.  Litvinov, A. Protopopova, C. Nagaswami, E. Russell, D.L. 
Siegel, C. H. Villa, D. Pan, V.R. Muzykantov, J.W. Weisel 
 
  
	  	  
118	  
6.1 Introduction  	  
Clot contraction results in the volume shrinkage of blood clots and has been 
implicated to play a role in processes such as hemostasis, thrombosis, and wound 
healing. Contractile forces are generated by platelets4,54 and transmitted through the 
fibrin network, resulting in the platelet-fibrin meshwork accumulating on the periphery 
of the clot and the erythrocytes being compacted into the core of the clot. 67 When 
erythrocytes become compacted they form a tessellated array and take on a polyhedral 
shape. 67 This shape change resulted in the terminology of polyhedrocytes and is due to 
the fact that erythrocytes are highly deformable cells that recurrently experience 
reversible shape changes due to fluid forces and traveling through the 
microcirculation. The presence of polyhedrocytes has been observed in both in vivo 
thrombi from mice and humans and in vitro clots. 67,90  
The volume fraction of erythrocytes is inversely related to the extent and rate 
of clot contraction, with the incorporation of erythrocytes resulting an increase in 
compressive and tensile resistance to the platelet-generated contractile forces. 143 
However, relatively little is known about the influence of the mechanical properties or 
deformability of the erythrocytes on clot contraction and polyhedrocyte formation. 
Reduced erythrocyte deformability is associated with a number of pathological 
conditions, such as hypertension, diabetes mellitus, atherosclerosis and smoking,  185-
189 but perhaps one of the best known diseases associated with increased erythrocyte 
rigidity is sickle cell disease (SCD). 190-192 SCD is a hypercoagulable state that 
contributes to vaso-occulsive events in the microcirculation and an increased risk of 
venous thromboembolism. 193-198  
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Erythrocytes contain the globular protein hemoglobin, which is responsibility 
for the transport of oxygen. 199 Hemoglobin is made up of two α chains and two β 
chains, in SCD patients an amino acid substitution in the β chains results in abnormal 
hemoglobin polymerization during circulation. 200 The mutation of a valine for a 
glutamine in the β chains results in the modification of charged groups to hydrophobic 
groups that polymerize during the oxygenation/de-oxygenation process and results in 
the formation of stiff cross-linked fibers of hemoglobin201-203 resulting in altered 
erythrocyte shape. 204 This manifests in altered cell rigidity and adhesiveness. 203,205 
The hemoglobin can associate with membrane proteins such as spectrin and alter their 
function. 206 Specifically, hemoglobin interacts with the spectrin network via band 3. 
207-209  Interestingly, altered mechanical properties have been found in patients with 
two mutations (Hb SS) but also in patients with a single S mutation (Hb SC). 190,191  
Here, we study differences in clot contraction between healthy donors and 
SCD patients, while probing erythrocyte rigidity as a mechanism for the observed 
decrease in clot contraction in SCD patients.  
6.2 Methods  
6.2.1 SCD Patients  
 Blood was collected from patients with SCD following informed consent in 
accordance with the University of Pennsylvania Institutional Review Board. SCD 
patients with Hb SS and Hb SC were included in the study if they were not receiving 
hydroxyurea treatment and had not recently received a blood transfusion.  
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6.2.2 Sample preparation 
 Blood samples were collected into 3.2% trisodium citrate 9:1 by volume, 
stored at room temperature and used within 4 hours. Erythrocytes were isolated 
through centrifugation at 200 g for 10 minutes and were washed three times in 
phosphate buffered saline. Platelet rich plasma (PRP) was obtained through 
centrifugation at 170 g for 15 minutes.  
 Erythrocytes were deoxygenated by placing a whole blood samples places into 
a 2ml multi-well plate in an Eppendorf Thermomixer (New Brunswick NJ) with a 
custom designed mount that provides an air-tight seal for the inlet/outlet nozzles. 
Samples were flushed with argon for 30 minutes at 37C under gentle agitation to 
maintain the maximal surface area for mixing.  
6.2.3 Scanning electron microscopy 
 Centrifuged erythrocytes and thrombin induced whole blood clots were fixed 
in 2% glutaraldehyde, dehydrated and then dried with hexamethyldisilazane. Samples 
were sputter-coated with gold-palladium and imaged using an FEI Quanta250 
scanning electron microscope (FEI, Hillsboro, OR). 
6.2.4 Atomic force microscopy   
Microscope glass coverslips (22x22x0.16 mm, Fisher Scientific, USA) were 
cleaned for 10 min using PDC-32G-2 Plasma Cleaner (Harrick Plasma, USA). 
Afterwards, a 20 µl drop of 0.1 mg/ml polyallylamine (Sigma-Aldrich, USA) was 
placed on the glass, kept for 2 min, removed from the surface and dried with a flow of 
air. To enforce cell attachment, a 20 µl drop of 0.1% glutaraldehyde (EMS, USA) was 
placed on the glass slide pretreated with polyallylamine, kept for 2 min, and washed 
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with 5 ml of milli-Q water. The remaining liquid was dried with a flow of air making 
the surface ready for deposition of erythrocytes. 
Isolated erythrocytes were washed 3 times in Alsever’s solution and stored at 
8C for up to 3 days. Prior to use the erythrocytes were re-suspended in phosphate 
buffered saline and added to the modified glass coverslip. Erythrocytes were allowed 
to attach for 3 minutes and then washed with phosphate buffered saline to remove the 
unattached cells. Residual washing buffer was removed from the gently without letting 
it dry completely. Cells were overlayed with 400 ul of phosphate buffered saline.  
Force-distance curves through the controlled indentation of the cells were 
obtained using an MFP-3D microscope (Asylum Research – Oxford Instruments, 
USA) and long triangular cantilever (Olympus, Japan). Force curves were acquired in 
force mapping mode using an indentation force of 0.5 nN with an indentation rate of 2 
mm/sec.  	  
6.2.5 Kinetics of clot contraction  
 Whole blood or reconstituted samples were incubated with CaCl2 (2mM final 
concentration) and then 1 U/ml of thrombin to initiate clotting and immediately 
transferred to a pre-lubricated plastic cuvette. The light scattering properties of the clot 
were tracked over the course of 20 minutes while at 37C to assess the change in clot 
size as previously described. 143  
6.2.6 Non-linear regression analysis of clot contraction  
 Kinetic curves of change in clot size with respect to time were analyzed using 
Prism GraphPad 6.0 
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𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝐶𝑙𝑜𝑡  𝑆𝑖𝑧𝑒 = 𝑡! < 𝑡 < 𝑡!                𝑦! − (𝑦! − 𝑦!)(1 − 𝑒!!! ! )𝑡! < 𝑡 < 𝑡!                                                                𝑦! − 𝑘!𝑡𝑡! < 𝑡 < 𝑡!"#                 𝑦! − (𝑦! − 𝑦!)(1 − 𝑒!!! ! ) 
where t1 and t2 correspond to time points at which the first derivative of the curve 
reaches a local minimum or maximum; y1 and y2 correspond to the extent of 
contraction at these time points, whereas y0 and y3 correspond to the extent of 
contraction at the beginning and end time points. 
6.2.7 Statistical analysis  
All statistics were completed using Prism GraphPad 6.0. Samples were 
analyzed for statistical significance using two-tailed unpaired t-tests with alpha=0.05. 
All data is presented as mean±SEM unless indicated otherwise. Significance is 
represented as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
6.3 Results  	  
6.3.1 Characterization of clot contraction in SCD patients  	  
 Optical tracking of clot size in blood obtained from patients with SCD revealed 
a 53% reduction (p<0.0001) in the extent of clot contraction at 20 minutes compared 
to healthy subjects (Figure 1A). SCD patients had a prolonged lag time (Figure 1B), a 
reduced average velocity (Figure 1C), and a reduced area over the curve (Figure 1D).  
Correlation analysis of the clot contraction parameters revealed significant correlations 
between extent of contraction, lag time, average velocity, and area over the curve 
(Supplemental Table 1); whereas, the extent of contraction and lag time were not 
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correlated in healthy individuals. There were no differences in extent of clot 
contraction between HbSS and HbSC patients (Supplemental Figure 1). In addition, 
there was no difference in the extent of clot contraction between oxygenated and 
deoxygenated samples from SCD patients (Supplement Figure 2).  
 
	  
Figure 6-1 Optical tracking of clot contraction in sickle cell disease patients and 
healthy individuals. Optical tracking was used to compared (A) extent of clot 
contraction, (B) lag time, (C) average velocity, and (D) area over the curve. 
Parameters for healthy individuals and patients with SCD were compaired using an 
unpaired, 2-tailed student t-test. ****P<0.0001. 
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6.3.2 Phase analysis of clot contraction in SCD patients  	  
 Clot contraction occurs in three kinetically distinct phases, where Phase 1 
corresponds to initiation of contraction, Phase 2 to linear contraction and Phase 3 to 
mechanical stabilization. Non-linear regression analysis was completed on the kinetic 
curves (Figure 2) and revealed that SCD patients had a 54% reduction in the rate 
constant for Phase 2 and a 44% reduction in the rate constant associated with Phase 3 
(Table 1) indicating impaired compaction of erythrocytes.  
 
	  
Figure 6-2 Average kinetic contraction curves for healthy subjects and SCD 
patients. Optical tracking was used to measure the change in clot size every 15 
seconds over the course of 20 minutes.  
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Table 6-1 Kinetic analysis of the phases of clot contraction 
 
Rate constants 
 
Healthy 
subjects 
 
Sickle Cell Disease 
patients  
Phase 2, %/sec  -0.072±0.003 -0.0329±0.0033**** 
Phase 3, 1/s 0.0026±0.00003 0.0015±0.00033 
 
 
 
 
6.3.3 Polyhederocyte formation in SCD patients  
 As clot contraction occurs the erythrocytes become compacted into the core of 
the blood clot and undergo deformation from their native biconcave shape to 
polyhedrocytes. Deformed erythrocytes that do not form a smooth tessellated network 
are referred to as intermediate forms. While images from the core of the clots formed 
from the blood of healthy donors reveal a smooth tessellated network of 
polyhedrocytes (Figure 3A) the clots formed from the blood of SCD donors reveal 
intermediate forms of erythrocytes but not a compact smooth polyhedrocyte network 
(Figure 3B).  
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Figure 6-3 Polyhedrocyte formation in healthy subjects and SCD patients. 
Scanning electron microscopy images of the core of clots formed from the blood of 
(A) healthy subjects and (B) SCD patients. 
6.3.4 Mathematical prediction of erythrocyte rigidity on clot contraction  
 
 Increased hematocrit reduces extent of clot contraction due to mechanical 
resilience of erythrocytes143,144 and thus it is possible that in addition to the volume 
fraction, the stiffness of erythrocytes can also affect the extent and rate of clot 
contraction.  It is known that SCD patients have an increased erythrocytes rigidity 
compared to healthy subjects, and that was confirmed here using atomic force 
microscopy (Supplemental Figure 3).  A three-element active viscoelastic 
mathematical model has been used to mimic clot contraction144 and predicts that 
increased erythrocyte rigidity will result in a decreased extent of clot contraction 
(Supplemental Figure 4).  
6.3.5 Effect of erythrocyte rigidity on polyhedrocyte formation  
 
 Polyhedrocyte formation corresponds with the occurrence of clot contraction. 
Here, we used centrifugation at speeds from 0-6000 g to mimic the contractile forces 
generated by platelets. This purely mechanical deformation was able to induce a 
tessellated polyhedrocyte network at forces as low as 1000 g (Figure 4). To examine if 
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increased rigidity influences the formation of polyhedrocytes, erythrocytes were 
incubated with 0.03 and 0.06% glutaraldehyde, which as been previously shown to 
alter erythrocyte rigidity. 210,211 Treatment with glutaraldyhyde prior to centrifugation 
resulted in a noticeable decrease in erythrocyte deformation and polyhedrocyte 
formation (Figure 4) even at higher centrifugal forces.  
 
	  
Figure 6-4 Polyhedrocyte formation in erythrocytes treated with glutaraldehyde. 
Centrifugation of erythrocytes revealed a transition from biconcave to polyhedral 
similar to what is observed in contracted blood clots. This transition was mitigated in 
erythrocytes treated with 0.03% and 0.06% glutaraldehyde, which increased 
erythrocyte rigidity. 	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6.3.6 Effect of naturally rigid llama ovalocytes on clot contraction  
 
As residual glutaraldehyde may have unwanted effects on platelets, clot 
contraction experiments were completed using naturally stiffer ovalocytes from 
llamas. Llama ovalocytes (Figure 5A) are naturally more rigid than human 
erythrocytes due to the presence of 2.5 times the amount of the structural protein 
spectrin, in so they can resist larger osmotic pressures. Isolated and washed llama 
ovalocytes and human erythrocytes were reconstituted at a volume fraction of 40% 
with a human platelet count of ~250,000/ml. There was a 28% decrease in the extent 
of clot contraction when the samples were reconstituted with llama ovalocytes 
compared to human erythrocytes (Figure 5B,C) and a reduction in the average velocity 
(Figure 5D). Specifically, there was a reduction in the rate of Phase 2 with the stiffer 
ovalocytes (Figure 5E).  The addition of more platelets, or more contractile force, 
results in an extent of clot contraction closer to that of the erythrocyte control, which 
shows that the increased contractile force is able to overcome the mechanical 
resistance.  
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Figure 6-5 Clot contraction with naturally rigid llama ovalocytes. (A) Scanning 
electron microscopy was used to assess llama ovalocytes that were resting, contracted 
with normal platelet count, or contracted using a higher platelet count. (B) Optical 
tracking was used to assess clot contraction in samples with human erythrocytes or 
llama ovalocytes. (C) Extent of clot contraction at 20 minutes, (D) average velocity, 
and (E) the rate of phase 2 were quantified. 
 
 
6.3.7 Effect of rigidifying antibodies on clot contraction  
 WrightB antibodies have been found to influence erythrocyte rigidity through 
their interaction with the band 3-glycophorin A. 210  The addition of WrightB 
antibodies resulted in more rigid erythrocytes compared to healthy subjects (Figure 
6A) and a trend toward a decrease in the extent of clot contraction (Figure 6B). 
Assessment of erythrocytes from the core of clots showed polyhedrocytes in the 
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absence of WrightB antibodies (Figure 6C) whereas, more intermediate forms were 
present in the presence of WrightB antibodies (Figure 6D). Centrifugation at 2000 g 
resulted in the formation of polyhedrocytes in the absence of antibodies (Figure 6E) 
while erythrocytes appeared less compacted in the presence of antibodies (Figure 6F).  
 
	  
Figure 6-6 Clot contraction with rigidifying antibodies. Representative single donor 
experiment revealed that (A) wrightB antibodies resulted in an increase in erythrocyte 
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rigidity which corresponded to (B) a slight decrease in the extent of contraction. 
Scanning electron microscopy was used to assess erythrocyte deformation in the core 
of clots made in the (C) absence or (D) presence of wrightB antibodies and following 
centrifugation of washed erythrocytes in the (E) absence or (F) presence of wrightB 
antibodies. 
 
6.4 Discussion  	  
 Pathological conditions that are associated with an increase in erythrocyte 
rigidity such as SCD, diabetes, and hypertension are also associated with an increased 
risk for thrombotic conditions such as vascular thromboembolism or stroke. 196 SCD is 
associated with platelet hypercoagulability, 212,213 activation of coagulation, 214,215 
deformed erythrocytes that become trapped in the microcirculation, 216 and impaired 
fibrinolysis. 194 Sickling of the erythrocytes leads to exposure of phosophatidylserine 
on the cell membrane217 and circulating hemoglobin, which can lead to enhanced 
platelet activation. 218   
 Clot contraction, or the volume shrinkage of the clot, is differentially 
influenced by the molecular and cellular composition of the blood. 143 Platelet 
activation enhances the extent of clot contraction, so it is perhaps surprising that a 
procoagulant condition such as SCD would result in a reduced extent of clot 
contraction. This first examination of clot contraction in SCD revealed a reduced 
extent of clot contraction in SCD patients compared to healthy individuals (Figure 1). 
This led to the hypothesis that the increased erythrocyte rigidity of SCD patients may 
contribute to this decreased extent of contraction. It is known that with increasing 
hematocrit there is a decrease in the extent of contraction. 143 While SCD patients, both 
HbSS and HbSC, have a lower hematocrit than healthy individuals, they also have less 
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deformable erythrocytes. Erythrocytes resist contraction through a tensile and 
compressive disruption of the active contractile forces. 144 Through the use of a 
recently developed three–element mathematical model144 it is evident that increased 
erythrocyte rigidity has the ability to dampen the extent of contraction in a manner 
similar to increased hematocrit (Supplemental Figure 4). The reduced rate of 
contraction in Phase 2 of clot contraction supports the hypothesis that the influence of 
erythrocytes is in reducing the overall extent of contraction, as it is known that 
erythrocytes play a critical role during this phase of contraction. However, there was 
no difference in extent of clot contraction following the deoxygenation of whole blood 
from SCD patients. While it would be expected that deoxygenation would result in 
increase in the percentage of sickle erythrocytes219 and transitively potentially 
influence the extent of clot contraction. The lack of influence is likely due to the fact 
that deoxygenation also results in an increase in the phosphatidylserine exposure on 
the erythrocyte surface, 219 which enhance platelet activation and counteract any 
potential difference in extent of clot contraction. In addition, based on mathematical 
model prediction show here (Supplemental Figure 3) the reduction in extent of clot 
contraction is lessened as the erythrocyte rigidity increases. SCD patients have 
erythrocytes that are on average 8 times stiffer than healthy erythrocytes, thus it is also 
likely the additional increase in erythrocyte stiffness would only have a limited 
influence on the process of clot contraction.  
 Platelet generated contractile forces are able to pack erythrocytes into the core 
of the clot and the cells are deformed into polyhedrocytes. 67 Here, we used 
centrifugation to mimic the contractile forces generated by platelets and saw that in 
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natural erythrocytes a tessellated network of polyhedrocytes formed at centrifugal 
forces of ~1000 g or higher (Figure 4). Treatment of erythrocytes with glutaraldehyde, 
which has been shown to decrease the deformability of the erythrocytes, resulted in 
less erythrocyte deformation not only at 1000 g but also at higher centrifugal forces. 
This confirms that erythrocyte deformability influences the compactness of the 
erythrocyte core of the contracted blood clot and further supports the idea that 
erythrocyte rigidity has the potential to influence extent of clot contraction.  
 To assess the role of erythrocyte rigidity in modulating the extent of clot 
contraction we performed experiments with naturally stiff ovalocytes from llamas, 
which resulted in a decrease in the extent of clot contraction and reduction in the rate 
of Phase 2 of contraction similar to what was observed in SCD patients (Figure 5). The 
addition of more platelets, corresponding to more contractile force, resulted in an 
increase in the extent of contraction and increased red cell deformation compared to 
lower platelet count. This further supports the idea that mechanical resistance 
conferred by the stiffer ovalocytes is balanced by the generation of contractile forces.  
Likewise, the addition of rigidifying WrightB antibodies results in a decrease in 
polyhedrocyte formation and a trend toward a decrease in extent of clot contraction.  
 In conclusion, the effect of erythrocyte rigidity on the extent of clot contraction 
and polyhedrocyte deformation has been explored for the first time. Clot contraction is 
associated with the formation of a good hemostatic seal and the restoration of blood 
flow past obstructive thrombi. Our results reveal that conditions with more rigid 
erythrocyte and increased risk of thrombotic conditions may alter clot contraction.  
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6.5 Supplement  	  	  	  
Table 6-2 Correlation of clot contraction parameters in sickle cell disease patients  
 Extent of 
Contraction 
Lag Time  Average 
Velocity  
Area over the 
Curve  
Extent of 
Contraction 
 0.897* -1.00**** -0.882* 
Lag Time 0.897*  -0.898* -0.946*** 
Average 
Velocity  
-1.00**** -0.898*  0.882* 
Area over the 
Curve  
-0.882* -0.946*** 0.882*  	  	  
  
 
 
	  
Figure 6-7 Clot contraction in HbSS and HbSC patients. Optical tracking was used 
to assess the extent of clot contraction in patients with HbSS and HbSC.  
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Figure 6-8 Effect of deoxygenation on extent of clot contraction. SCD patients’ 
whole blood was deoxygenated and compared to matched samples that were not 
deoxygenated for influence on extent of clot contraction.  
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Figure	   6-­‐9	   Rigidity of erythrocytes from healthy subjects and SCD patients. 
Atomic force microscopy measurements confirmed that erythrocyte from SCD patients 
are more rigid than erythrocytes from healthy individuals.	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Figure 6-10 Mathematical prediction of erythrocyte rigidity on clot contraction. 
A previously established three-element active viscoelastic mathematical model was 
used to assess the influence of relative erythrocyte rigidity on the extent of clot 
contraction. 	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Chapter 7 Blood Clot Contraction is Impaired in Acute Ischemic Stroke 	  
 
In this Chapter we examine clot contraction in blood from patients with a recent 
ischemic stroke, which is a result of arterial thrombosis. This study provides an 
examination of clot contraction and correlations with clinical parameters such as 
stroke severity and etiology. The studies are complemented with an examination of 
platelet dysfunction as the mechanistic origin of the reduction in clot contraction 
described here. 
 
This research was originally published in Atherosclerosis, Thrombosis, and Vascular 
Biology. V. Tutwiler, A.D. Peshkova, I.A. Andrianova, D.R. Khasanova, J.W. Weisel, 
R.I. Litvinov. Contraction of blood clots is impaired in acute ischemic stroke. Athero 
Thromb Vasc Biol. 2017;37:271-279. 
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7.1 Introduction  
Stroke is a leading cause of death and disability worldwide220,221 and accounts 
for 1 in every 20 deaths in the US each year. 222,223 Despite this clinical importance and 
numerous studies on circulatory disorders in the brain vessels, the pathogenesis of 
stroke remains largely unclear and the results of stroke prophylaxis and treatment are 
unsatisfactory. 224 Brain damage caused by abnormalities of cerebral blood flow is 
often ischemic by nature221 and is associated with thrombosis or thromboembolism, 
indicating involvement of hemostatic reactions. 225,226 Hypercoagulability and changes 
in blood rheology in combination with local dysfunction and/or destruction of 
endothelium comprise a pathogenic basis for ischemic stroke. 225,227-229 In addition to 
disorders of plasma and vascular hemostasis, platelet activation plays a role in the 
ischemic stroke. 225,229,230 Platelet stimulation and aggregation is followed by release of 
potent triggers of the coagulation cascade and secondary platelet activation.  
A main physiological activator of platelets is thrombin, an enzyme that forms 
in the blood irrespective of the initial cause of intravascular blood clotting. 
Concomitant with platelet activation, thrombin converts fibrinogen, a soluble plasma 
protein, into an insoluble fibrin gel made of a filamentous network. 43,116,117 Fibrin 
sticks to activated platelets via the integrin receptor αIIbβ3 to form a platelet-fibrin 
meshwork comprising the structural basis of a hemostatic clot or an obstructive 
thrombus. 43,231,232 When the blood clot is formed in a tube, it undergoes volume 
shrinkage and liquid serum is expelled. This process is called clot contraction or 
retraction. 54 The cellular and molecular composition of the blood clot has been found 
to influence the rate and extent of clot contraction. 143 Importantly, contraction occurs 
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not only in vitro but also inside a vessel if a clot or thrombus is formed. 67 The 
importance of clot contraction in vivo is based on at least two mechanisms: (i) at the 
site of tissue injury the active decrease in clot size reduces blood loss by pulling 
together wound edges, and (ii) blood flow is recovered past a contracted formerly 
obstructive thrombus, the latter being hypothetically an important compensatory or 
adaptive mechanism in thrombotic states. 5,54,67  
Despite potential medical significance, clot contraction has not been studied 
systematically in clinical settings mainly because of no standardized and automated 
methods for registration and quantification of this process. Previously, a limited 
number of studies assessed extent of clot contraction in vitro subjectively as a visible 
ratio of the volume of serum and the reduced volume of the clot. It is not surprising 
that the parameters of clot contraction under various circumstances are hardly 
comparable and highly scattered with the normal range of the extent of contraction 
varying from 20% to 90%. In this work we employ a recently described instrumental 
technique143 that enabled us to quantify the kinetics of blood clot contraction in normal 
and disease states. 
  The goal of this work was to evaluate the potential pathogenic importance of 
clot contraction in acute ischemic stroke by correlating the parameters of clot 
contraction with clinical and laboratory characteristics. 
7.2 Methods and Materials  
7.2.1 Patients and inclusion criteria  
Informed consent was obtained from patients suffering a recent stroke and 
healthy donors under the approval of the Ethical Committee of the Interregional 
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Clinical Diagnostic Center (ICDC, Kazan, Russia) and in accordance with the 
Declaration of Helsinki. Informed consent was obtained from a legal representative if 
the stroke patients were physically and/or mentally incapable of giving consent. 96 
patients with acute ischemic stroke (85 studied for clot contraction and 11 studied for 
platelet functionality) and 11 patients with transient ischemic attack (TIA) were 
enrolled within 12 hours after the onset of clinical symptoms prior to receiving any 
medication. Diagnosis of ischemic stroke or TIA was confirmed for all of the subjects 
based on clinical assessment and magnetic resonance imaging (MRI). Stroke and TIA 
patients were excluded from this study if by the time of examination they received 
anticoagulant, thrombolytic or antiplatelet drugs.  
The average age in the stroke patients’ main group (68±9 years, n=85) did not 
quite match the average age of the control group comprising healthy donors (58±13 
years, n=79, M±SD). However, in a separate study it was shown that the extent and 
rate of clot contraction in a group of 16 elderly patients with an average age of 65±11 
years did not differ from the younger healthy control subject used as a control in this 
study, but was significantly different from the ischemic stroke patients of the same age 
(Figure S1).  
Acute ischemic stroke causal subtypes were defined using the Trial of Org 
10172 in Acute Stroke Treatment (TOAST) for all the patients. The NIH Stroke Scale 
(NIHSS) was used to measure stroke severity. Patients were also classified according 
to the Oxfordshire Community Stroke Project (OCSP). We used modified the Rankin 
Scale (mRS) to measure the degree of disability in patients before hospital discharge. 
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Volume of damage was assessed using the Alberta Stroke Program Early CT score 
(ASPECTS). Clinical characteristics of the stroke patients can be found in Table 1.   
 
7.2.2 Blood collection and sample processing  
Venous blood samples were collected within 6 hours after the onset of stroke 
symptoms. Blood was drawn under aseptic conditions without venous stasis using 
vacutainers, stored at room temperature and analyzed within 4 hours for both stroke 
patients and healthy donors. Blood samples were collected into 3.2% trisodium citrate 
9:1 by volume (S-Monovette tubes, Sarstedt, Germany). One blood sample was used 
directly to examine the blood clot contraction. Another citrated blood sample was 
centrifuged (1500g, 10 min) to obtain platelet-poor plasma (PPP) and used for blood 
coagulation tests. A third blood sample was stabilized with K3-EDTA (1.6 mg/mL 
final concentration) and used for hematological tests. A non-stabilized whole blood 
sample was mixed with a clotting activator silicate (Sarstedt, Germany) and allowed to 
clot for 20-30 minutes at 37°C followed by centrifugation (2000g, 10 min) to obtain 
serum which was used for biochemical blood tests.  
 
7.2.3 Coagulation, hematological, and biochemical tests  
An automated coagulometer Sysmex CA-1500 (Sysmex, Canada) was used 
with fresh citrated plasma samples for the following tests: activated partial 
thromboplastin time (aPTT), prothrombin time, INR, fibrinogen concentration, 
concentrations of antithrombin III, plasminogen, protein C, and D-dimer 
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concentration. Cell count was performed in EDTA-treated whole blood samples with 
an ABX Pentra 60 cell counter (hematology analyzer) (Horiba, Japan).  
The following parameters were analyzed: erythrocyte count, mean corpuscular 
volume, hematocrit, hemoglobin, mean corpuscular hemoglobin, leukocyte count, 
monocyte count, neutrophil count, lymphocyte count, eosinophil count, basophil 
count, platelet count, and mean platelet volume.  
Blood chemistry analyses were performed with RX Imola (Randox, UK) and 
Advia 1200 (Siemens, Germany) analyzers (Siemens, Germany). Serum 
concentrations of albumin, total serum protein, total bilirubin, glucose, alanine 
aminotransferase, aspartate aminotransferase, creatinine, urea, magnesium ion, sodium 
ion, and potassium ion were measured with RX Imola. Cholesterol, triglycerides, low 
density lipoprotein cholesterol, and high density lipoprotein cholesterol analyses were 
performed on Advia 1200. Serum S-100B protein concentration was assessed by 
immunoassay with Cobas e411 (Roche, Switzerland). 
 
7.2.4 Continuous optical tracking of contracting blood clots in vitro  
Optical tracking of contracting blood clots was performed using a novel 
automated assay143 that was applied in clinical settings for the first time. Samples from 
patients and healthy donors were activated under standard conditions with 1 U/ml 
thrombin (Sigma-Aldrich, cat #T8885) and 2 mM CaCl2 (final concentrations). 
Activated samples were quickly transferred to 12x7x1 mm transparent plastic cuvettes 
which were pre-coated with a residual layer of 4% Triton X-100 (Sigma-Aldrich, cat 
#90002-93-1) in phosphate buffered saline to prevent sticking of the clot to the 
	  	  
144	  
chamber. Cuvettes were then added to the Thrombodynamics Analyzer System (Figure 
1A) where a thermostatic chamber kept the samples at 37°C. Images of the clots were 
taken every 15 seconds for 20 minutes to track the changes in clot size based on the 
light scattering properties of the clot through the use of a light emitting diode and a 
CCD camera. Following data collection and computational processing, a kinetic curve 
(relative clot size vs. time) was plotted from the data and assessed for the following 
parameters: extent of clot contraction at 20 minutes, the lag time (time to reach 5% 
contraction), the average velocity of contraction, and the area over the curve (AOC) 
(Figure 1B). The AOC is an informative parameter that characterizes the intensity of 
entire process of clot contraction by integrating the extent and rate of contraction and 
the lag time.  
 
7.2.5 Non-linear regression analysis of the kinetics of clot contraction  
The kinetic curves of clot contraction were analyzed using a piecewise function 
in Prism GraphPad 6.0, as previously described.143 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒  𝐶𝑙𝑜𝑡  𝑆𝑖𝑧𝑒 = 𝑡! < 𝑡 < 𝑡!                𝑦! − (𝑦! − 𝑦!)(1− 𝑒!!! ! )𝑡! < 𝑡 < 𝑡!                                                                𝑦! − 𝑘!𝑡𝑡! < 𝑡 < 𝑡!"#                 𝑦! − (𝑦! − 𝑦!)(1− 𝑒!!! ! ) 
 
where t1 and t2 correspond to time points at which the first derivative of the curve 
reaches a local minimum or maximum; y1 and y2 correspond to the extent of 
contraction at these time points, whereas y0 and y3 correspond to the extent of 
contraction at the beginning and end time points. Three phases of clot contraction have 
been recently revealed143 and the rates and rate constants of contraction for each phase 
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were determined through curve fitting with the piecewise function. This analysis 
allows for the abnormalities in clot contraction to be localized to a specific phase of 
contraction.  
 
7.2.6 Effects of platelet count and fibrinogen concentration on clot contraction in 
vitro 
To obtain samples with varying platelet counts, platelet-rich plasma was 
combined with platelet-poor plasma in increasing volume fractions to obtain the 
desired platelet concentration. To obtain samples with varying fibrinogen 
concentrations,  isolated platelets were collected through centrifugation of  platelet-
rich plasma at 640g for 10 minutes in the presence of PGE1 (1 µg/ml final 
concentration), they were washed and re-suspended in a modified Tyrode’s buffer with 
increasing concentrations of purified human fibrinogen (Hyphen Biomed, France). 
Clot formation and contraction was initiated with 1 U/ml thrombin and 2 mM CaCl2 
(final concentrations) and the extent of contraction was measured after 20 minutes of 
incubation at 37°C. Three independent clot contraction experiments were performed 
for each experimental condition. 
 
7.2.7 Platelet isolation by gel-filtration 
To perform studies on isolated platelets from healthy subjects or ischemic 
stroke patients, citrated blood was centrifuged at room temperature at 200g for 10 min 
to obtain platelet-rich plasma (PRP). Platelets from PRP were isolated by gel filtration 
on Sepharose 2B (GE Healthcare, Sweden) equilibrated with Tyrode’s buffer (4 mM 
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HEPES, 135 mM NaCl, 2.7 mM KCl, 2.4 mM MgCl2, 5.6 mM D-glucose, 3.3 mM 
NaH2PO4, 0.35 mg/ml bovine serum albumin, pH 7.4). Platelet count was performed 
in a hemocytometer with a 400× magnification. Isolated platelets were used within 3 
hours after blood collection.  
 
7.2.8 Flow cytometry of quiescent and activated platelets 
Isolated platelets were studied before and after activation with thrombin-
receptor activation peptide (TRAP) (Bachem Americas Inc., USA) added at 50 µM for 
3 min at room temperature. To quantify expression of P-selectin and fibrinogen-
binding capacity, platelets (200,000 in 50 µl) were incubated at room temperature for 
10 min either with anti-human CD62P phycoerythrin-labeled murine antibodies (BD 
Biosciences, USA) (0.045 µg/ml final concentration) or with Alexa fluor 488-labeled 
human fibrinogen (5 µg/ml final concentration) (ThermoFisher Scientific, USA). After 
incubation with the labeled ligands, the cells were analyzed using FacsCalibur flow 
cytometer equipped with BD CellQuest™ software (BD Biosciences, USA). Platelets 
were gated based on the size and granularity using Forward Scatter (LFS) and Side 
Scatter (LSS) channels and 5,000 cells were counted in each sample. For detection of 
platelets bearing Alexa fluor 488-labeled fibrinogen and anti-CD62P PE-labeled 
antibodies we used two channels with green and yellow filters, respectively. To 
quantify expression of P-selectin and fibrinogen-binding capacity, platelets (200,000 
in 50 µl) were incubated at room temperature for 10 min either with anti-human 
CD62P R-phycoerythrin-labeled murine antibodies (BD Biosciences, USA) (1.5 µl per 
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sample) or with Alexa fluor 488-labeled human fibrinogen (5 µg/ml final 
concentration) (ThermoFisher Scientific, USA). 
FlowJo X software was used for data analysis (Fig. S3). Paired samples of 
isolated platelets from 11 stroke patients and 11 healthy donors were analyzed in 
parallel.  
 
7.2.9 Scanning electron microscopy of platelets 
Isolated platelets (1,000,000 in 100 µl of phosphate buffered saline, pH 7.4) 
were fixed in a 2% glutaraldehyde solution (final concentration) for 90 minutes at 
room temperature. Fixed platelets were layered on a carbon filter (0.4 µm pore size) 
and centrifuged at 150g for 7 min. The samples were rinsed three times for 5 min with 
the phosphate buffered saline, dehydrated serially in 30, 50, 70, 50, 90, 95 vol% and 
three times with 100 vol% ethanol, then dried overnight with hexamethyldisilazane 
(HMDS). A thin film of gold-palladium was layered on the samples using a sputter 
coater (Quorum Q 150T ES, Quorum Technologies, UK). Micrographs were taken 
using a scanning electron microscope Merlin (Zeiss, Germany)(Fig. S4). Isolated 
platelets from 3 healthy donors and 6 stroke patients were prepared for scanning 
electron microscopy. Not less than 10 randomly selected images were analyzed for 
each platelets preparation and the total number of cells counted was 892 and 311 for 
stroke patients and healthy subjects, respectively.   
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7.2.10 Statistical analysis  
All statistics were completed using Prism GraphPad 6.0. Samples were 
analyzed for statistical significance using two-tailed unpaired t-tests or a chi-square 
test with alpha=0.05 between control donors and stroke patients or between subtypes 
of stroke. A Pearson correlation test was used to determine the coefficients of 
correlation and significance of correlations for parametric data and a Spearman 
correlation was used for non-parametric data. All data is presented as mean±SEM 
unless indicated otherwise. Significance is represented as *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
 
7.3 Results 
7.3.1 Comparison of hemostatic and hematological profiles in stroke patients 
and healthy donors  
 Hemostatic and hematological parameters for stroke patients and healthy 
donors are shown in Table 1. Comparison of these parameters revealed an elevation in 
fibrinogen and D-dimer levels and a decrease in the rate of ADP-induced platelet 
aggregation in stroke patients (Table 1). In addition, stroke patients had a reduced 
platelet count, and increased fibrinogen level, hematocrit, erythrocyte sedimentation 
rate, and leukocyte count. In vitro model experiments with variation of the platelet 
count and fibrinogen levels suggest that clot contraction can be directly modulated by 
these blood constituents. In particular, clot contraction was enhanced by the increasing 
number of platelets (Figure S2A), while fibrinogen had a dose-dependent inhibitory 
effect (Figure S2B), consistent with the changes in blood composition observed in the 
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stroke patients. Since the molecular and cellular composition of the blood impacts the 
process of clot contraction, 143 these differences collectively suggest that clot 
contraction has the potential to differ in healthy donors and stroke patients.  
 
Table 7-1 Hemostatic and hematological parameters in stroke patients and 
healthy subjects 
Parameters  
(normal ranges are shown in 
parentheses) 
Healthy subjects 
(n=79) 
Patients with IS (n=85) 
Hemostatic Parameters  
aPTT (26-36), sec. 32.1±0.5 35.4±2.4 
Prothrombin ratio (70-130), sec. 103.6±1.5 105.8±2.8 
INR (0.85-1.15) 0.99±0.01 1.00±0.02 
Fibrinogen (1.8-4.0), g/L 2.7±0.1 3.3±0.2** 
Thrombin time (14-21), sec. 17.7±0.2 17.4±0.4 
D-dimer (0-0.5), µg/ml 0.23±0.03 1.7±0.4*** 
Antithrombin III (80-120), % 90.5±1.0 94.1±4.9 
Plasminogen (80-135), % 111.8±2.9 109.8±4.3 
Protein С (70-130), % 104.3±2.1 103.7±2.9 
Maximal ADP-induced platelet 
aggregation (60-90), % 
64.3±1.6 62.0±4.4 
Rate of ADP-induced platelet 
aggregation (30-45), %/min. 
36.6±1.0 24.3±2.4**** 
Hematological Parameters  
Platelet count (180-320), ×109/L 286±10 252±8** 
Mean platelet volume (8,6-12,6), 
fL 
9.5±1.4 8.4±0.1* 
Red blood cells (3-5), ×1012/L 4.5±0.1 4.5±0.1 
Hematocrit (36-48), % 38.5±0.5 41.6±0.6*** 
Hemoglobin (120-160), g/L  134.1±1.8 139.3±2.2 
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Color index (0.85-1.05) 0.93± 0.01 0.92±0.01 
Mean cell volume  
(80-100), fL 
85.6±0.8 92.2±0.9**** 
Mean cell hemoglobin (30-35), pg 32.1±0.4 30.9±0.3* 
Leukocytes (4-9), ×109/L 5.8±0.2 7.8±0.2**** 
Eosinophils (0,5-5), % 3.0± 0.3 2.0±0.1** 
Monocytes (3-11), % 6.2±0.2 8.1±0.3**** 
Lymphocytes (19-37), % 34±1 23±1**** 
Basophiles (0-1), % 0.4±0.1 0.49±0.02 
Neutrophils (47-78), % 58.8±1.1 66.3±1.0**** 
Erythrocyte sedimentation rate 
(ESR) (0-15), mm/hr 
8.5±1.0 19.4±2.1*** 
 
 
 
7.3.2 	   Characterization of clot contraction in stroke patients 
 Automated optical tracking of clot size (Figure 1A,B) revealed a 60% 
reduction in the average extent of clot contraction at the end point in stroke patients 
relative to healthy donors (Figure 1C), which resulted in stroke patients having a 
significantly larger clot size. Stroke patients also had a reduced average velocity and 
area over the curve (AOC) while having a prolonged lag time (Figure 1D-E). Cross-
correlation of clot contraction parameters revealed that extent of clot contraction, 
average velocity, and AOC were all strongly correlated with each other, suggesting a 
mechanistic relationship between the parameters. Interestingly, while lag time and 
extent of clot contraction were not significantly correlated in healthy donors, there was 
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a significant negative correlation between these two parameters in stroke patients, 
suggesting that reduced platelet activity increases the lag time and decreases the extent 
of clot contraction (Tables S1-S2).  
 To see whether patients suffering a transient ischemic stroke (TIA) have more 
normalized clot retraction, blood samples from patients with TIA were analyzed. It 
was found that TIA patients also had a significantly reduced extent of contraction, 
average velocity, lag time, and AOC (p<0.0001 for all the parameters), whereas clot 
contraction in TIA did not significantly differ from ischemic stroke patients (Table 
S3).  
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Figure 7-1 Optical tracking system used for measurements of clot contraction.  
(A) Depicts the optical analyzer (side view) used to measure light scattering during the 
process of clot contraction. (B) The changes in relative clot size are converted into a 
kinetic curve that can be analyzed for (a) the extent of clot contraction at 20 minutes, 
(b) the lag time or the time to 5% contraction, and (c) the area over the curve (AOC) 
that characterizes the entire process of clot contraction and integrates the extent and 
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rate of contraction and the lag time. Optical tracking was used to assess differences in 
between healthy subjects and stroke patients (A) extent of clot contraction, (B) average 
velocity of contraction, (C) AOC and (D) lag time.  Parameters for healthy subjects 
and stroke patients were compared using an unpaired, two-tailed Student’s t-test. 
****P<0.0001.  	  	  
 
7.3.3 	   Kinetic phase analysis of clot contraction in stroke patients  
  It has been shown previously that clot contraction in the blood of healthy 
subjects occurs in three phases: initiation of contraction (Phase 1), linear contraction 
(Phase 2) and mechanical stabilization (Phase 3). 143 Regression analysis conducted on 
average kinetics curves (Figure 2) revealed that stoke patients and healthy donors did 
not have a difference in the duration of the different phases or in the rate constant 
associated with Phase 1 (Table 2). However, the rate constants of the linear Phase 2 
and the exponential Phase 3 were significantly reduced by 2 times and 10 times, 
respectively, in stroke patients compared to healthy subjects, indicating impairment of 
the mechanisms of compaction (Phase 2) and stabilization of the clots (Phase 3). 
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Figure 7-2 Averaged kinetic clot contraction curves obtained in the blood of 
stroke patients (n=85) and healthy subjects (n=79). Optical tracking was used to 
measure the relative changes in clot size over 20 minutes with 15-second intervals. 
Data is represent at mean ± SEM.  
 	  	  	  
Table 7-2 Phase kinetic parameters of clot contraction in stroke patients and 
healthy subjects 
 
Rate constants 
 
Healthy 
subjects 
 
Stroke patients 
Phase 1, 1/s 0.023±0.006 0.014±0.005 
Phase 2, %/sec  -0.073±0.002 -0.0210±0.0003**** 
Phase 3, 1/s 0.0021±0.0004 0.00029±0.00006**** 	  	  	  	  	  
7.3.4 	   Correlation between contraction parameters and laboratory tests  
 Because the observed differences between clot contraction in healthy subjects 
and stroke patients were likely related to disorders of hemostasis and changed blood 
composition, we investigated correlations between the extent of clot contraction and 
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hemostatic, hematological, and biochemical parameters (Table S4). The main finding 
was that the extent of clot contraction moderately but significantly correlated with the 
platelet count in stroke patients. We also revealed slight but significant correlations 
between extent of clot contraction and prothrombin time (prothrombin index and INR) 
and hematocrit in healthy subjects, whereas these correlations were not present in 
stroke patients. In stroke patients only monocyte count weakly but significantly 
correlated with extent of clot contraction (r2=0.2839, p<0.001).  
 
7.3.5 Analysis of platelet function and morphology in stroke patients 
Because platelets are critical for the contractile force generated during clot 
retraction, we studied the functionality of platelets in ischemic stroke using flow 
cytometry-based evaluation of the baseline activity of quiescent platelets and their 
responsiveness to chemical activation. We used thrombin-receptor activating peptide 
(TRAP) to mimic the effect of thrombin on PAR-receptors without a risk of fibrin 
formation that would complicate the assay. Platelet reactivity was assessed by surface 
expression of P-selectin and by the ability to bind fibrinogen as a measure of the 
integrin αIIbβ3 activation. In addition, isolated unstimulated platelets from ischemic 
stroke patients were studied with scanning electron microscopy to assess their 
functional status reflected by their shape. In stroke, platelets were initially activated as 
revealed by a higher level of P-selectin expression in unstimulated cells (Table 3 and 
Figure S3). This observation was confirmed by the frequently observed shape change 
and formation of filopodia in platelets from stroke patients (34%) compared to 
morphologically altered platelets from healthy subjects (9%, p<0.0001)(Figure S4). In 
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response to TRAP-induced stimulation, platelets from the blood of ischemic stroke 
patients had a significantly lower expression of P-selectin compared to TRAP-
activated normal platelets. TRAP-induced stimulation also resulted in reduced 
fibrinogen-binding capacity compared to the TRAP-activated normal platelets. 
Collectively, these results indicate that in ischemic stroke, platelets are initially 
partially activated and have a reduced responsiveness to a thrombin-like stimulus. It is 
noteworthy that the ratio of activated versus quiescent cells for both fluorescent 
markers was about 2-4-fold higher in healthy donors compared to stroke patients, 
suggesting, in combination with the reduced exposure of P-selectin and fibrinogen-
binding activity, that the stroke platelets have a substantially decreased overall 
activation potential. As a matter of fact, contraction in the group of stroke patients 
studied for platelet functionality was significantly impaired with an average extent of 
28±7% versus 51±1% for control (p<0.0001). 
 
 
Table 7-3 Functional characterization of platelets isolated from the blood of 
ischemic stroke patients and healthy donors before and after stimulation of the 
cells with thrombin receptor-activating peptide (TRAP)# 
 P-selectin expression Fibrinogen-binding capacity 
Quiescent 
platelets 
TRAP-
activated 
Activated/ 
quiescent 
ratio 
Quiescent 
platelets 
TRAP-
activated 
Activated/ 
quiescent 
ratio 
Healthy 
donors  
(n=11) 3.3±0.8 83.6±3.7 
 
 
~25 1.0±0.3 58.3±5.6 
 
 
~58 
Ischemic 
stroke 
patients 
(n=11) 9.9±5.1* 71.1±7.3** 
 
 
 
~7 1.1±0.4 42.9±7.4*** 
 
 
 
~39 
#Numbers (M±SEM) represent relative flow cytometry counts (%) for the fractions of 
platelets bearing fluorescently labeled fibrinogen or antibodies to P-selectin.  
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*p<0.05; ***p<0.01, ***p<0.001 between the donors and patients 
 
	  
Figure 7-3 Clot contraction parameters in the blood of two groups of ischemic 
stroke patients segregated based on the NIH Stroke Score values: <15 (minor to 
moderate stroke) and >15 (severe stroke). Optical tracking was used to assess 
differences in (A) extent of clot contraction, (B) average velocity of contraction, (C) 
AOC and (D) lag time.  Parameters for stroke patients were compared using an 
unpaired, two-tailed Student’s t-test. *P<0.05, **P<0.01. 
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7.3.6 Analysis of clot contraction based on the severity of stroke 
 The NIHSS is a validated clinical methodology to assess the severity of stroke 
in scale from 0 to 42 where <15 corresponds to a minor to moderate stroke and >15 
corresponds to a moderate-severe or severe stroke. mRs measures rank the level of 
disability following stroke with 0 representing no symptoms and 5 representing severe 
disability. 233 The ASPECTS value is inversely related to the area of damage as 
determined through a topographical evaluation of damage. 234 Within the cohort of 
patients in this study the NIHSS value correlated strongly with mRs and inversely with 
ASPECTS (Table S5). 
The stroke patient population was divided based on NIHSS value to compare 
those with a value <15 to those with a value >15. We found that patients with more 
severe strokes (NIHSS >15) had a moderately but significantly increased extent of clot 
contraction, average velocity, AOC, and a reduced lag time when compared to minor 
and moderate stroke (NIHSS <15) (Figure 3). It is noteworthy that regardless of stroke 
severity the patients had a significantly reduced extent of clot contraction compared to 
healthy subjects and neither subgroup of stroke patients differed significantly from the 
total stroke patient population (Table S6-7). Hemostatic, hematological, and 
biochemical parameters were compared for the populations of stroke patients divided 
by NIHSS (Table S7). Patients with an NIHSS >15 had a faster aPTT, increased 
fibrinogen, D-dimer, platelet count, leukocyte count, and Protein S-100 level.  
 
	  	  
159	  
  
 
Table 7-4 Clinical classification of stroke patients enrolled in this study 
TOAST Classification 
 
 
Cardioembolic Large Artery  
Atherosclerotic  
Small vessel 
occlusion 
 
Total Patients 
Number of 
patients, n (%) 
33 (39) 45 (54) 6 (7) 84 (100) 
Male gender, n 
(%) 
13 (39) 25 (56) 3 (50) 41 (48) 
Age, years 69±2 68±1 60±4 68±1 
Ischemic Stroke Classifications 
NIHSS at time 
of admission 
(median; 1st, 3rd 
quartile) 
9; 4.5, 17 7; 3, 13 4; 3.5, 6 7; 4; 13.5 
mRs  (median; 
1st, 3rd quartile) 
3; 2, 4.5 3; 2, 4 1; 0.75, 1.75 3; 2, 4 
ASPECT score  
(median; 1st, 3rd 
quartile) 
7; 3, 8 8; 3, 8 9; 9, 9 7; 3.5, 8.5 
OCSP 
classification, n 
(%) 
    
  TACI 9 (27) 10 (22) 0 19 (23) 
  PACI 20 (60) 21 (47) 1 (17) 42 (50) 
  LACI 4 (12) 13 (29) 2 (33) 19 (23) 
  POCI 0 (0) 1 (2) 3 (50) 4 (5) 
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7.3.7 Analysis of clot contraction based on etiology of stroke  
 To reveal if the notable alterations in clot contraction in stroke patients had an 
etiology-related pathogenic significance, we investigated differences between 
subpopulations of stroke patients as defined by the TOAST classification (Table 4), 
which allows for a distinction to be made between the following etiologies of ischemic 
stroke: 1) large-vessel atherosclerosis, 2) cardioembolism, 3) small-vessel occlusion, 
4) stroke of other determined etiology, and 5) stroke of undetermined etiology. 235 Due 
to the small number of patients with TOAST subtypes 3-5 we preceded with analysis 
of clot contraction in patients with cardioembolic and atherothrombotic strokes. 
Assessment of extent of clot contraction based on stroke subtype revealed that there 
was a lower extent of clot contraction in patients with cardioembolic strokes when 
compared with patients with atherothrombotic strokes (Figure 4).  	  
 
	  
Figure 7-4 Clot contraction parameters in the blood of patients of clinical 
subpopulations of ischemic stroke as defined by TOAST. The extent of clot 
contraction is reduced in patients with cardioembolic type strokes (n=33) compared to 
atherothrombotic type strokes (n=45). *P<0.05 
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7.4 Discussion  
 Stroke is a leading cause of death and disability worldwide. 144,223 While the 
pathogenesis of ischemic stroke is complex and heterogeneous, a common link 
between the different etiologies is increased activity of the coagulation and fibrinolytic 
systems229 in conjunction with macro- and micro vessel disruption228 manifesting in 
thrombotic events. A thrombus or thrombotic embolus can result in blockage of blood 
flow to a portion of the brain; size and location of the thrombotic event influences 
stroke severity and functional outcome. 236 Brain tissue is a prominent source of tissue 
factor (TF) 237 and locations of brain damage are associated with high levels of TF and 
other procoagulant compounds, 238 which can intensify hypercoagulability and 
potentially lead to exhaustion of anticoagulant mechanisms and/or functional 
impairment of platelets.239 
 Information gleaned from in vitro and ex vivo studies of clot structure has been 
widely used to inform clinical findings. 240 Thrombi collected from ischemic stroke 
patients have a platelet-fibrin network interspersed with cells, and those rich in RBCs 
are generally more susceptible to thrombolysis. 241 In ischemic stroke the structure of 
thrombi is non-homogenous, but, on average RBCs comprise 34% of the volume242 
which can influence the process of clot contraction. 143 Interestingly, fibrin clots 
formed in the blood from ischemic stroke patients had abnormal fibrin ultrastructure 
that could influence contraction of the fibrin-platelet network. 240 Collectively, this 
provides the need for an examination of clot contraction in samples collected from 
patients with ischemic stroke.  
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 Blood clot contraction remains the least studied stage of blood clotting. This 
work is the first systematic assessment of clot contraction in ischemic stroke. The 
main finding of this work is that clots formed from the blood of patients with ischemic 
stroke have a reduced extent of clot contraction when compared to clots formed from 
the blood of healthy subjects (Figure 1). This result is somewhat unexpected as 
ischemic stroke is associated with a procoagulant activity; 228 but the aggregate of 
laboratory values collected from this cohort of ischemic stroke patients sheds some 
light on potential mechanisms for impaired clot contraction.  
 Platelets contain acto-myosin machinery that generates contractile forces4,55,56 
that are propagated through the clot via platelet-fibrin interactions. 61,62 Therefore, 
reduced contraction in stroke patients is likely due to reduced number and 
functionality of platelets (Table 1). We confirmed the mechanistic importance of the 
quantitative and qualitative changes in platelets for clot contraction through in vitro 
experiments with varying platelet counts (Figure S2A) as well as through flow 
cytometry (Table 3 and Figure S3) and scanning electron microscopy (Figure S4) of 
platelets from stroke patients. Based on the surface expression of P-selectin, fibrinogen 
binding capacity and morphology, platelets in the blood of stroke patients are initially 
activated and, more importantly, have a dramatically reduced capacity to respond to a 
thrombin-like activating stimulus. This is consistent with an earlier report that platelets 
from ischemic stroke patients are insensitive to thrombin in vitro27, which may result 
either from cleavage of PAR-receptors or metabolic exhaustion or other mechanisms. 
While a reduced platelet count in stroke is moderate (Table 1) and can have a 
relatively minor contribution to impaired clot contraction, it is platelet dysfunction that 
	  	  
163	  
is likely to be the major pathogenic mechanism for reduced clot contraction observed 
in the blood of stroke patients. Both the disruption in platelet number and function 
results in partial contractile inefficiency.	  143	  143	   
The prolonged lag phase observed in ischemic stroke (Figure 1) could be, in 
part, because of increase of antithrombin III activity following activation of the 
clotting cascade (Table 1), which inhibits thrombin and other clotting factors, 243 
resulting in the slightly prolonged aPTT observed in stroke patients (Table 1). 
Reduced thrombin activity strongly correlates with impaired clot contraction, and 
could be a factor here despite addition of exogenous thrombin to initiate clotting. 143  
Increased fibrinogen level which can accompany ischemic stroke244 (Table 1) 
can suppress clot contraction, which was confirmed in the in vitro experiments (Figure 
S2B). Higher fibrinogen concentration results in increased fibrin mass and more fibers 
not associated with activated platelets/platelet aggregates, which can impede clot 
contraction. 43,143 In stroke patients, fibrin and RBCs can undergo oxidative and 
proteolytic changes that result in the formation of densely matted deposits of fibrin and 
RBCs, which have been implicated to play a role in persistent thrombi. 245,246 The 
abnormal fibrin structure associated with ischemic stroke247-249 results in lower clot 
permeability and a slower rate of lysis. 249  
Contractile forces that are generated by platelets are able to compress RBCs 
tightly into the core of clots. 67 Compacted RBCs form a tessellated network and 
acquire a polyhedral shape, resulting in the terminology polyhedrocytes. 67 
Polyhedrocytes have been found inside coronary thrombi extracted from patients with 
myocardial infarction90, confirming that intravascular clots undergo contraction. 
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Increased hematocrit results in a reduced extent and rate of clot contraction143 and the 
higher hematocrit in stroke patients (Table 1-2, Figure 2) is consistent with this 
inhibitory effect and could be additional mechanism of impaired contraction in stroke 
patients.  
Based on this data analysis, we propose that collectively the reduced platelet 
count, increased hematocrit, and increased fibrinogen contribute to the impaired 
mechanism of clot contraction, which results in vessel occlusion and brain infarct. The 
compromised contraction of an intravascular clot or thrombus may play an important 
role in the pathogenesis of ischemic stroke. Although severity of stroke and infarct 
size are largely determined by the diameter and location of the occluded vessel, the 
ability of the thrombi to contract either more or less can aggravate or alleviate the 
course of ischemic brain damage. For example, if clot or thrombus contraction results 
in a 50% reduction in the vessel cross-sectional area this would translate to a reduction 
of blood flow to 24% of that with no clot, whereas the impaired contraction seen in the 
stroke patients, resulting in an 80% reduction in the vessel cross-sectional area, would 
reduce the flow rate to 4% of the original. 
Interestingly, clot contraction is also reduced in TIA similar to the reduction 
seen in ischemic stroke patients (Table S3) indicating that clot contraction is impaired 
in these patients. TIA is characterized as a focal neurological deficit that lasts less than 
24 hours and, while ischemic in nature, does not result in infarction. 250 Patients with a 
recent TIA are at a high risk for the occurrence of an ischemic stroke251,252 and 15% of 
ischemic stroke patients presented with a previous TIA. 253 Our findings suggest that a 
premorbid status and predisposition to thrombosis, such as are seen in TIA and 
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ischemic stroke, are critical determinants for the ability of clots to contract rather than 
a transitory episode of cerebral vascular occlusion and ischemia that may or may not 
result in persistent thrombosis and/or thromboembolism. While rapid treatment of TIA 
has the potential to help reduce the incidence of ischemic stroke, 254,255 the TIA 
samples in our study were examined prior to the administration of any anticoagulant, 
thrombolytic or antiplatelet drugs. 
Our results show, that despite an overall impairment of contraction in stroke 
patients, severe strokes had a relative increase in extent of clot contraction compared 
to minor/moderate stroke (Figure 4). NIHSS >15 also had a higher Protein S-100 level, 
a molecular marker of brain damage, which is correlated with infarct volume, 
functional outcome and ongoing ischemia. 256 We propose that in some cases of stroke 
with focal brain damage, the contractile activity of clots and thrombi can be improved 
as a potential compensatory mechanism to decrease the consequences of thrombosis 
and restore blood flow. In patients with severe ischemic brain damage the blood brain 
barrier is disrupted257 and massive amounts of TF are released into systemic 
circulation resulting in activation of the extrinsic pathway of blood coagulation. 258-260 
It has been shown that the level of brain damage is associated with the amount of TF 
that is released. 261,262 Also ischemic stroke patients have increased TF-bearing 
microparticles263 and TF expression on monocytes. 264   
We hypothesize that increased TF could potentially cause a secondary wave of 
thrombin generation, resulting in a faster aPTT (Table S6) and higher fibrinogen 
turnover in severe stroke patients. 265 Thrombin can induce highly active platelets in 
severe ischemic stroke patients, which can be determined through expression of P-
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selectin. 266,267 Platelet hyperactivity in combination with increased platelet count 
(Table S6) could explain the increased extent of contraction in patients with more 
severe stroke compared to less severe stroke (Figure 3).  
	  
Figure 7-5 A hypothetical pathogenic role of clot contraction in ischemic stroke. 
The pathogenic basis of ischemic stroke is formation of a thrombus or thrombotic 
embolus blocking a brain vessel and causing focal brain damage. Contraction of the 
intravascular clot or thrombus is impaired in stroke patients due to platelet dysfunction 
and reduced platelet count, increased hematocrit, and increased fibrinogen. This has 
the potential to aggravate occlusion of a blood vessel and brain damage. In some 
cases, brain infarct results in the release of coagulation factors, such as tissue factor, 
which may trigger a secondary wave of thrombin formation, leading to an enhanced 
extent of clot contraction that may provide a compensatory mechanism to improve the 
cerebral blood flow.  
 
 
 
 
 
We propose a dual role of clot contraction in the ischemic stroke (Figure 5). 
Impaired clot contraction results due to changes in blood composition; this impaired 
clot contraction has potential as a pathogenic factor that aggravates the course of 
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disease by increased blockage of blood flow. Enhanced clot contraction occurs in 
atherothrombotic patients compared to cardioembolic patients (Figure 4).  This 
supports that TF can potentially enhance contraction in subpopulations of stroke 
patients because atherothrombotic stroke patients have increased TF268 and D-dimer, 
creating a thrombogenic state, 269 and increased P-selectin expression on platelets, 
indicative of hyperactivity. 270,271 Cardioembolic strokes are not a result of platelet 
hyperfunction but rather arise due to blood stasis. 272 This in conjunction with 
marginally enhance clot contraction in severe strokes supports that an increased 
thrombogenic state may result in the enhanced contraction observed here; this 
enhanced clot contraction has potential as a compensatory or adaptive factor in 
ischemic stroke. However, this potential requires further examination. 
In summary, the pathophysiological significance of clot contraction in 
thrombotic states has been explored for the first time. Clot contraction is associated 
with the restoration of blood flow past otherwise obstructive thrombi, potentially 
influencing the outcome of thrombosis. 5,54,67 However, compressed, dense thrombi are 
more impermeable and may be resistance to fibrinolysis. Consequently, clinical 
consequences of clot contraction in vivo may be ambiguous, resulting in either 
aggravation or relief of the thrombotic state. Our results reveal that further systematic 
studies of the clinical importance of clot contraction are worthwhile, as they could 
inform a novel pathogenic mechanism and result in potential laboratory tests that 
improve diagnosis of and prognosis in thrombotic conditions such as ischemic stroke.  
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7.5 Supplement  	  	  	  	  
Table 7-5 Correlation coefficients between clot contraction parameters in healthy 
donors 
 Extent of 
contraction 
Lag time Average 
velocity 
Area over 
the curve 
Extent of 
contraction 
- 0.011 0.968**** 0.733**** 
Lag time 0.011 - 0.184 -0.298* 
Average 
velocity 
0.968**** 0.184 - 0.641**** 
Area over the 
curve 
0.733**** -0.298* 0.641**** - 
 	  	  
 	  	  
Table 7-6 Correlation coefficients between clot contraction parameters in stroke 
patients 
 Extent of 
contraction 
Lag time Average 
Velocity 
Area over 
the curve 
Extent of 
contraction 
- -0.516**** 0.990**** 0.687**** 
Lag time -0.516**** - -0.456**** -0.430*** 
Average 
velocity 
0.990**** -0.456**** - 0.737*** 
Area over 
the curve 
0.687**** -0.430**** 0.737**** - 	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Table 7-7 Clot contraction parameters in healthy subjects, patients with TIA, and 
stroke patients, total and based on NIH Stroke Scale 
  Healthy 
Subjects 
(n=79) 
TIA 
(n=11) 
Total  
Stroke 
(n=85)  
NIHSS <15 
(n=63) 
NIHSS>15 
(n=17) 
Extent of 
contraction, 
%  
 
51±1 
 
25±3 
 
23±1 
 
22±1 
 
28±2 
Lag time, 
sec.  
74±5 226±43 243±17 260±20 179±27 
Average 
velocity, 
%/sec.  
 
0.041±0.001 
 
0.020±0.003 
 
0.019±0.001 
 
0.018±0.001 
 
0.022±0.001 
AOC, a.u. 420±7 207±31 162±8 150±9 205±15 
 
 
 
Table 7-8 Correlation coefficients between hemostatic parameters and extent of 
clot contraction 
Parameters Healthy subjects Stroke patients 
aPTT 0.089 0.175 
Prothrombin time 0.306** 0.049 
Thrombin time 0.134 0.181 
Fibrinogen -0.073 -0.205 
Platelet count 0.089 0.244* 
Hematocrit -0.253* 0.045 
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Table 7-9 Correlation coefficients between clinical end point parameters 
 NIHSS mRs ASPECTS TOAST  OCSP 
NIHSS - 0.68**** -0.69**** -0.20 -0.64**** 
mRs 0.68**** - -0.46** -0.19 -0.52**** 
ASPECTS -0.69**** -0.46** - 0.26 0.74**** 
TOAST  -0.2 -0.19 0.26 - 0.32** 
OCSP  -0.64**** -0.52**** 0.74**** 0.32** - 
 
 
 
 
Table 7-10 Significance for comparison of clot contraction parameters in healthy 
subjects and stroke patients based on NIH Stroke Scale 	   NIHSS 
<15 
vs. 
NIHSS 
>15 
NIHSS 
<15 vs. 
Healthy 
Subjects  
NIHSS 
<15 vs. 
Total 
stroke 
NIHSS 
>15 vs. 
Healthy 
Subjects 
NIHSS 
>15 vs. 
Total 
stroke 
Healthy 
vs. 
Total 
stroke 
Extent of 
contraction, %  
*	   ****	   ns	   ****	   ns	   ****	  
Lag time, sec.  ns	   ****	   ns	   ****	   ns	   ****	  
Average 
velocity, %/sec.  
*	   ****	   ns	   ****	   ns	   ****	  
AOC, a.u. *	   ****	   ns	   ****	   ns	   ****	  
 
 
 
 
 
 
 
 
 
	  	  
171	  
 
Table 7-11 Comparison of laboratory parameters based on NIH Stroke Scale 
Parameters (normal ranges are 
shown in parentheses) 
NIHSS <15 
(n=63)  
NIHSS >15 
(n=17) 
Hemostatic Parameters  
aPTT (26-36), sec. 32.2±0.5 29.0±0.8** 
Prothrombin ratio (70-130), sec 108.8±3.0 99.5±0.2 
INR (0.85-1.15) 0.97±0.01 0.99±0.01 
Fibrinogen (1.8-4.0), g/L 2.9±0.1 3.4±0.3* 
Thrombin time (14-21), sec. 17.4±0.4 17.4±1.4 
D-dimer (0-0.5), µg/ml 0.6±0.09 1.7±0.3*** 
Antithrombin III (80-120), % 91.4±6.0 100±8.4 
Plasminogen (80-135), % 106.6±5.6 116.2±6.5 
Maximal ADP-induced platelet 
aggregation (60-90), % 
64.8±5.3 50.3±5.7 
Rate of ADP-induced platelet 
aggregation (30-45), %/min. 
23.8±2.5 19.8±3.3 
 
Hematological Parameters  
Platelet count (180-320), ×109/L 250±9 263±16** 
Red blood cells (3-5), ×1012/L 4.6±0.08 4.4±0.16 
Hematocrit (36-48), % 41.7±0.7 40.9±1.5 
Hemoglobin (120-160), g/L  138.8±2.6 141.5±4.1 
Color index (0.85-1.05) 0.92±	  0.01 0.94±0.01 
Mean cell volume (MCV) 
(80-100), fL 
91.1±0.9 94.7±1.4 
Mean cell hemoglobin (MCH) (30-
35), pg 
30.1±0.3 31.2±0.5 
Leukocytes (4-9), ×109/L 7.6±0.2 8.7±0.5* 
Eosinophils (0.5-5), % 2.1±	  0.1 1.7±0.2 
Monocytes (3-11), % 8.2±0.3 7.8±0.7 
Lymphocytes (19-37), % 23.2±1 23±2.2 
Basophiles (0-1), % 0.49±0.02 0.45±0.05 
Neutrophils (47-78), % 66±1.1 67±2.4 
PMNLs (1.5-8),×109/L 4.9±0.2 6.1±0.5* Erythrocyte	  sedimentation	  rate	  (ESR) (0-15), mm/hr 15.9±1.7 21.8±3.9 
Biochemical Tests  Triglycerides	  (<150),	  mg/dL	   150±9 110±8* Protein	  S-­‐100	  (<0.12),	  µg/L	   0.09±0.1 0.18±0.05** AST	  (10-­‐36),	  U/L	   22.7±1.1 28.1±3.2* Glucose	  (70-­‐100),	  mg/dL	   122±3.6 140±10.8* 
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Figure 7-6 Clot contraction in age matched samples. Extent of clot contraction was 
compared for the healthy subjects included in this study (58±13 years, n=79), stroke 
patients (68±9 years, n=85), and a healthy subjects population age matched to the 
stroke patients (65±11 years, n=16). Parameters were compared using an ANOVA. 
****P<0.0001. 	  	  	  
	  
Figure 7-7 Effects of platelets (A) and fibrinogen (B) on clot contraction in vitro. 
Optical tracking was used to access the effects of platelets and fibrinogen across low, 
normal, and high values on the final extent of clot contraction in vitro. The results are 
averaged from 3 independent experiments for each experimental condition. 
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Figure 7-8 Representative raw data from flow cytometry of platelets isolated 
from the blood of a healthy donor and an ischemic stroke patient under various 
experimental conditions. The platelets were incubated with either anti-human CD62 
phycoerythrin-labeled antibodies or Alexa fluor 488-labeled human fibrinogen before 
and after activation with thrombin receptor-activating peptide (TRAP). Each plot 
represents the peak of counts for a fraction of fluorescing platelets superimposed on 
the peak of total platelet counts (around 5,000 total counts each). Numbers (%) 
represent a portion of the fluorescing platelets. 	  	  	  
	  
Figure 7-9 Representative scanning electron micrographs of unstimulated 
platelets isolated from the blood of a healthy donor (A) and an ischemic stroke patient 
(B), showing a higher degree of spontaneous activation of the unstimulated (quiescent) 
platelets in ischemic stroke reflected by the shape change and formation of filopodiak 	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Chapter 8 Activated Monocytes Enhance Platelet-Driven Contraction of 
Blood Clots via Tissue Factor Expression 	  
The studies completed in this chapter supplement the examination of clot contraction 
in ischemic stroke patients described in Chapter 7. Here, we examine the role of tissue 
factor expressing monocytes and inflammation in the modulation of clot contraction. 
This study builds upon the increased extent of clot contraction observed in patients 
with more severe strokes compared to those with mild/moderate strokes as stroke 
severity is associated with tissue factor release. 
 	  
In collaboration with A.D Peshkova, G.L. Ming, I.A. Andrianova,  
R.I. Litvinov, J.W. Weisel 
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8.1 Introduction  
 Clot contraction or retraction is the volumetric shrinkage of blood clots, 53,54,144  
and is driven by contractile forces generated by platelets. 4,54 This process, which 
occurs in vitro and in vivo, has been implicated in the restoration of blood flow past 
otherwise obstructive thrombi and has the potential to be a vital compensatory 
mechanism in thrombotic states. 5,54,67,273 The cellular composition of the blood has 
been found to influence the rate and extent of clot contraction; 143 however, the role of 
activated monocytes in clot contraction has not been investigated. Leukocytes, such as 
monocytes and neutrophils, are recruited to the site of vessel injury and present in 
increased numbers in patients with various thrombotic disorders. 274  
Local inflammation can enhance hemostatic processes by amplifying clot 
initiation and limiting fibrinolysis. 275 In particular, inflammatory cells such as 
monocytes are known to express tissue factor (TF) on their surfaces in various disease 
states such as atherosclerosis, heart disease, and severe sepsis. 10,276,277 TF expression 
is known to occur following activation with agonists such as phorbol-12-myristate-13-
acetate (PMA) and bacterial lipopolysaccharide. 278,279 TF on activated blood and 
endothelial cells, through its role in thrombin formation, is critical for clot formation 
and clot contraction to occur. 54,280 Thrombin converts fibrinogen to fibrin43 and 
activates platelets, 57 which facilitates changes needed for platelet actin-myosin 
contraction to occur.58 
Blood cells and vascular endothelial cells that come in direct contact with the 
circulating blood do not express TF under normal physiological conditions. TF is 
expressed by endothelial and mononuclear cells in response to injury, as well as to a 
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number of different inflammatory extracellular stimuli, including LPS, TFN-a, IL-1, 
IL-2, IL-6, interferon-γ, as well as in response to initiation of the coagulation process 
and thrombosis. 281,282 TF produced by monocytes is the main source of blood-borne 
TF. 281,282  
The expression of TF on monocytes is involved in thrombus formation in 
various pathological conditions such as inflammatory diseases, 283 sepsis, 284 and 
cancer. 285 Recently, monocyte-expressed TF has been proposed as the main protein 
responsible for the thrombotic complications of atherosclerosis. The presence of TF 
coding mRNA has been reported in macrophage foam cells and monocytes adjacent to 
the cholesterol clefts in atherosclerotic plaques from patients undergoing carotid 
endarterectomy. 286 A role for monocyte TF has been proposed in unstable coronary 
syndromes. 277,287 In particular, increased expression of TF was found in atherectomy 
specimens from patients with unstable angina287,288 or myocardial infarction. 289  
Clinical studies have confirmed that activated monocytes contribute to 
thrombosis mainly because of their TF expression. 290,291 After plaque injury, as is 
observed in angioplasty, exposure of cellular and extracellular TF to the circulating 
blood plays a pivotal role in mediating fibrin-rich thrombus formation leading to acute 
coronary syndromes. 292 TF expressed on monocytes/macrophages is up-regulated by 
inflammatory cytokines and oxidized lipids from the plaque. 144,293 Despite ample 
evidence for the critical importance of monocyte-expressed TF in thrombosis, the role 
of inflammatory cells bearing TF in the remodeling of blood clots has never been 
studied. The novelty of our work is the effects of activated monocytes mediated by TF 
on clot contraction. 
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Collectively, these data motivate a need to test the role of activated monocytes 
as modulators of clot contraction, which may be a pathogenic factor that regulates 
local blood flow and potentially affects the course and outcomes of ischemic tissue 
damage. In addition, modulating the degree of clot shrinkage or densification may 
affect permeability and hence the susceptibility of a clot or thrombus to enzymatic 
lysis, and make it more or less stable and/or prone to embolization. We hypothesize 
that activated monocytes enhance the process of clot contraction, which may suggest 
an additional pathophysiologic mechanism of shrinkage of a hemostatic clot or 
obstructive thrombus in inflammatory conditions with important pathogenic 
consequences. 
8.2 Methods and Materials  
8.2.1 Isolation of monocytes  
Blood samples were collected into 3.8% sodium citrate (9:1, v/v) from 58 
healthy aspirin-free donors following informed consent under approval by the Ethical 
Committee of the Interregional Clinical Diagnostics Center (Kazan, Russia). All 
procedures were carried out in accordance with the approved guidelines. Citrated 
blood was centrifuged at 200g for 10 minutes, then platelet-rich plasma was removed 
and phosphate buffered saline (PBS)-EDTA buffer (137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 1.8 mM KH2PO4, 0.1% bovine serum albumin, 2 mM EDTA) was 
added to the sediment in a volume equal to the removed PRP supernatant. This cell 
suspension was diluted 1:1 with the PBS-EDTA buffer and layered on top of Ficoll-
Paque™ Premium (GE Healthcare Biosciences). After centrifugation at 1,100g for 20 
min at room temperature, the peripheral blood mononuclear cells (PBMCs) were 
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collected, then washed three times in PBS-EDTA buffer (300g; 10 minutes; 4°C) and 
suspended in the same buffer. Monocytes were isolated from PBMCs through the use 
of Dynabeads Untouched Human Monocytes Kit (ThermoFisher) according the 
manufacturer’s protocol. Isolated monocytes were washed in the PBS-EDTA buffer 
(300g; 10 minutes; 4°C) and finally re-suspended in PBS without EDTA. 
8.2.2 Characterization of the isolated monocytes 
Cell purity was determined using a flow cytometer (FACSCalibur, BD 
Biosciences) with fluorescently labeled antibodies (BioLegend, San Diego, CA) 
against CD14 (monocytes) and CD41 (platelets) with isotype controls. Preparations 
contained 98-100% monocytes of all mononuclear cells and the contamination of 
platelets varied from 10 to 27 platelets/monocyte (Fig. 3). The cells were utilized 
within 1-6 hours and the viability was determined to be 91-100% with propidium 
iodide and trypan blue exclusion assays. Cell counts in blood samples and in monocyte 
preparations were performed either in a hemocytometer (at 400x) or with an ABX 
Pentra 60 analyzer (Horiba, Japan).  
8.2.3 Treatment of the monocytes with activators and inhibitors 
Monocytes suspended at 1.5×106/ml in phosphate buffered saline, pH 7.4, 
containing 0.1% bovine serum albumin, were activated with 50 ng/ml PMA for 15 
minutes at 37oC and then washed by double centrifugation to remove PMA. To inhibit 
TF expression via blocking of signaling pathways, a fraction of isolated monocytes 
was incubated with 250 µM of a peroxisome proliferator-activated receptor α agonist 
(PPARα agonist or WY-14643) 144,294 at 37oC for 10 minutes prior to PMA activation 
followed by double centrifugation to remove PPARα (see Fig. S3). PPARα has been 
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shown to play a role in regulation of inflammation and agonists to this receptor have 
been used therapeutically with marked cardiovascular benefits. PPARα agonists have 
been shown to influence inflammation and vascular functioning/remodeling295 because 
PPARα activation leads to inhibition of the inflammatory response. The addition of a 
PPARα agonist results in signaling through the nuclear factor kB pathway which can 
ultimately suppress tissue factor expression. 294,296 The TF promoter region contains 
both activator protein-1 and nuclear factor-kB responsive elements297 which allows for 
PPARα to inhibit the generation and expression of TF. However, the nuclear factor kB 
pathway has been implicated in a complex crosstalk with other transcription factors 
such as sTAT3 and p53, 298 and ultimately lead to the enhanced expression/secretion of 
factors such as monocyte chemotactic protein-1, tumor necrosis factor-alpha, 
interleukin-1β. 299 Thus, using the PPARα agonist alone does not eliminate the 
influence of one of these other factors and that was why we coupled these studies with 
the inhibition of TF with anti-TF antibodies as well as addition of exogenous TF to 
mimic its effects on activated monocytes. 
To block the procoagulant activity of TF, 20 µg/ml of rabbit anti-human TF 
IgG (Sekisui Diagnostics, Product No. ADG4502) was added to PMA-activated 
monocytes for 5 minutes at room temperature. Isolated monocytes were re-suspended 
in phosphate buffered saline, pH 7.4, containing 0.1% bovine serum albumin, at 
1.5×106/ml and added back to citrated whole blood at a final concentration equal to the 
initial monocyte count. The average monocyte count in the blood samples was 
(0.30±0.02)×109/l. The number of added monocytes was matched to the initial 
monocyte count, making the total content double the initial monocyte content.  
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8.2.4 Assessments of TF expression on the activated monocytes  
To quantify the expression of TF (CD142), ~50,000 monocytes in 50 µl of PBS 
were incubated at +4°C for 30 min with 5 µl of anti-human CD142 phycoerythrin(PE)-
labeled murine antibodies (BD Biosciences) and with 3 µl of anti-human CD14 
peridinin-chlorophyll proteins (PerCP)-labeled murine antibodies (BD Biosciences). 
After incubation with the labeled antibodies, the cells were analyzed using 
FacsCalibur flow cytometer equipped with BD CellQuest™ software (BD 
Biosciences). Monocytes were gated based on the size and granularity using Forward 
Scatter (FSC) and Side Scatter (SSC) channels and 1,000 cells were counted in each 
sample (Fig. 2C). The results of the TF ELISA (TF ELISA kit, Abcam, Cambridge, 
MA) show that monocyte activation results in an increase of TF expression from 
1.1±0.3 pg/106 cells to 105±5 pg/106 cells at 50 ng/ml PMA and 145±21 pg/106 cells 
at 100 ng/ml PMA.  
8.2.5 	   Isolation and characterization of platelets  
Platelets were isolated from the same blood samples used to isolate monocytes. 
Platelets were collected in the void volume after gel-filtration of PRP on Sepharose 2B 
(GE Healthcare, Sweden) equilibrated with Tyrode’s buffer (4 mM HEPES, 135 mM 
NaCl, 2.7 mM KCl, 2.4 mM MgCl2, 5.6 mM D-glucose, 3.3 mM NaH2PO4, 0.35 
mg/ml bovine serum albumin, pH 7.4). Platelet count was performed in a 
hemocytometer with a 400× magnification. Platelets were used within 3 hours after 
blood collection. Cell viability was about 97% based on the maintenance of the 
mitochondrial membrane potential (Δψm) determined by flow cytometry using a Δψm-
sensitive fluorescent dye MitoTracker DeepRed FM (Invitrogen, USA). Non-activated 
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and PMA-activated platelets were added to whole blood in the concentration 
corresponding to the number of contaminating platelets present in the monocyte 
preparations to confirm that the PMA-activated platelets were not enhancing 
contraction induced by PMA-activated monocytes.   
Isolated platelets were stimulated with 50 ng/ml PMA for 15 minutes. The 
results show that PMA indeed activates platelets as judged from PMA-induced 
expression of P-selectin and active integrin αIIbβ3 capable of binding fibrinogen (Fig. 
S1). In the presence of PMA, the extent of contraction was also moderately but 
insignificantly higher (Fig. S2), implying the trend to enhancement of platelet 
contractile function on top of added thrombin-induced platelet activation. These results 
justify the necessity of the negative control experiments that we performed with PMA-
activated platelets to ensure that the stimulating effect of PMA on clot contraction was 
due to monocytes, not the contaminating platelets. The lack of stimulating effects of 
PMA-activated platelets in our control experiments described in the manuscript was 
because the number of platelets added back to the blood was too small and comprised 
only about 1-2% of the natural platelet count. 
8.2.6 Clot contraction with addition of TF 
Lipidated TF (EXTEM®, Rotem) was diluted in 20 mM HEPES buffer, pH 7.4, 
containing 150 mM NaCl, then added to citrated blood 1 minute prior to addition of 
thrombin and Ca2+ at the final concentrations of 0.625%, 1.25% and 2.5% of the initial 
commercially available stock solution corresponding to 1.1 pM, 2.5 pM, and 5 pM TF 
determined by ELISA. A corresponding volume of the diluting buffer was added as a 
control without TF. 
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8.2.7 Kinetics of clot contraction  
 Kinetics of clot contraction was studied using an original method as previously 
described. 143 Briefly, blood clotting and contraction were induced by adding final 
concentrations of 2 mM CaCl2 and 1 U/ml human thrombin (Sigma-Aldrich) so that 
the clot formed within 1 minute. Samples were quickly transferred to plastic cuvettes 
(12x7x1mm) that were pre-lubricated with a residual layer of 4% Triton X-100 to 
prevent fibrin sticking. The cuvettes were placed into the Thrombodynamics Analyzer 
System (HemaCore, Russia) and clot size was tracked optically every 15 seconds for 
20 minutes. Kinetic curves were analyzed for extent of clot contraction at the end 
point, average velocity of contraction, and time to reach 5% contraction (lag time). 
Using a lower thrombin concentration or other clotting triggers, such as TF, without 
thrombin resulted in prolonged clot formation that allowed erythrocytes to settle, 
which reduced reproducibility of the assay. With a higher thrombin concentration the 
clot formed rapidly before the blood sample could be transferred to the cuvette. 
8.2.8 Phase analysis of clot contraction  
Rates of the phases of clot contraction were determined using non-linear 
regression analysis as previously described. 143 Clot contraction occurs in three phases: 
initiation of clot contraction (Phase 1), linear contraction (Phase 2), and mechanical 
stabilization (Phase 3). The instantaneous first derivative of the kinetic curve was 
taken to determine local minimum and maximum, which marked the transitions 
between phases. The Phase 1 and Phase 3 were fitted with an exponential decay 
equation and Phase 2 was fitted with a linear equation (Fig. 1D).  
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8.2.9 Statistical analysis  
 115 contracted clots were analyzed, with experiments for each condition 
performed at least in triplicate on cells independently isolated from different donors. 
Statistics were completed using GraphPad Prism 6.0 using an ANOVA or repeated 
measures ANOVA followed by Tukey’s test or an exact sum of squares F test. 
Significance was assessed at a 95% confidence level.  
	  
Figure 8-1 Effects of activated monocytes on clot contraction. Isolated non-
activated monocytes or PMA-activated monocytes were supplemented to whole 
citrated blood. Clotting and clot contraction were initiated with 2 mM CaCl2 and 1 
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U/ml thrombin followed by optical tracking of clot size. (A) Representative raw 
images showing an initially uncontracted clot and clots after 20-minute contraction 
obtained from the same blood sample under standard experimental conditions after 
addition of non-activated and PMA-activated monocytes. (B) Average extent of clot 
contraction and (C) average velocity of contraction at 20 minutes, determined after 
addition of non-activated and PMA-activated monocytes (n=8). (D) The averaged 
kinetic contraction curves (n=8) with and without monocyte activation were used to 
determine the rates of the three phases of clot contraction separated by the vertical 
lines. Insert – the comparative rates of Phase 2. The results are presented as mean ± 
SEM. **p<0.01. 	  	  	  
8.3 Results  
8.3.1 Activated monocytes stimulate clot contraction  
Since monocytes are incorporated into clots and thrombi, we hypothesized that 
monocytes have the potential to influence the rate and extent of clot contraction by 
direct or indirect cooperation with platelets. 300 PMA-activated monocytes added to 
whole blood were found to enhance the extent and velocity of clot contraction (Fig. 1, 
A-C) when compared to monocytes that had not been activated with PMA. Addition of 
non-activated monocytes alone did not change contraction parameters, such that under 
the same conditions the extent of contraction with and without resting monocytes was 
51±3% and 48±1%, respectively (p=0.3).  
To exclude the possibility that the observed effects were due to contaminating 
platelets, we performed control experiments with isolated gel-filtered platelets 
activated with PMA (Fig. S1). We added them to the blood samples in a corresponding 
amount, which comprised ~1-2% of the platelet count naturally present in the blood 
sample. Under these conditions, activated platelets by themselves did not induce any 
noticeable increase in the extent of clot contraction, which was 47±4% (PMA-
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activated platelets) vs 51±1% (non-activated platelets, p=0.4), indicating that the 
detected effects were due to the activated monocytes that augmented the contractile 
activity of endogenously present platelets. Monocyte preparations contained 98-100% 
monocytes of all mononuclear cells and the contamination of platelets varied from 10 
to 27 platelets/monocyte (Fig. 3). 
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Figure 8-2 Effects of cell-expressed or purified TF on clot contraction. (A) 
Average extent of clot contraction and (B) average velocity of clot contraction at 20 
minutes after addition to whole blood of non-activated monocytes (normal 
contraction), PMA-activated monocytes, and PMA-activated monocytes treated with a 
PPARα agonist, an inhibitor of TF expression, prior to PMA activation (n=24). (C, D) 
The fraction of TF-expressing (CD142-positive) monocytes determined by flow 
cytometry in the CD14-positive monocyte populations under various experimental 
conditions indicated. (C) Raw flow cytometry peaks from a representative experiment 
are shown. The monocyte population is shown in light gray peaks, while the fractions 
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of TF-expressing monocytes are shown in dark gray peaks and numbers in italics. (D) 
The average percent of TF-expressing monocytes under various experimental 
conditions indicated (n=3). (E) Average extent of clot contraction and (F) average 
velocity of clot contraction at 20 minutes after addition to whole blood of non-
activated monocytes (normal contraction), PMA-activated monocytes and PMA-
activated monocytes treated with inhibitory anti-TF antibodies (n=3). (G) Average 
extent of clot contraction and (H) average velocity of clot contraction at 20 minutes 
after addition to whole blood of lipidated TF at a final concentration of 1 pM, 2.5 pM, 
and 5 pM fitted with an exponential (n=4). The results are presented as mean ± SEM. 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
 	  	  
8.3.2 Phase analysis 
The results of our previous study143 show that clot contraction is a dynamic 
process that is best described as following three kinetically discernable phases that 
result in reducing the bulk volume of the clot over time: an initiation period (Phase 1), 
which is followed by “linear contraction” (Phase 2) and then clot stabilization (Phase 
3). Specifically, Phase 1 requires platelets and fibrinogen, Phase 2 requires the 
additional presence of RBCs, and Phase 3 requires cross-linking of fibrin by factor 
XIIIa. Here, we found that Phase 1 and Phase 3 had the same rate constants in both the 
presence and absence of activated monocytes (Fig. 1D), while Phase 2 was 
characterized by an increase in the rate of contraction (Fig. 1D - insert), suggesting 
that the PMA-stimulated monocytes assist the actively contracting platelets in better 
overcoming the resistance to contraction of the erythrocyte/fibrin matrix. 
It has been recently shown that the mechanical properties of the constitutive 
components of the clot and their dynamic interactions largely determine the kinetics 
and the degree of clot contraction. 143,144 Platelets have an active contractile machinery 
that generates mechanical forces propagated across the clot. Fibrin is a viscoelastic 
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material that can be described mechanically as a semiflexible and deformable polymer 
network. The incorporation of RBCs in the blood clot volume modulates the 
uniformity of the fibrin network, affects the mechanical properties of the clot, and 
impedes the process of clot contraction proportionally to the volume fraction of RBCs. 
143 RBCs are easily deformed and when subjected to compressive forces such as those 
generated by contracting platelets the RBCs become packed in the core of the blood 
clot and take on a polyhedral shape. 67 Based on the quantitative prediction of a 
recently developed model of clot contraction, 144 the monocytes added to the blood by 
themselves will not have much of an effect on the mechanics of clot contraction 
because the volume fraction and the number of exogenous and endogenous monocytes 
[about (0.5-1.0)×106 cells/ml] is miniscule compared to the RBCs and platelets. 
	  
Figure 8-3 Flow cytometry of isolated monocytes. Representative raw data of a flow 
cytometry experiment with a freshly isolated monocyte preparation incubated with 
mouse anti-human CD14 antibodies (monocytes are CD14-positive) and mouse anti-
human CD41 antibodies (platelets are CD41-positive) for 30 min at 4°C in the dark. 
The preparation contains ~98% CD14+ monocytes (A, dark grey) of all mononuclear 
cells (A, light grey). The ratio of CD14+ monocytes (B, dark grey) to CD41+ platelets 
(B, light grey) is roughly 1:10. 
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8.3.3 The promoting effect of activated monocytes on clot contraction is 
mediated by TF expression 
In certain pathological conditions, activated monocytes can express TF, a 
potent initiator of clotting via the extrinsic pathway, on their cell surface. 10,276,277 To 
probe whether TF expression is the mechanism through which activated monocytes 
influence the process of clot contraction, we suppressed the TF activity in two ways. 
First, we applied a PPARα agonist, which inhibits signaling pathways involved in TF 
expression. 294,296 The addition of PPARα agonist-treated monocytes resulted in a 
restoration of clot contraction parameters to being insignificantly different from the 
control (with or without non-activated monocytes) and significantly different from 
activated monocytes (Fig. 2 A, B). Importantly, this compound caused a 78% decrease 
in the average number of monocytes bearing TF on their surface following 15 minutes 
of incubation with PMA (Fig. 2 C, D). Second, since the PPARα agonist may have 
other effects on monocyte signaling pathways, anti-TF antibodies were used to 
selectively inhibit procoagulant TF activity. Treatment of PMA-activated cells with 
anti-TF antibodies completely abrogated the stimulating effect of activated monocytes 
on the extent of clot contraction down to the level of non-activated monocytes (Fig. 2 
E, F). This result corroborates the conclusion that PMA-activated monocytes enhance 
clot contraction through their TF expression.   
Conversely, the addition of lipidated purified TF to whole blood was used to 
mimic the TF expression on PMA-activated exogenous monocytes added to blood 
samples. TF caused a dose-dependent exponential increase in the extent and rate of 
clot contraction (Fig. 2 G, H), which was abrogated in the presence of anti-TF 
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antibodies (Fig. 2 G, H), the same used to suppress TF on the PMA-activated 
monocytes (Fig. 2D).  
In summary, our data provide evidence that the mechanism by which activated 
monocytes assist the contracting platelets in overcoming the resistance of the 
RBC/fibrin matrix is due to enhanced platelet activation via additional endogenous 
thrombin generated by monocyte-expressed TF. The stimulating effects of activated 
monocytes on clot contraction were eliminated by inhibition of TF expression and 
were reproduced by addition of purified TF. 
 
	  
Figure 8-4 Relationship between the degree of vessel obstruction and blood flow. 
Thrombotic vessel obstruction increases the vascular resistance as described by 
Poiseuille's law, which says that resistance is inversely related to the radius to the 
fourth power. Therefore, if the radius (or diameter) of a vascular segment is reduced 
by one-half, the resistance or the volumetric blood flow within that narrowed segment 
increases by 16-fold, which is a dramatic effect relative to the change in degree of 
vessel obstruction. Based on the Poiseuille's equation:  
Volume flow rate = π*(pressure difference)*(radius)4/8*(viscosity)*(length)   
the change in the cross-sectional area corresponding to a decrease of the degree of 
vessel obstruction from 56% to 48% will result in an increase in the volumetric blood 
flow by about 30%. 
 	  	  	  
8.4 Discussion 
The degree of contraction can be an important modulator of the blood flow in 
thrombotic conditions and there is emerging indirect evidence that the degree and the 
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rate of contraction of clots and thrombi may be an important pathogenic factor that 
affects the local blood hydrodynamics and the course and outcome of thrombosis. 
5,273,301 Although the severity of thrombosis and thromboembolism is largely 
determined by the diameter and location of the occluded vessel, the ability of the 
thrombi to contract either more or less can dramatically affect the degree of vessel 
obstruction and its hydrodynamic consequences. Based on Poiseuille's Law, if 
thrombosis results in an 80% reduction in the vessel cross-sectional area, this would 
translate to a reduction of blood flow to 4% of that with no clot. Fig. 4 shows that 
relatively minor changes in the cross-sectional area of a thrombus (by about 8% as 
observed in our experiments) cause significant changes in the volumetric blood flow 
(by about 30%). Moreover, there is a strong inverse correlation between the degree of 
arterial blockage and flow shear rate, which is a strong modulator of platelet function 
and thrombus formation, growth and stability. Therefore, even a relatively small 
variation in the degree of contraction of an obstructive thrombus or thrombotic 
embolus, can cause substantial hemodynamic and pathogenic consequences. Our 
results indicate that activated inflammatory cells can strongly modulate the local blood 
flow in the obstructed vessels by changing the size of a thrombus formed at the site of 
inflammation.      
The promoting effect of activated monocytes on clot contraction is mediated by 
TF on the cell surface. Regardless of whether it is expressed on cells or purified, TF 
leads to thrombin production, which triggers platelet activation and contraction. Based 
on the total content of TF in PMA-activated monocytes of about 100 pg/106 cells (as 
determined by ELISA of the cell lysates), the amount of TF added to the blood with 
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~0.3×106/ml PMA-activated monocytes in our experiments is ~30 pg/ml or ~1 pM 
(with TF mol. weight of 35 kDa), which is enough for intensive thrombin 
generation302. As determined with ELISA of the commercially available stock solution 
of TF (EXTEM), the final concentrations of TF added to the blood in our experiments 
corresponds to 5, 2.5, and 1.1 pM of TF, respectively, which is similar to the amount 
added with PMA-activated monocytes. It has been shown that activated monocytes at 
a concentration of 0.5×106/ml generate ~200 nM thrombin, 303 then in our experiments 
the PMA-activated monocytes added at 0.3×106/ml should have generated ~120 nM of 
endogenous thrombin, which is more than 8 nM of exogenous thrombin (see 
calculations in the Supplementary Information). This amount of endogenous thrombin 
is still below an overall thrombin generation potential determined by the normal 
prothrombin level of about 1.3 µM in plasma or 700 nM in whole blood. 304  
It is not unexpected that PMA-activated monocytes enhance clot contraction; 
however, the TF-dependent enhancement of clot contraction occurs on top of the high 
activity of exogenous thrombin added to induce clot formation and platelet activation. 
This points to an underappreciated importance of endogenously or locally generated 
thrombin activity for the process of clot contraction. It suggests that endogenous 
thrombin generated at the site of thrombosis is a more potent platelet activator due to 
higher local enzymatic activity, resistance to antithrombins, and/or preferential 
localization on or near the platelet membrane.  
It is possible that the exogenous thrombin, like thrombin formed in the 
systemic blood flow, is inactivated quickly, while the endogenously or locally 
generated thrombin is being formed continuously over time after the overall 
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antithrombin potential has been reduced or exhausted. From the literature, the relative 
sensitivity of systemic versus local thrombin activity to antithrombins has been studied 
in clinical and experimental settings. It has been shown that acute coronary syndrome 
patients did not benefit when given systemic direct antithrombins in a safe dose, 
implying that local thrombin-induced platelet activation is prevalent and less sensitive 
to thrombin inhibition. 305  Similarly, inhibition of the coagulation factors X, XI or 
thrombin dramatically reduce the degree of platelet activation and microaggregate 
formation in the bloodstream without affecting the degree of local platelet deposition 
and aggregation on the surface of immobilized collagen. 306 These and other data 
support the notion that endogenous thrombin generated at the site of thrombosis is a 
more potent platelet activator for a number of reasons, including resistance to 
antithrombins. 
Despite a large gap in the fundamental understanding of mechanisms that 
control clot shrinkage in vitro and in vivo, there are a number of conceivable 
mechanisms that underlie the potential effects of clot contraction on the course of 
ischemic tissue damage, e.g. in ischemic stroke.  Obviously, a thrombus or thrombotic 
embolus results in blockage of blood flow to a portion of the brain; size and location 
of the thrombotic event influences stroke severity and functional outcome. 236 Brain 
tissue is a prominent source of tissue factor307 and the location of brain damage is 
associated with high levels of TF and other procoagulant compounds, 238 which can 
intensify hypercoagulability and potentially lead to exhaustion and functional 
impairment of platelets, including their contractile function. 308 Thrombi collected 
from ischemic stroke patients have a platelet-fibrin network interspersed with cells, 
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and RBCs on average comprise 34% of the volume, 242 which can influence the 
process of clot contraction. 143  Fibrin clots formed in the blood from ischemic stroke 
patients have abnormal fibrin ultrastructure that could influence contraction of the 
fibrin-platelet network. 240  Collectively, these data provide explanations for the 
recently revealed impaired contraction of clots from the blood of ischemic stroke 
patients, which displayed a strong correlation with clinical characteristics of the course 
and outcomes of ischemic stroke. 273 In addition, following clot contraction, the tight 
seal that is formed around the injured tissue significantly reduces clot or thrombus 
permeability that is critical to thrombolytic therapy because permeation dictates 
penetration of plasminogen activators. 309 The effects of local conditions on clot 
contraction and permeability are poorly understood, yet highly relevant to thrombus 
growth, stability, susceptibility to embolization, fibrinolysis, and bleeding. 
In summary, the data indicate that inflammatory cells, such as activated 
monocytes, have the potential to enhance clot contraction. This effect can be attributed 
to the increased TF expression on the monocyte’s surface that produces endogenous 
thrombin as a powerful source of fibrin formation and platelet activation. The 
monocyte-modulated contraction of blood clots and thrombi may comprise a novel 
mechanistic interplay between monocytes and platelets or between inflammation and 
thrombosis. In view of these findings, the increased monocyte count, their activation 
and local accumulation that is associated with many (pro)thrombotic conditions may 
represent a new pathogenic and/or compensatory mechanism that stimulates 
contraction of blood clots and thrombi. It is possible that the promoting effect on clot 
contraction is not restricted to activated monocytes, and other TF-expressing cells 
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have this potential as well. However, our findings emphasize the biological 
significance of monocytes as an important player in thrombosis and hemostasis 
associated with inflammation. 
 
8.5 Supplement  
 
	  
Figure 8-5 Representative data from flow cytometry of platelets isolated from the 
blood of a healthy donor before and after PMA-induced activation. The platelets 
were incubated with either anti-human CD62p phycoerythrin-labeled antibodies (top) 
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or Alexa fluor 488-labeled human fibrinogen (bottom) before (left) and after (right) 
activation with 50 ng/ml PMA. Each plot represents the peak of counts for the fraction 
of fluorescing platelets. Numbers within each panel (in %) represent the portion of the 
fluorescing platelets. 
 
 
 
 
	  
Figure 8-6 Influence of PMA on clot contraction. The extent and average velocity 
of clot contraction in the absence and presence of 50 ng/ml PMA, showing that PMA 
moderately enhances clot contraction. 
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Chapter 9 Reduced Contraction of Blood Clots in Patients with Venous 
Thromboembolism is a Novel Embologenic Mechanism 	  	  
To complete the examination of clot contraction across thrombotic conditions in this 
chapter we examine the process of clot contraction in venous thromboembolism. These 
studies are coupled with an examination of platelet function as the mechanism of 
reduction of clot contraction. 	  
 
In collaboration with A.D. Peshkova, D.V. Malyasyov, R.A. Bredikhin, G.L. Minh, 
I.A. Andrianova, C. Nagaswami, J.W. Weisel, R.I. Litvinov 
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9.1 Introduction 
Deep venous thrombosis (DVT) of the lower limbs, isolated or associated with 
pulmonary embolism (PE), complicates many diseases and remains one of the most 
challenging medical and social problems due to a relatively high incidence and life-
threatening risk. DVT and PE are collectively referred to as venous thromboembolism 
(VTE) and are among the leading causes of death from cardiovascular diseases. 310 In 
the United States alone, there are more than 200,000 new cases of VTE registered 
annually, with approximately 10% of these cases associated with PE. Mortality during 
the first three months in patients with PE varies from 1.4% to 17.4%.311,312  Moreover, 
VTE has long-term complications; in fact, at 3 years post VTE 35-70% of patients 
have a disability caused by chronic venous insufficiency and other consequences of 
the post-thrombotic syndrome. 311 Despite numerous studies on VTE the causes and 
pathogenic mechanism of DVT and PE are not fully understood and the results of 
prevention and treatment of VTE remain unsatisfactory. 
Virchow’s triad characterizes the most general cause of VTE and is a 
combination of blood hypercoagulability, changes of blood rheology, and local 
destruction of the endothelium. 313,314 However, the molecular and cellular mechanisms 
underlying these abnormalities are not fully understood. In addition to endothelial 
cells, blood cells contribute substantially to the pathogenesis of VTE. 300 Venous 
thrombi are known to not only be rich in fibrin but also to have activated platelets, 
platelet aggregates, red blood cells, and white blood cells present. The presence of 
white blood solidifies the connection of venous thrombosis with local inflammation. 
300,315  
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The role of platelets is perhaps one of the least explored aspects of venous 
thrombosis and thromboembolism; however, there is evidence that suggests that 
platelets may not only be involved in clot formation, but also in the subsequent growth 
and remodeling of a thrombus. 67,143 It is well known that in vitro a blood clot 
undergoes spontaneous volumetric shrinkage, which is known as clot contraction or 
retraction. This process is driven by platelet contractile proteins, actin and myosin, that 
form an active complex which generates a mechanical force by the molecular 
mechanism similar to muscle contraction. 54,173 If the ability of clots and thrombi to 
shrink in volume is maintained in vivo, it may be implicated in the restoration of blood 
flow past otherwise obstructive thrombi and has the potential to be a vital 
compensatory mechanism in thrombotic states. 5,67,273  
Despite the potential clinical importance of contraction of blood clots and 
thrombi, a systematic study of this process has not been performed in venous 
thrombosis. The aim of this study was to determine a possible pathogenic role and 
clinical significance of contraction of blood clots in VTE by studying the kinetics of 
clot contraction in the blood of patients with VTE in correlation with clinical 
characteristics and laboratory parameters. 
 
9.2 Methods and Materials 
9.2.1 Patients and exclusion criteria 
55 patients with newly diagnosed VTE were included in the study. Clinical 
subgroups are presented in Table 1. DVT was verified by duplex ultrasonography of 
the vessels using the GE Logiq 700 EXP unit. Based on the level of thrombotic 
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occlusion the patients with VTE were segregated to the distal thrombosis of the 
femoral-popliteal segment (27 or 49% patients) or proximal iliofemoral thrombosis 
(28 or 51% patients). Based on the duration of symptoms, the patients were divided 
into the subgroups with acute (<21 days) and subacute (>21 days) thrombosis. Patients 
with suspected PE underwent CT scan of the chest with contrast. This procedure was 
performed in 32 (58%) patients, of which 23 (71%) were diagnosed with PE. Among 
the patients diagnosed with PE an embolus occluding >50% of the pulmonary artery 
(massive PE) occurred in 2 (9%) patients; occlusion of 30-50% of the vascular bed 
(sub-massive PE) occurred in 8 (35%), and only small branches of the pulmonary 
artery (<30% of the vascular bed) were occluded in 13 (56%) patients. 
VTE patients were excluded from this study if they were given anticoagulants, 
thrombolytics or antiplatelet drugs prior to examination, which complicated and 
delayed substantially data acquisition. An inescapable exception from this rule was 
made for four DVT patients that underwent thrombectomy followed by scanning 
electron microscopy of the thrombi to analyze cellular composition.   
The gender- and age-matched control group consisted of 60 aspirin-free 
healthy donors consisted of 37 (62%) men and 23 (38%) women with the average age 
of 51±2 years (compare with VTE patients in Table 1). 
9.2.2 Blood collection and processing 
Informed consent was obtained from patients with a newly diagnosed VTE and 
healthy donors under approval of the Ethical Committee of the Interregional Clinical 
Diagnostic Center (ICDC, Kazan, Russia). All procedures were carried out in 
accordance with the approved guidelines. Venous blood was drawn at the time of 
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admission of patients to the emergency room. Blood was collected in vacutainers 
containing 3.8% trisodium citrate 9:1 by volume (S-Monovette tubes, Sarstedt, 
Germany), stored and processed at room temperature and analyzed within 4 hours. 
Blood was then divided into two samples. One sample was used in the clot contraction 
assay. The other citrated blood sample was centrifuged (1500g, 10 min) to obtain 
platelet-poor plasma (PPP) and used for blood coagulation tests. Another blood sample 
was stabilized with K3-EDTA (1.6 mg/mL final concentration) and used for 
hematological tests. A non-stabilized whole blood sample was mixed with a clotting 
activator silicate (Sarstedt, Germany) and allowed to clot for 20-30 minutes at 37°C 
followed by centrifugation (2000g, 10 min) to obtain serum for biochemical blood 
tests. 
9.2.3 Continuous optical tracking of contracting blood clots in vitro 
Determination of the kinetics and the extent of clot contraction were carried out 
using the original method based on the optical detection of clot size over time using 
the Thrombodynamics Analyzer System (HemaCore, Moscow, Russia). Samples from 
patients and healthy donors were activated under standard conditions with 1 U/ml 
human α-thrombin (Sigma-Aldrich, USA) and 2 mM CaCl2 (final concentration). 
Activated samples (80 µl) were quickly transferred to a 12x7x1 mm transparent plastic 
cuvette that was pre-coated with a residual layer of 4vol% Triton X-100 in phosphate 
buffered saline to prevent sticking of the clot to the chamber. The transparent cuvette 
was placed into the 37°C, temperature-controlled chamber of the Thrombodynamics 
Analyzer instrument. Images of the clots were taken every 15 seconds for 20 minutes 
to track the changes in clot size based on the light scattering properties of the clot 
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through the use of a light emitting diode and a CCD camera. The images then were 
computationally analyzed to retrieve primary parameters of clot contraction: the 
percent contraction, the lag time, the area over the curve and the average velocity.  
9.2.4 Platelet isolation 
Fresh citrated blood of VTE patients or healthy donors was centrifuged at 200g 
for 10 min at room temperature to obtain platelet-rich plasma (PRP). Platelets were 
collected in the void volume after gel-filtration of PRP on Sepharose 2B (GE 
Healthcare, Sweden) equilibrated with Tyrode’s buffer (4 mM HEPES, 135 mM NaCl, 
2.7 mM KCl, 2.4 mM MgCl2, 5.6 mM D-glucose, 3.3 mM NaH2PO4, 0.35 mg/ml 
bovine serum albumin, pH 7.4). Platelets were used within 3 hours after blood 
collection. Cell viability was about 97% based on the maintenance of the 
mitochondrial membrane potential (Δψm) determined by flow cytometry using a 
Δψm-sensitive fluorescent dye MitoTracker DeepRed FM (Invitrogen, USA). Platelet 
count was performed in a hemocytometer with a 400× magnification. 
9.2.5 Flow cytometry of quiescent and activated platelets 
Platelet functionality was assessed by expression of P-selectin (CD62p) and 
active integrin αIIbβ3 (determined by its fibrinogen-binding capacity) before and after 
activation with thrombin-receptor activation peptide (TRAP) (Bachem Americas Inc., 
USA). TRAP was added to isolated cells at 50 µM for 3 minutes at room temperature. 
Then platelets (200,000 in 50 µl) were incubated at room temperature for 10 minutes 
either with anti-human CD62p phycoerythrin-labeled murine antibodies (BD 
Biosciences, USA) (0.045 µg/ml final concentration) or with Alexa fluor 488-labeled 
human fibrinogen (5 µg/ml final concentration) (ThermoFisher Scientific, USA). After 
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incubation with the labeled ligands the cells were analyzed using a FacsCalibur flow 
cytometer equipped with BD CellQuest™ software (BD Biosciences, USA). Platelets 
were gated based on the size and granularity using Forward Scatter (LFS) and Side 
Scatter (LSS) channels and 5,000 cells were counted in each sample. For detection of 
platelets bearing Alexa fluor 488-labeled fibrinogen and anti-CD62 PE-labeled 
antibodies we used two channels with green and yellow filters, respectively. FlowJo X 
software was used for data analysis. Each sample of platelets isolated from 11 VTE 
patients was analyzed in parallel with control sample from a healthy donor. 
9.2.6 Scanning electron microscopy of platelets 
Isolated platelets (1,000,000 in 100 µl of phosphate buffered saline, pH 7.4) 
were fixed in 2% glutaraldehyde (final concentration) for 90 minutes at room 
temperature. Fixed platelets were layered on a carbon filter (0.4 µm pore size) and 
centrifuged at 150g for 7 minutes. The samples were rinsed three times for 5 minutes 
with the phosphate-buffered saline, dehydrated serially in 30, 50, 70, 50, 90, 95 % by 
volume and three times with 100% ethanol, and dried overnight with 
hexamethyldisilazane (HMDS). A thin film of gold-palladium was layered on the 
samples using a sputter coater (Quorum Q 150T ES, Quorum Technologies, UK). 
Micrographs were taken using a scanning electron microscope Merlin (Zeiss, 
Germany). Isolated platelets from 4 healthy donors and 4 patients with VTE were 
prepared for scanning electron microscopy. Not less than 10 randomly selected images 
were analyzed from each platelet preparation and a total of 4211 and 480 cells were 
analyzed from VTE patients and healthy subjects, respectively.    
	  	  
204	  
9.2.7 Scanning electron microscopy of venous thrombi 
Four fresh thrombi extracted from deep veins of lower limbs during surgical 
thrombectomy were washed in saline and fixed in 2% glutaraldehyde. The fixed clots 
were cut-open, then washed in 50 mM sodium cacodylate with 100 mM NaCl (pH 7.4) 
and prepared as described in the previous section. The interiors of the thrombi were 
examined in a FEI Quanta 250 scanning electron microscope (FEI, Hillsboro, OR). For 
each thrombus 10–15 high magnification micrographs taken at randomly chosen 
locations to eliminate selection bias were analyzed. 
9.2.8 Coagulation, hematological, and biochemical tests 
An automated coagulometer Sysmex CA-1500 (Sysmex, Canada) was used 
with fresh citrated plasma samples for the following tests: activated partial 
thromboplastin time (aPTT), prothrombin time, INR, fibrinogen concentration, 
concentrations of antithrombin III and D-dimer concentration. ADP-induced platelet 
aggregation was studied using an optical method (Biola, Russia). Cell count was 
performed in EDTA-treated whole blood samples with an ABX Pentra 60 cell counter 
(hematology analyzer) (Horiba, Japan). The following parameters were analyzed: 
erythrocyte count, mean corpuscular volume, hematocrit, hemoglobin, mean 
corpuscular hemoglobin, color index, leukocyte count, monocyte count, neutrophil 
count, lymphocyte count, eosinophil count, basophil count, platelet count, and mean 
platelet volume. Blood chemistry tests were performed with RX Imola (Randox, UK) 
and Advia 1200 (Siemens, Germany) analyzers (Siemens, Germany).  
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9.2.9 Statistical analysis 
Statistical analyses were done using Prism GraphPad 6.0. Data were analyzed 
for statistical significance using a two-tailed unpaired t-test or a chi-square test with a 
95% confidence level (p=0.05) between the clinical groups and subgroups. Pearson’s 
correlation analysis was used for parametric data and Spearman’s rank correlation was 
used for non-parametric data. The results are presented as mean ± SEM unless 
otherwise indicated.  
Table 9-1 Clinical characteristics of patients with VTE 
Characteristics of thrombosis  
Level of 
occlusion  
Proximal 28 (51%) 
Distal 27 (49%) 
Floating part  
of a thrombus 
>7 cm 4 (7%) 
<7 сm 26 (47%) 
No 25 (46%) 
Thrombosis Provoked 8 (15%) 
Unprovoked 
 
47 (85%) 
Duration of 
symptoms 
 
>21 days (subacute) 10 (18%) 
< 21 days (acute) 45 (82%) 
 
 Comorbidities  
Malignant neoplasms  7 (17%) 
Acute infections  1(2%) 
Thrombosis of superficial veins  14 (25%) 
Cardiac ischemia  5 (9%) 
Hypertonic disease 20 (36%) 
Diabetes 5 (9%) 
 
Risk factors  
Varicose disease of the lower extremities in history  19 (35%) 
Acute disorders of cerebral circulation in history  4 (7%) 
Extensive trauma 4 (7%) 
Immobilization of more than 4 days  5 (9%) 
Prior operation (4 weeks) 2 (4%) 
VTE in history  8 (15%) 
Thrombophilia 3 (5%) 
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Smoking 20 (36%) 
Obesity (BMI>30 kg/m2)  11 (20%) 
Oral contraception 1 (2%) 
 
9.3 Results  
9.3.1 Evidence for contraction of venous thrombi occurring in vivo 
It has been recently shown that contraction of blood clots in vitro is 
accompanied by mechanical deformation of red blood cells to polyhedral shape or 
polyhedrocytes. 67 Therefore, the formation of polyhedrocytes is a morphological 
signature of clot shrinkage and can be used to identify contraction of clots and thrombi 
in vivo.	   We analyzed the cellular composition of venous thrombi and found that 
polyhedrocytes comprised at least 40% of all RBCs within thrombi, with the average 
volume fraction of RBCs of about 30% (Fig. 1). In addition, we observed intermediate 
forms between biconcave RBCs and fully-formed polyhedrocytes. These results 
provide evidence for that platelet-driven shrinkage of venous thrombi occurs in vivo, 
implying that variations of the clot size can potentially modulate the degree of 
obstruction of a blood vessel as well as the mechanical and fibrinolytic stability of 
venous thrombi. 
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Figure 9-1 Representative scanning electron micrographs of the interior of venous 
thrombi containing compressed polyhedral erythrocytes (polyhedrocytes) as a 
morphologic signature of contraction. The corresponding images were taken from 
four thrombi at 2,000x (A, C, E, G) and 5,000x (B, D, F, H). Magnification bars = 10 
µm.  
. 
 
9.3.2 Characterization of clot contraction in VTE patients  
Despite clot initiation occurring in the same manner, clots formed from the 
blood of patients with VTE contracted significantly slower and to a lesser extent than 
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clots formed from the blood of healthy donors (Table 2, Fig. 2). Specifically, there was 
a ~2-fold reduction in the average velocity, degree of clot contraction and area over 
the kinetic curve, as well a ~3-fold increase in the lag time in patients with VTE 
compared to healthy subjects. It has been previously shown that clot contraction in the 
blood of healthy subjects occurs in 3 phases: initiation of contraction (phase 1), linear 
contraction (phase 2), and mechanical stabilization (phase 3). 143 Regression analysis 
conducted on average kinetics curves (Fig. 3A) revealed that in VTE patients and 
healthy donors all three phases were significantly different as marked on the graph. 
The rate/rate constants of all three phases were significantly reduced in VTE patients 
compared with healthy subjects, indicating impairment of the mechanisms of 
contraction initiation, compaction, and stabilization of the clots (Fig. 3B-D). 
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Figure 9-2 Clot contraction parameters in the blood of VTE patients versus 
healthy donors. A – extent of clot contraction, B – lag time, C – area over the curve, 
D – average velocity. 
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Table 9-2 Clot contraction parameters in VTE patients and healthy subjects 
  VTE patients 
(n=55)  
Healthy subjects 
(n=60) 
Extent of contraction, %  33±1*** 48±1 
Lag time, sec.  185±14*** 108±5 
Average velocity, %/sec × 10-3  0.26±0.01*** 0.41±0.01 
AOC, a.u. 208±10 *** 371±10 	  	  	  	  	  	  
	  
Figure 9-3 Phase analysis of Healthy Subjects and VTE Patients. (A) Averaged 
kinetic clot contraction curves obtained in the blood of VTE patients (n=55) and 
heathy subjects (n=60). Optical tracking was used to measure the relative changes in 
clot size during 20 min with 15-s intervals. (B-D) The rate constants between the three 
phases of clot contraction curves shown in A. Data are shown as mean ± SEM. 	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9.3.3 Relationship of clot contraction parameters with laboratory tests 
The changes in clot contraction might be related to variations in some 
hemostatic parameters (Table 3). In VTE patients there was a near 30-fold indopt the 
crease in D-dimer levels, indicating the intravascular fibrin deposition, associated with 
a relatively high fibrinogen level, characteristic of hypercoagulability. At the same 
time, the rate of ADP-induced platelet aggregation was decreased in VTE patients, 
suggesting reduced sensitivity to platelet activators. Partial platelet dysfunction in 
combination with increased level of fibrinogen in the blood are likely to contribute to 
the reduced ability of blood clots to contract in patients with VTE as observed in 
ischemic stroke. 273 Correlation analysis did not reveal any strong links between the 
parameters of clot contraction and other laboratory tests (shown in Table 3), which 
indirectly points to the prevalence of local reactions over systemic changes in blood 
composition for contractility of clots and thrombi. Among potential local modulators 
of clots contraction are inflammatory cells (neutrophils and monocytes) which are 
significantly increased in VTE (Table 3) and are known to get incorporated into 
venous thrombi300,316 and affect platelet activity. 300,317  
 
	  
Figure 9-4 Representative scanning electron micrographs of unstimulated 
platelets isolated from the blood of a VTE patient (A) and a healthy donor (B), 
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showing a higher degree of activation of the unstimulated (quiescent) platelets in VTE 
reflected by the shape change, formation of filopodia, and tendency to aggregate. 
 
 
 
Table 9-3 Laboratory parameters in VTE patients and healthy donors 
Parameters (normal ranges are shown in 
parentheses) 
VTE patients (n=55) Healthy subjects 
(n=60) 
Hemostatic parameters  
aPTT (26-36), sec. 32.5±0.8 32.1±0.5 
Prothrombin ratio (70-130), sec 95.5±3* 103.6±1.6 
Fibrinogen (1.8-4.0), g/L 3.9±0.3*** 2.7±0.1 
Thrombin time (14-21), sec. 16.8±1.0 17.7±0.2 
D-dimer (0-0.5), µg/ml 6.6±1.7*** 0.23±0.03 
Antithrombin III (80-120), % 90.2±8.8 90.5±1.0 
Prothrombin time (9.8-12.1), sec. 12.4±0.9 11.1±0.1 
Maximal ADP-induced platelet aggregation 
(60-90), % 
55.9±15 64.3±1.6 
Rate of ADP-induced platelet aggregation 
(30-45), %/min. 
21.9±7.5** 36.6±1.0 
Hematological parameters 
Platelet count (180-320), ×109/L 275±16 286±10 
Red blood cells (3-5), ×1012/L 4.3±0.1* 4.5±0.1 
Hematocrit (36-48), % 38±0.1 39.5±0.6 
Hemoglobin (120-160), g/L  130±4*** 146±2 
Color index (0.85-1.05) 0.92±0.02 0.93± 0.01 
Mean cell volume (MCV) 
(80-100), fL 
89.9±2.0* 85.6±0.8 
Mean cell hemoglobin (MCH) (30-35), pg 31.7±1.1 32.1±0.4 
Leukocytes (4-9), ×109/L 8.7±0.4*** 5.8±0.2 
Eosinophils (0.5-5), % 2.7±0.2 3.0± 0.3 
Monocytes (3-11), % 7.7±0.4*** 6.2±0.2 
Lymphocytes (19-37), % 23±1*** 34±4 
Basophiles (0-1), % 0.68±0.1 0.4±0.1 
Neutrophils (47-78), % 66.3±1.0* 58.8±1.1 
RDW (11-14.8), % 13.3±0.4* 14.2±0.1 
Mean platelet volume (8.6-12.6) fL 7.8±0.1* 9.4±1.4 
Biochemical tests 
Protein (60-83), g/L 70.2±0.8*** 72.8±0.5 
Bilirubin (5-17),	  µmol/L 13.0±1.1*** 8.4±0.3 
Creatinine (53-97), µmol/L 84.7±2.3 87.2±1.6 
Urea (2.4-6.4), mmol/L 5.3±0.2** 4.4±0.2 
Cholesterol (3.6-5.2), mmol/L 4.8±0.3 4.6±0.1 
ALT (5-40), U/L 29.4±3.4* 20.6±1.3 
AST (10-36), U/L  27.7±2.6*** 17.6±0.7 
Glucose (3.6-6), mmol/L 6.2±0.2*** 5.1±0.1 
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9.3.4 Analysis of platelet function and morphology in VTE patients 
Because platelets are critical for the contractile force generated during clot 
retraction, we studied the functionality of platelets in VTE using flow cytometry-based 
evaluation of the baseline activity of quiescent platelets and their responsiveness to 
chemical activation. We used thrombin receptor-activating peptide (TRAP) to mimic 
the effect of thrombin on PAR receptors. Platelet reactivity was assessed by surface 
expression of P-selectin and by the ability to bind fibrinogen as a measure of the 
integrin αIIbβ3 activation. In addition, isolated unstimulated platelets from VTE 
patients were studied with scanning electron microscopy to assess their functional 
status reflected by their shape.  
In VTE, platelets were initially activated as revealed by the frequently 
observed shape change and formation of filopodia in platelets from VTE patients 
(75%, n= 4211) compared to morphologically altered platelets from healthy subjects 
(41%, n= 480, p<0.001) (Fig. 4, Table 4). There was no significant difference in the 
background platelet activation assessed by the levels of P-selectin expression and 
αIIbβ3 activation in unstimulated cells (Table 4 and Fig. 5). Unlike in resting platelets, 
in response to TRAP-induced stimulation, platelets from the blood of VTE patients 
had a significantly lower expression of P-selectin compared to TRAP-activated normal 
platelets. TRAP-induced stimulation also resulted in the reduced fibrinogen-binding 
capacity compared to the TRAP-activated normal platelets. Collectively, these results 
indicate that in ischemic stroke platelets are initially activated and have a reduced 
responsiveness to a thrombin-like stimulus. It is noteworthy that the ratio of activated 
versus quiescent cells for both fluorescent markers was about 2-6-fold higher in 
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healthy donors compared to stroke patients, suggesting, in combination with the 
reduced exposure of P-selectin and fibrinogen-binding activity, that the VTE platelets 
have a substantially decreased overall activation potential. As a matter of fact, 
contraction in the group of VTE patients studied for platelet functionality was 
significantly impaired with an average extent of 32±2% versus 48±1% for control 
(p<0.001). 
 
 
Table 9-4 Functional and morphological characterization of platelets isolated 
from the blood of VTE patients and healthy donors before and after activation 
with TRAPa 
 P-selectin expressionb Fibrinogen-binding capacityb  
Shape changec Quiescent 
platelets 
TRAP-
activated 
platelets 
Activated/ 
quiescent 
ratio 
Quiescent 
platelets 
TRAP-
activated 
platelets 
Activated/ 
quiescent 
ratio 
VTE 
patients  
(n=11) 
1.5±0.4 30.0±6.6* 20 1.3±0.67 41.3±8.4* 7 75±4%*** 
 Healthy 
donors 
(n=11) 
0.9±0.3 43.0±5.8 44 1.35±0.4 60.2±7.3 42 41±2% 
aTRAP stands for thrombin receptor-activating peptide  
bNumbers (mean ± SEM) represent relative flow cytometry counts (%) for the fractions of platelets 
bearing antibodies to P-selectin or fluorescently labeled fibrinogen.  
cNumbers (mean ± SEM) represent fractions of isolated platelets (%) with shape changes characteristic 
of spontaneous platelet activation determined with scanning electron microscopy. 
*p<0.05; **p<0.01; ***p<0.001 
 
9.3.5 Clot contraction and clinical characteristics of VTE patients 
Clinical analysis revealed important relationships between the changes in 
contraction of blood clots and the incidence of thromboembolism, the size of the 
floating part of a thrombi is measured with ultrasonography, and duration of VTE 
symptoms (Table 5). The most significant finding is that the degree and rate of clot 
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contraction were remarkably reduced in patients with PE compared to patients with 
isolated DVT, while both populations were still significantly reduced compared to the 
healthy donors (Table 5, Fig. 6). This result is important because it suggests that less 
compacted clots may be prone to embolization and the impaired contraction of 
thrombi may increase the likelihood of thromboembolism. Relative shortening of the 
contraction lag time was observed in DVT patients with a floating head of a thrombus, 
which is known to be associated with an increased risk of embolization. 318 In patients 
with acute thrombosis lasting <21 days parameters clot contraction was significantly 
suppressed compared to VTE patients with subacute thrombosis lasting >21 days 
(Table 5). 
The revealed relationships between impaired clot contraction and clinical 
characteristics of VTE patients have two important aspects. First, it points to a 
potential pathogenetic significance of clot contraction in VTE, including the 
mechanistic basis of thromboembolism. Second, the parameters of clot contraction in 
vitro may be considered as additional diagnostic and prognostic criteria of DVT-
associated PE.  
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Table 9-5 Blood clot contraction in the clinical sub-groups of patients with VTE 
 
Clinical sub-groups of VTE 
patients 
Parameters of clot contraction (M±SEM) 
Extent of 
contraction, 
% 
Lag time, 
sec. 
Average 
velocity, %/sec
×10-3 
AOC, 
a.u. 
Pulmonary 
embolism 
No (n=31) 35±2 206±16 0.29±0.01 238±13 
Yes (n=23) 29±2*  157±21* 0.23±0.02* 214±17 
 
Floating part  
of a thrombus 
No (n=26) 38±2 207±18 0.30±0.01 247±13 
Yes (n=29) 29±2** 166±18 0.23±0.02** 210±14 
 
Duration of 
symptoms 
 
<21 days 
(n=45) 
32±2 198±15 0.26±0.01 220±11 
>21 days 
(n=10) 
 36±3 128±19* 0.29±0.02 264±24* 
 
 
 
	  
Figure 9-5 Representative raw data from flow cytometry of platelets isolated 
from the blood of a healthy donor and a VTE patient under various experimental 
conditions. The platelets were incubated with either anti-human CD62 phycoerythrin-
labeled antibodies or Alexa fluor 488-labeled human fibrinogen before and after 
activation with thrombin receptor-activating peptide (TRAP). Each plot represents the 
peak of counts for a fraction of fluorescing platelets superimposed on the peak of total 
platelets counts (around 5,000 total counts each). Numbers (%) represent a portion of 
the fluorescing platelets. 
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Figure 9-6 Clot contraction parameters in the blood of patients with DVT and PE 
(n=31) versus DVT alone (n=23). A – extent of clot contraction, B – lag time, C – 
area over the curve, D – average velocity. 
	  	  	  
9.4 Discussion 
The process of mechanical remodeling or contraction of clots remains one of 
the least studied steps of blood coagulation, especially in vivo. Systematic clinical 
studies of clot contraction in thrombotic disorders began to appear recently273,319,320 
and immediately attracted attention. 321 This work is the first comprehensive 
investigation of clot contraction in VTE patients. 
First, we asked whether clot contraction is relevant for VTE. Using 
polyhedrocytes, the compressed RBCs found in the core of a thrombus, as a 
morphological signature of contraction, we have shown clearly that venous thrombi 
undergo shrinkage or compression in vivo (Fig. 1). Polyhedrocytes have been found 
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earlier in coronary thrombi extracted from patients with myocardial infarction, 67,90,322 
so there is strong evidence that contraction of clots and thrombi does occur in vivo, 
including venous thrombi. As a part of the thrombotic process, contraction of clots and 
thrombi is proposed to modulate the degree of vessel occlusion as well as the density, 
mechanical properties, and permeability of thrombi. 67,143  
There is emerging indirect evidence that the degree and the rate of contraction 
of clots and thrombi may be an important pathogenic factor that affects the local blood 
hydrodynamics and the course and outcomes of thrombosis. 5,273,301 Although the 
severity of thrombosis and thromboembolism is largely determined by the diameter 
and location of the occluded vessel, the ability of the thrombi to contract either more 
or less can dramatically affect the degree of vessel obstruction and its hydrodynamic 
consequences. Based on Poiseuille's Law, if thrombosis results in an 80% reduction in 
the vessel cross-sectional area, this would translate to a reduction of blood flow to 4% 
of that with no clot. Therefore, even a relatively small variation in the degree of 
contraction of an obstructive thrombus or thrombotic embolus, can cause substantial 
hemodynamic and pathogenic consequences. Another important pathophysiological 
aspect is the ability of clot contraction to affect the integrity of a thrombus and its 
predisposition to embolization. The overall point of this study was to reveal whether 
the ability of thrombi to contract is fully maintained in VTE and whether the variable 
degree of clot volume shrinkage is a substantial pathogenic factor in venous 
thrombosis and thromboembolism.  
The primary finding is that in the blood of patients with VTE the ability of 
clots to contract is significantly reduced compared with blood of healthy people (Table 
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2, Fig. 2). Moreover, in patients with DVT complicated with PE disorders of 
contraction are significantly more pronounced than in patients with isolated DVT 
without PE (Table 5, Fig. 6). The phenomenon of reduced clot contraction in VTE is 
presumably explained by a combination of several mechanisms.  
Firstly, reduced clot contraction is due to platelet dysfunction caused by partial 
activation of platelets in VTE patients (Figs. 4 and 5). Based on the morphology and 
surface expression of P-selectin, fibrinogen-binding capacity, we found that platelets 
in the blood of VTE patients are initially activated and, more importantly, are partially 
refractory to a thrombin-like activating stimulus. In support of this mechanism 
considerable reduction in speed of ADP-induced platelet aggregation in patients with 
VTE (Table 3) was observed. This background platelet activation and exhaustion are 
likely due to thrombinemia associated with thrombosis, leading to depletion of 
platelets’ energy potential making platelets partially non-functional. 239 Contractility is 
also impaired in low energy potential because	   platelets contain ATP-dependent 
actomyosin machinery that generates contractile forces4,55,56 that are propagated 
through the clot via platelet-fibrin interactions. 61,323 Therefore, disruption in platelet 
function results in partial contractile inefficiency in the blood of VTE patients. 
Secondly, the reduction of contraction in VTE was possibly caused by an 
increase of fibrinogen level (Table 3) that might inhibit clot contraction by increasing 
the elasticity of the fibrin network. 143,144 VTE is accompanied by 
hyperfibrinogenemia324 that is a source of fibrin deposition in blood vessels, as 
evidenced by a substantial rise in the level of D-dimer, which is a molecular marker of 
stabilized fibrin toward fibrinolytic cleavage. 325  
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It cannot be excluded that contraction of blood clots and thrombi in vivo can be 
modulated by inflammatory white blood cells that accumulate at the site of damage on 
the vessel wall and are incorporated into a venous thrombus. 274,275,316 Activated 
neutrophils promote formation of the DNA-containing neutrophil extracellular traps 
(NETs), which, in turn, stimulate the factor XII-dependent thrombosis, 300 as well as 
the activation, adhesion and aggregation of platelets that play the key role in 
contraction of blood clots. 143,144   
Prevention and early diagnosis of PE is one of the major problems in VTE. 
Clinical characteristics of DVT are not specific for PE, so the early diagnosis is 
difficult, while in cases of clinically suspect PE quick and objective confirmation of 
the diagnosis is required. 326,327 The test for D-dimer does not resolve the problem 
because D-dimer is not specific for PE328 and there are no other laboratory criteria for 
thromboembolism and for embologenicity of venous thrombi. Investigating the 
dynamics of clot contraction may partially fill this gap because some correlations of 
the parameters of clot contraction with clinical signs of DVT provide evidence for the 
potential practical importance of the clot contraction assay. 
The most profoundly reduced contraction of blood clot observed in patients 
with PE (Table 5, Figure 4) are likely associated with formation of a less compact 
venous thrombus that is prone to mechanical and/or enzymatic fragmentation. In other 
words, the laboratory parameters reflecting a remarkable reduction of blood clot 
contraction in patients with DVT should be considered as a sign of a greater risk of 
embolism.  
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Another important finding is that a larger floating head in venous thrombi 
correlated with accelerated initiation of clot contraction, indicating faster platelet 
activation perhaps due to enhanced local thrombin generation (Table 5). It is known 
that the unfixed part of a venous thrombus is often localized at the confluence of the 
large inflowing vessels. Intense hemodynamic flow in this location promotes further 
thrombus growth and precludes its adhesion to the vessel wall, which, in combination 
with local thrombin generation, enhances formation of the floating part of the 
thrombus with a significant risk of embolism. Growth of the floating thrombus 
combined with reduced contractility may increase the likelihood of the rupture of the 
floating part, resulting in thromboembolism.  
The parameters of reduced clot contraction in VTE were partially normalized 
with time (Table 5). It is likely due to replacement of the older dysfunctional platelets 
with new functionally active cells that partly restore the ability of blood clots and 
thrombi to contract. The increased contraction over time may comprise a 
compensatory mechanism for recanalization of the obstructed vessels and may signify 
a favorable course of the disease.  
In summary, our data demonstrate that the clot contraction assay may be 
helpful for risk assessment and diagnosis of thromboembolism as well as evaluation of 
the prognosis of VTE. There was a significant decrease in contraction of clots in 
patients with VTE compared to healthy donors largely due to platelet dysfunction and 
hyperfibrinogenemia. Importantly, in patients with PE the parameters of contraction 
were significantly lower than in patients with isolated DVT. The presence and size of 
the floating part of a thrombus correlated with the impaired contraction, again 
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suggesting a relationship of reduced contraction with a risk of thromboembolism. The 
impaired clot contraction tended to normalize after 21 days of thrombosis. The results 
indicate an important pathogenic role of contraction of clots and thrombi as a novel 
embologenic mechanism, as well as a possibility of using the clot contraction assay as 
an early diagnostic and prognostic test for embolic complications in VTE. 
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Chapter 10 Blood clot contraction influences internal and external fibrinolysis  
 
The goal of Specific Aim 3 was to examine how differences in clot contraction between 
healthy individuals and patients with pathological conditions influences the process of 
clot contraction. This will allow for a complete understanding of process of clot 
contraction and how the processof clot contraction can be capitalized on to promote 
clot resolution in a thrombotic setting.  Here, we use inhibitors of clot contraction to 
modulate the extent of clot contraction and explore the rate of internal and external 
fibrinolysis between contracted clots and clots with impaired contraction. 
 
In collaboration with S. Zatysev, D.B. Cines, R.I. Litvinov, J.W. Weisel 
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10.1 Introduction  
  Blood clots are typically dissolved by the fibrinolytic system after 
fulfillment of their hemostatic function. 43,109,329 Fibrinolysis occurs following the 
activation of plasminogen by tissue-type plasminogen activator (t-PA) into plasmin. 
Plasmin proteolytically degrades the fibrin network and results in the release of fibrin 
degradation products. Fibrinolysis occurs in a physiological setting when clot 
formation and fibrinolysis are triggered to occur concurrently; this is termed internal 
or intrinsic fibrinolysis. 330 In the setting of clinical thrombosis, called external or 
extrinsic fibrinolysis, the lytic agent such as t-PA is administered externally to resolve 
thrombosis.  331 The susceptibility of the blood clot to fibrinolysis is influenced by the 
clot structure. 332 In particular, changes in fibrin clot structure such as diameter, 
orientation, and clot age have been shown to influence the efficacy of lysis. 49,333-336  
 As fibrinolysis and clot structure are closely linked it is reasonable that clot 
contraction could influence the rate of fibrinolysis. Blood clot contraction, or 
retraction, is the volume shrinkage of the blood clot, 53,54 which is driven by platelet 
generated contractile forces4 and results in the compaction of red blood cells (RBCs) 
and the expulsion of serum.30,64 Clot contraction has the ability to alter the structure of 
the blood clot. 337 Specifically contraction can change fibrin structure, reduce clot 
permeability, and result in the exclusion of serum, which includes soluble 
plasminogen. 109,110 The amount of plasminogen in the clot has been correlated with 
the susceptibility to lysis. 338 The presence of RBCs in the clot volume has been cited 
for their influence on increased lysis in clots of cardioembolic origin compared to 
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more fibrin rich clots. 339 In addition, incorporation of RBCs has been shown to 
influence the fibrin structure. 49 During clot contraction RBCs become compacted into 
the core of the clot, further reducing the permeability, while fibrin and platelets are 
primarily on the outside of the clot. 67 Here, we examine how the extent of clot 
contraction influences both internal and external fibrinolysis.  
10.2 Methods  
10.2.1 Sample preparation  
 Blood was collected from healthy individuals following informed consent in 
accordance with the guidelines established by the Institutional Review Board at the 
University of Pennsylvania or the Ethical Committee of the Interregional Clinical 
Diagnostic Center (Kazan, Russia) and the Declaration of Helsinki. Blood was drawn 
into 3.2% trisodium citrate 9:1 by volume, stored at room temperature, and used 
within 4 hours.  
10.2.2 Inhibition of clot contraction  
 The extent of clot contraction was impaired through the use of Latrunculin A 
(Abcam; final concentration 4uM), ReoPro (Sigma, final concentration 100ug/ml), and 
Blebbistatin (Sigma, final concentration 200uM) which were added to the blood 30 
minutes prior to initiation of clotting.  
10.2.3 Effect of clot contraction on external fibrinolysis  
 Anti-coagulated whole blood was mixed with tracer 125I-labeled fibrinogen 
(Sigma), activated with 2 mM CaCl2  (final concentration) and 1U/ml thrombin 
(Sigma), and transferred to borosilicate tubes that were pre-lubricated with 4% Triton 
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X-100 to prevent fibrin sticking. Clots were allowed to form and contract for 30 
minutes following activation and then overlaid with 200 ul of PBS containing a final 
concentration of 75ng/ml t-PA. Samples were incubated at 37C and radioactivity in the 
supernatant was measured. 
10.2.4 Effect of expelled serum on external fibrinolysis  
 To examine the influence of expelled serum from contracting blood clots on 
the rate of lysis the clot were prepared as described in the previous section. Following 
30 minutes of contraction the expelled serum was removed and replaced with 
phosphate buffered saline (PBS), PBS plus plasminogen, or platelet poor plasma. Clots 
were incubated at 37C for 15 minutes, overlaid with 200 µl of PBS containing a final 
concentration of 75ng/ml t-PA, and the radioactivity in the supernatant was measured 
10.2.5 Effect of clot contraction on internal fibrinolysis   
 Internal lysis was measured using an optical tracking system 
(Thrombodynamics Analyzer System). 75ng/ml t-PA (final concentration) was added 
to anti-coagulated whole blood, and then clotting was initiated through the addition 2 
mM CaCl2  (final concentration) and 1U/ml thrombin. Samples were quickly 
transferred to pre-lubricated plastic 12x7x1 plastic cuvettes. Cuvettes were added to 
the Thrombodynamics Analyzer System where there was a thermostatic chamber that 
kept samples at 37C. Images of the clot were collected every 100 seconds to track 
changes in size and intensity based on the light scattering properties of the clot through 
the use of a light emitting diode and a CCD camera.  
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10.2.6 Statistical analysis  
 All statistics were completed using Prism GraphPad 7.0. Samples were 
analyzed for significance using a two way ANOVA with an alpha=0.05 between 
samples with normal and impaired contraction.   
 
10.3 Results  
10.3.1 Inhibition of clot contraction  
 Clot contraction was inhibited through the use of Reo-Pro (Abciximab), which 
blocks the αΙIbβ3 receptor on platelets; Latrunculin A, which disrupts actin 
polymerization; and Blebbistatin, which inhibits myosin IIa. All inhibitors resulted in a 
time-dependent reduction in the extent of clot contraction when compared to the 
control (Figure 1), which were not significantly different from each other.  
	  
Figure 10-1 Inhibition of clot contraction. ReoPro, Latrunculin A (Lata), and 
Blebbisatin (Bleb) were used to impair (A) the kinetics and (B) extent of clot 
contraction. **** P<0.0001. 
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10.3.2 Effect of clot contraction on external fibrinolysis  
 Since the external administration of fibrinolytic agents is used to treat 
thrombosis331 and clot contraction is reduced in certain thrombotic conditions, we 
investigated the influence of extent of clot contraction on fibrinolysis. Whole blood 
samples were allowed to contract for 30 minutes prior to addition of t-PA and then 
lysis was assessed through the release of radioactive fibrin-degradation products over 
time.  Samples with impaired clot contraction lysed at a rate 4x faster than in samples 
with normal clot contraction during the first 4 hours following addition of t-PA. 
Significant differences in the release of fibrin degradation products were observed as 
early at 30 minutes after addition of t-PA (Figure 2).  In the absence of t-PA the 
release of fibrin degradation products was only increased at 24 hours after addition of 
t-PA whereas contracted clots in the presence of t-PA showed an increase in lysis at 2 
hours after addition of t-PA (Supplemental Figure 1). Significant differences in the 
presence and absence of t-PA were evident only after 2 hours of lysis (Supplemental 
Figure 2), again pointing to the delayed external lysis in contracted clots.  
 Results were no different with removal of the expelled serum from contracted 
blood clots, suggesting that inhibitors of fibrinolysis that are present in the expelled 
serum were not responsible for the reduction in lysis in contracted blood clots 
(Supplemental Figure 3).  Furthermore, removal of serum and supplementation of 
plasminogen revealed that there was enough plasminogen incorporated into contracted 
blood clots to allow fibrinolysis to occur.  
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Figure 10-2 Effect of clot contraction on the process of external fibrinolysis. 
ReoPro, Latrunculin A, and Blebbistatin were used to impair the extent of clot 
contraction. 75ng/ml tPA was added following 30 minutes of clot contraction. The 
release of radioactive fibrin degradation products was used as a measure of external 
fibrinolysis. * P<0.05, **** P<0.0001. Analysis completed using a two way ANOVA.  
 	  	  	  
10.3.3 Effect of clot contraction on internal fibrinolysis  
 Internal fibrinolysis occurs as the natural resolution of clots. To assess internal 
fibrinolysis we added tPA at the same time as the initiation of clotting, to allow the 
fibrinolytic to occur just after coagulation occurs. Lysis was measured by assessing the 
reduction in clot size with the result that the addition of tPA caused a greater reduction 
of clot size, compared to contracting clots in the absence of tPA (Supplemental Figure 
2) with differences in relative clot size beginning at 25 minutes following initiation of 
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clotting. Contracted samples lysed at a rate 2x faster than clots with impaired 
contraction (Figure 3).  
	  
Figure 10-3 Effect of clot contraction on the process of internal fibrinolysis. 
ReoPro, Latrunculin A, and Blebbistatin were used to impair the extent of clot 
contraction. 75ng/ml tPA was added directly prior to the initiation of clotting. The 
reduction in clot size was measured to assess the resolution of the clot. *** P<0.001. 
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10.4 Discussion  
 This study provides a comparison of the effect of clot contraction on both 
internal and external fibrinolysis. Clot contraction is altered in thrombotic conditions 
such as ischemic stroke273 with a reduction in the extent of clot contraction. These 
conditions are often treated with thrombolytic agents. Thus, there is a need to 
understand how differences in the extent of clot contraction influence the efficacy of 
fibrinolysis.  
Our results on the effect of clot contraction on external fibrinolysis are 
consistent with the previous observations of reduced fibrinolytic degradation in plasma 
and whole blood systems. 115,337,340,341 In our system we are able to keep the 
composition of the blood consistent regardless of extent of clot contraction, whereas 
previous studies resulted in varying clot composition or structure to study the extent of 
clot contraction.  340,341 Following clot contraction the platelets and fibrin move to the 
outside of the clot while the RBCs are compacted into the core of the clot, making the 
clot less permeable. 67 The rate of fibrinolysis is influenced by the permeability of the 
clot as this dictates the delivery rate of tPA342 and this has the potential to influence 
the rate of external fibrinolysis in contracted blood clots. However, we would expect 
that the localization of fibrin to the surface of the clot would limit the dependence of 
the lysis rate on permeability. Importantly, it has been shown that clots made of thin 
fibers lyse slower than clots made of thicker fibers in a looser arrangement, showing 
the importance of fibers per volume on the rate of fibrinolysis. 111,113,332,343,344 The 
density of fibrin on the clot surface provides a potential explanation as to why external 
fibrinolysis occurs at a slower rate in contracted blood clots despite the localization of 
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much of the fibrin fibers to the exterior of the clot. To exclude the possibility that 
external lysis is limited by inhibitors of fibrinolysis, such as PAI-1 from platelets, that 
are present in the serum expelled during the contraction process we compared 
contracted clots in the presence of serum, PBS, PBS + plasminogen, and platelet poor 
plasma. There were no differences in the extent of clot contraction between these 
samples, which confirmed that in our system the plasminogen that was incorporated 
into the clot during the formation was enough for lysis to occur. This also indicates 
that the presence of inhibitors of fibrinolysis in the serum is not responsible for the 
reduced rate of lysis in contracted blood clots. This further suggests that the difference 
in external lysis between contracted and uncontracted blood clots is due to the 
differences in fibrin structure and clot permeability.  
 To examine internal lysis we added the lytic agent at the same time that 
clotting was induced in a concentration such that lysis did not begin until after the clot 
was formed. In internal fibrinolysis the rate of lysis is not dependent on the 
permeability of the clot due to the distribution of the t-PA throughout the entire clot. 
330 This study is the first examination of the role of clot contraction on internal 
fibrinolysis in whole blood and interestingly the effect is the direct opposite of what is 
observed in external lysis. The collection of lysing fibers in close proximity to each 
other has been shown to accelerate the rate of fibrinolysis111,113,345 and attributed to 
enabling plasmin to move between fibers more efficiently. 111,330 Since contracted clots 
have an agglomeration of fibrin on the surface of the clot compared to uncontracted 
clots, it is likely that this contributes to the more efficient lysis in contracted clots 
observed here. In contrast to the external lysis where the permeability of clot 
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influences the rate of lysis in internal lysis the tPA is already incorporated into the 
fibrin network. In addition, since the tPA is incorporated into the clot during formation 
and the contracted clot is smaller in volume it is likely the contracted clot has a higher 
tPA concentration/volume than the clots with impaired contraction.  
 We need to better understand how extent of clot contraction influences the rate 
of fibrinolysis. This is particularly important in thrombotic conditions where 
fibrinolytic agents are added externally to promote lysis. These findings have the 
potential to provide information as to which patients will have a better response to the 
administration of fibrinolytic agents and aid in the development of targeted 
therapeutics.  
10.5 Supplement 
	  
Figure 10-4 Effect of tPA on external lysis. Release of fibrin degradation products 
was measured from contracting blood clots with tPA (black) and without tPA (gray). 
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comparison to paired measurement at 30 minutes. # represents differences between 
samples with and without tPA. Analysis completed with a two-way ANOVA. 	  	  	  
	  
Figure 10-5 Effect of serum on external lysis. Release of fibrin degradation products 
was measured from contracting blood clots with serum, PBS, PBS +plasminogen,  and 
platelet poor plasma.  
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Figure 10-6 Effect of tPA on internal fibrinolysis. Reduction in clot size was 
measured for samples with and without tPA. Significant differences were observed at 
times later than 25 minutes using a multiple time t-test. 
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Chapter 11 Conclusions and Recommendations for Future Work 	  
Despite the clinical implications of blood clot contraction in hemostasis and 
thrombosis it remains the least studied area of the clotting process. This work 
contributes the first systematic examination of the mechanisms of blood clot 
contraction.  Through the development of a novel tracking methodology I determined 
that blood clot contraction is differentially influenced by the cellular and molecular 
composition of the blood. The use of non-linear regression analysis allowed me to 
determine that clot contraction occurred in three kinetically distinct phases: initiation 
of contraction (Phase 1), linear contraction (Phase 2), and mechanical stabilization 
(Phase 3).  Platelet count and function coupled with platelet-fibrin binding was critical 
for the initiation of clot contraction for sustained contraction to occur. Erythrocytes 
interfered with the process of clot contraction during Phase 2 and their concentration 
was inversely related to the overall extent of clot contraction. During mechanical 
stabilization, the properties of the structural network became paramount and Factor 
XIIIa crosslinking played a key role. These studies revealed that clot contraction is a 
multifactorial and multistep process, which was not previously known. These studies 
also revealed the importance of quantitatively studying the time dependent mechanism 
of clot contraction as this revealed differences in the process of clot contraction that 
are not evident from single time point measurements. The methodology developed 
here provides the foundation needed to systematically study the process of clot 
contraction. Going forward these studies could be complemented with an examination 
of the signaling pathways that are vital for the clot contraction process to occur.  
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During the contraction process platelets and fibrin move to the outside of the 
clot while the erythrocytes are compacted into the core of clot. During the compaction 
process erythrocytes undergo mechanical deformation and change from their native 
biconcave shape to that of a polyhedron. Here, I examined the properties of both 
biconcave and deformed cells and determined that they do not undergo any changes in 
surface area to volume ratio but rather under a change in shape, becoming more 
elliptical in nature. The polyhedrocytes had a median of 13 sides with the majority of 
faces being quadrilaterals. These studies support the idea that erythrocytes are not 
passive players in the coagulation process and show for the first time the 3-
dimensional structure of polyhedrocytes. These studies also support the notion that 
formation of polyhedrocytes is a useful marker of the occurrence of clot contraction.  
Combining the summation of this knowledge led to the development of a three-
element active viscoelastic mathematical model of contracting blood clots. This model 
revealed that clot contraction was governed by the viscoelastic properties of the matrix 
rather than the poroelastic nature of the matrix in our experimental settings. In addition 
this allowed me to further probe the influence of increased erythrocytes on the 
dampening of clot contraction and I determined that erythrocytes result in both a 
tensile and compressive resistance, which resulted in a decrease in the extent of 
contraction coupled with a seemingly paradoxical increase in generation of contractile 
force. Prior to the development of this model, the nature of the influence of 
erythrocytes on the process of clot contraction was not known and importantly I 
showed that it is not only the volume of erythrocytes that influences clot contraction 
but also the mechanical rigidity of the cells. This model not only informed our 
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knowledge of clot contraction but also provides the foundation needed to, in the future, 
study the influence of blood flow on the stability and embolization of contracting 
blood clots as would be likely to occur in thrombotic conditions. In addition, this 
model has implications beyond blood clot contraction. Due to the conservation of 
contractile elements, this model can be applied to a setting such as wound healing 
where other contractile cells, fibroblasts, interact with a viscoelastic matrix that is 
embedded with cells. In conclusion, this study provides the first model of active 
contractile cells interacting with a poro-viscoelastic matrix.  
It was hypothesized that clot contraction would be altered in people with (pro)-
thrombotic conditions when compared to healthy individuals due to their altered blood 
composition. Here, I showed for the first time that clot contraction is reduced in 
patients with (pro)-thrombotic conditions and that clot contraction may have a 
pathological significance in clot contraction. In the future, this examination of clot 
contraction in pathological conditions could be expanded to include not only 
thrombotic conditions but also bleeding conditions. The novel methodology developed 
here provides the foundation needed to explore mechanistic differences in clot 
contraction between thrombotic conditions and bleeding disorders in the future.  
 SCD patients tend to the hypercoagulable and have increased erythrocyte 
rigidity. The mathematical model of contracting blood clots developed here showed 
that increased erythrocyte rigidity would have an effect similar to increased 
erythrocyte volume fraction did, due to the largely mechanical influence of the 
incorporation of these cells into the matrix of the contracting blood clots. An 
examination of blood from SCD patients determined that the extent of clot contraction 
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was reduced in this patient population. Probing the role of erythrocyte rigidity through 
the use of chemical crosslinking, antibodies, and naturally rigid cells, I was able to 
determine that increased rigidity of erythrocytes did result in a reduced extent of clot 
contraction and lessened polyhedrocyte formation. This is critical not only for SCD 
patients but for other known modulators of erythrocyte rigidity such as smoking, 
hypertension, diabetes etc. Studies of the influence of erythrocyte rigidity on the 
permeability of the clot and transitively the delivery of medication in these patients 
who are more likely to develop thrombotic conditions would be an interesting and 
worthwhile pursuit in the future.  
My studies revealed that erythrocyte rigidity is not the only pathological factor 
that influences the process of clot contraction. The examination of blood clotting from 
ischemic stroke patients revealed a reduced extent of clot contraction, and this 
reduction in clot contraction correlates with a lower platelet count and platelet 
dysfunction. Correlations with stroke severity and etiology suggest that clot 
contraction may be a pathogenic factor in ischemic stroke and an underappreciated 
factor that could influence the outcome of stroke. This study of reduction in clot 
contraction would benefit from the examination of a larger patient population to 
further explore the correlation between stroke severity/outcome and the extent of clot 
contraction. In addition, a long-term study of patients at risk for stroke would help to 
gain information about whether reduced extent of clot contraction occurs prior to the 
stroke and may be a risk factor or is a consequence coupled with the occurrence of 
thrombosis.  
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Importantly, there was also a reduced extent of clot contraction in patients with 
deep vein thrombosis. Like ischemic stroke patients, this reduction in clot contraction 
is coupled with a platelet dysfunction. Interestingly, the extent of clot contraction was 
even further reduced in patients with pulmonary embolism compared to patients with 
isolated deep vein thrombosis alone. These results reveal that clot contraction may 
play an important pathogenic role in the mechanism(s) of embolization. In the future, 
this study might greatly benefit from the exploration of clot contraction as an early 
diagnostic or prognostic test for the risk of embolic complication in the setting of 
venous thrombo-embolism.   
Importantly, I conducted a thorough examination of clot contraction in patients 
with thrombotic conditions originating from venous and arterial conditions. The 
holistic examination of (pro)-thrombotic conditions shows for the first time the 
possible importance of clot contraction in thrombotic conditions. The combination of a 
mechanistic examination of the influence of clot composition on clot contraction 
coupled with a study of thrombotic conditions reveals that clot contraction exists in a 
force balance that has the ability to be influenced by changes in the clot composition.  
Ultimately, after a blood clot is formed it must be resolved in a healthy 
circulatory system. My results reveal that the extent of clot contraction differently 
influences the rate of internal physiological fibrinolysis and external fibrinolysis, 
which is a model for clinical thrombolysis. The faster resolution of contracted clots in 
a setting of internal lysis may point to easier clot resolution in healthy subjects than in 
those with a predisposition to the development of thrombosis. The reduced rate of lysis 
in contracted clots for external lysis has the potential to inform the therapeutic 
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treatment of patients with thrombotic conditions and/or predict which patients would 
respond better to fibrinolytic treatments. This warrants further exploration in the 
future. In addition, future work could also include a mechanistic examination of 
differences in external and internal fibrinolysis with respect to clot contraction.  
In summary, my studies have provided a novel methodology to study the time 
dependent mechanisms of clot contraction while determining that clot contraction can 
be differentially modulated by the composition of the clot. My studies also included 
the first examination of the pathological importance of clot contraction in thrombotic 
conditions. Lastly, I examined how impaired clot contraction, similar to the reduction 
observed in thrombotic conditions, influenced the rate of internal and external 
fibrinolysis. Collectively these studies show that clot contraction has the potential to 
serve as a diagnostic assay and/or a therapeutic target.  	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